EP3720456A1 - Improved enrichment methods for preparing tannic acid compositions - Google Patents
Improved enrichment methods for preparing tannic acid compositionsInfo
- Publication number
- EP3720456A1 EP3720456A1 EP17934010.4A EP17934010A EP3720456A1 EP 3720456 A1 EP3720456 A1 EP 3720456A1 EP 17934010 A EP17934010 A EP 17934010A EP 3720456 A1 EP3720456 A1 EP 3720456A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- tannic acid
- tannic
- solvent
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002258 tannic acid Polymers 0.000 title claims abstract description 517
- 235000015523 tannic acid Nutrition 0.000 title claims abstract description 517
- 239000000203 mixture Substances 0.000 title claims abstract description 349
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 title claims abstract description 329
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 title claims abstract description 311
- 239000001263 FEMA 3042 Substances 0.000 title claims abstract description 311
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 title claims abstract description 311
- 229940033123 tannic acid Drugs 0.000 title claims abstract description 311
- 238000000034 method Methods 0.000 title claims abstract description 158
- 102000004674 D-amino-acid oxidase Human genes 0.000 claims abstract description 54
- 108010003989 D-amino-acid oxidase Proteins 0.000 claims abstract description 54
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 36
- 208000015114 central nervous system disease Diseases 0.000 claims abstract description 32
- 208000008589 Obesity Diseases 0.000 claims abstract description 30
- 235000013305 food Nutrition 0.000 claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 239000002417 nutraceutical Substances 0.000 claims abstract description 13
- 235000021436 nutraceutical agent Nutrition 0.000 claims abstract description 13
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 8
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 8
- 208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 180
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 168
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 149
- 239000002904 solvent Substances 0.000 claims description 136
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 120
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 96
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 73
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 64
- 239000007787 solid Substances 0.000 claims description 53
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 46
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 46
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 43
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 43
- 208000035475 disorder Diseases 0.000 claims description 43
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 40
- 241000196324 Embryophyta Species 0.000 claims description 34
- 240000003152 Rhus chinensis Species 0.000 claims description 30
- 235000014220 Rhus chinensis Nutrition 0.000 claims description 30
- 229910052751 metal Inorganic materials 0.000 claims description 29
- 239000002184 metal Substances 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 24
- 239000003610 charcoal Substances 0.000 claims description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 23
- 239000012044 organic layer Substances 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 20
- 235000020824 obesity Nutrition 0.000 claims description 20
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 20
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 19
- 229920005989 resin Polymers 0.000 claims description 19
- 239000011347 resin Substances 0.000 claims description 19
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 18
- 230000006399 behavior Effects 0.000 claims description 18
- 208000019901 Anxiety disease Diseases 0.000 claims description 17
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 16
- 229920001353 Dextrin Polymers 0.000 claims description 16
- 239000004375 Dextrin Substances 0.000 claims description 16
- 235000019425 dextrin Nutrition 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 15
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 14
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 14
- 239000010410 layer Substances 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 13
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- 241001206332 Rhus potaninii Species 0.000 claims description 11
- 235000013402 health food Nutrition 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 10
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 10
- 210000003169 central nervous system Anatomy 0.000 claims description 10
- 239000002798 polar solvent Substances 0.000 claims description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 9
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 8
- 241000920652 Quercus lusitanica Species 0.000 claims description 8
- 208000007415 Anhedonia Diseases 0.000 claims description 7
- 208000028017 Psychotic disease Diseases 0.000 claims description 7
- 235000013178 Rhus coriaria Nutrition 0.000 claims description 7
- 244000264648 Rhus coriaria Species 0.000 claims description 7
- 235000010889 Rhus javanica Nutrition 0.000 claims description 7
- 241000161285 Rhus punjabensis var. sinica Species 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 7
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 7
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- 208000030814 Eating disease Diseases 0.000 claims description 6
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 6
- 208000004454 Hyperalgesia Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 244000269722 Thea sinensis Species 0.000 claims description 6
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 6
- 208000016620 Tourette disease Diseases 0.000 claims description 6
- 235000014632 disordered eating Nutrition 0.000 claims description 6
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 6
- 208000036640 Asperger disease Diseases 0.000 claims description 5
- 201000006062 Asperger syndrome Diseases 0.000 claims description 5
- 206010010904 Convulsion Diseases 0.000 claims description 5
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 5
- 208000008967 Enuresis Diseases 0.000 claims description 5
- 208000020358 Learning disease Diseases 0.000 claims description 5
- 201000002832 Lewy body dementia Diseases 0.000 claims description 5
- 206010065604 Suicidal behaviour Diseases 0.000 claims description 5
- 206010042458 Suicidal ideation Diseases 0.000 claims description 5
- 208000029560 autism spectrum disease Diseases 0.000 claims description 5
- 206010005159 blepharospasm Diseases 0.000 claims description 5
- 230000000744 blepharospasm Effects 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 5
- 201000003723 learning disability Diseases 0.000 claims description 5
- 208000005346 nocturnal enuresis Diseases 0.000 claims description 5
- 208000019906 panic disease Diseases 0.000 claims description 5
- 208000016686 tic disease Diseases 0.000 claims description 5
- 241000993444 Acacia mearnsii Species 0.000 claims description 4
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 4
- 235000006010 Bixa orellana Nutrition 0.000 claims description 4
- 244000017106 Bixa orellana Species 0.000 claims description 4
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
- 208000002330 Congenital Heart Defects Diseases 0.000 claims description 4
- 241001070947 Fagus Species 0.000 claims description 4
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 201000001431 Hyperuricemia Diseases 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 4
- 208000004166 Obesity Hypoventilation Syndrome Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 244000220503 Persea thunbergii Species 0.000 claims description 4
- 235000004267 Persea thunbergii Nutrition 0.000 claims description 4
- 206010035004 Pickwickian syndrome Diseases 0.000 claims description 4
- 240000001416 Pseudotsuga menziesii Species 0.000 claims description 4
- 235000008572 Pseudotsuga menziesii Nutrition 0.000 claims description 4
- 244000294611 Punica granatum Species 0.000 claims description 4
- 235000014360 Punica granatum Nutrition 0.000 claims description 4
- 240000007274 Quercus cerris Species 0.000 claims description 4
- 235000009073 Quercus cerris Nutrition 0.000 claims description 4
- 241001424341 Tara spinosa Species 0.000 claims description 4
- 235000006468 Thea sinensis Nutrition 0.000 claims description 4
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 4
- 240000006365 Vitis vinifera Species 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 235000021028 berry Nutrition 0.000 claims description 4
- 235000012978 bixa orellana Nutrition 0.000 claims description 4
- 201000001883 cholelithiasis Diseases 0.000 claims description 4
- 208000028831 congenital heart disease Diseases 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 208000001130 gallstones Diseases 0.000 claims description 4
- 235000002532 grape seed extract Nutrition 0.000 claims description 4
- 229920000591 gum Polymers 0.000 claims description 4
- 208000003532 hypothyroidism Diseases 0.000 claims description 4
- 230000002989 hypothyroidism Effects 0.000 claims description 4
- 208000000509 infertility Diseases 0.000 claims description 4
- 230000036512 infertility Effects 0.000 claims description 4
- 231100000535 infertility Toxicity 0.000 claims description 4
- 208000024714 major depressive disease Diseases 0.000 claims description 4
- 206010027175 memory impairment Diseases 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
- 208000001797 obstructive sleep apnea Diseases 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 239000008177 pharmaceutical agent Substances 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 206010012335 Dependence Diseases 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 3
- 208000035154 Hyperesthesia Diseases 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- 201000004810 Vascular dementia Diseases 0.000 claims description 3
- 206010053552 allodynia Diseases 0.000 claims description 3
- 208000022371 chronic pain syndrome Diseases 0.000 claims description 3
- 201000002342 diabetic polyneuropathy Diseases 0.000 claims description 3
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 3
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- 208000022821 personality disease Diseases 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 208000018652 Closed Head injury Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- GPEHQHXBPDGGDP-UHFFFAOYSA-N acetonitrile;propan-2-one Chemical compound CC#N.CC(C)=O GPEHQHXBPDGGDP-UHFFFAOYSA-N 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 description 101
- QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 85
- 230000000694 effects Effects 0.000 description 84
- 239000000243 solution Substances 0.000 description 58
- 201000010099 disease Diseases 0.000 description 53
- 238000002347 injection Methods 0.000 description 42
- 239000007924 injection Substances 0.000 description 42
- 230000006977 prepulse inhibition Effects 0.000 description 42
- 235000019441 ethanol Nutrition 0.000 description 37
- 239000003814 drug Substances 0.000 description 29
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 235000002639 sodium chloride Nutrition 0.000 description 26
- 239000003981 vehicle Substances 0.000 description 26
- 238000012360 testing method Methods 0.000 description 25
- 230000033001 locomotion Effects 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 22
- 239000000706 filtrate Substances 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 22
- 230000003542 behavioural effect Effects 0.000 description 20
- 238000007912 intraperitoneal administration Methods 0.000 description 20
- 229940124597 therapeutic agent Drugs 0.000 description 20
- 239000000463 material Substances 0.000 description 19
- 230000001149 cognitive effect Effects 0.000 description 17
- 238000000605 extraction Methods 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 17
- 230000036506 anxiety Effects 0.000 description 15
- 239000000969 carrier Substances 0.000 description 15
- 230000036278 prepulse Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 238000001914 filtration Methods 0.000 description 14
- 230000015654 memory Effects 0.000 description 14
- 229910052925 anhydrite Inorganic materials 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 208000013403 hyperactivity Diseases 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 208000000114 Pain Threshold Diseases 0.000 description 12
- 238000011161 development Methods 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 231100000673 dose–response relationship Toxicity 0.000 description 12
- 230000037040 pain threshold Effects 0.000 description 12
- -1 D-serine Chemical class 0.000 description 11
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 11
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 11
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 11
- 230000006735 deficit Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
- 229930006000 Sucrose Natural products 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 238000009227 behaviour therapy Methods 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 230000002269 spontaneous effect Effects 0.000 description 10
- 229960004793 sucrose Drugs 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 238000013401 experimental design Methods 0.000 description 9
- 239000012847 fine chemical Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000035863 hyperlocomotion Effects 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 239000012154 double-distilled water Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000006886 spatial memory Effects 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 239000000883 anti-obesity agent Substances 0.000 description 7
- 229940125710 antiobesity agent Drugs 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 239000012535 impurity Substances 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000007529 anxiety like behavior Effects 0.000 description 6
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001647 drug administration Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229920002492 poly(sulfone) Polymers 0.000 description 6
- 230000036362 sensorimotor function Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000031836 visual learning Effects 0.000 description 6
- 208000016261 weight loss Diseases 0.000 description 6
- 239000013585 weight reducing agent Substances 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 208000037765 diseases and disorders Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000013016 learning Effects 0.000 description 5
- 231100000682 maximum tolerated dose Toxicity 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 238000003305 oral gavage Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 229920001864 tannin Polymers 0.000 description 5
- 239000001648 tannin Substances 0.000 description 5
- 235000018553 tannin Nutrition 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000513231 Kaburagia Species 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 4
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000007267 depressive like behavior Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- 230000006742 locomotor activity Effects 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000013557 residual solvent Substances 0.000 description 4
- 238000012502 risk assessment Methods 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 3
- 241001485107 Nurudea Species 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 229960001058 bupropion Drugs 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000011369 resultant mixture Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 230000003936 working memory Effects 0.000 description 3
- CETWSOHVEGTIBR-FORAGAHYSA-N (2s)-2,6-diamino-n-[(2s)-1-phenylpropan-2-yl]hexanamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.NCCCC[C@H](N)C(=O)N[C@@H](C)CC1=CC=CC=C1 CETWSOHVEGTIBR-FORAGAHYSA-N 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241001274607 Andricus quercuscalicis Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- 208000020706 Autistic disease Diseases 0.000 description 2
- VPAXJOUATWLOPR-UHFFFAOYSA-N Conferone Chemical compound C1=CC(=O)OC2=CC(OCC3C4(C)CCC(=O)C(C)(C)C4CC=C3C)=CC=C21 VPAXJOUATWLOPR-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 2
- 229930195711 D-Serine Natural products 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 229930182820 D-proline Natural products 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGFYECXYGUIODH-UHFFFAOYSA-N Guanfacine hydrochloride Chemical compound Cl.NC(N)=NC(=O)CC1=C(Cl)C=CC=C1Cl DGFYECXYGUIODH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000721570 Melaphis Species 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- 241001516602 Schlechtendalia chinensis Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 235000016213 coffee Nutrition 0.000 description 2
- 235000013353 coffee beverage Nutrition 0.000 description 2
- 229920002770 condensed tannin Polymers 0.000 description 2
- JECGPMYZUFFYJW-UHFFFAOYSA-N conferone Natural products CC1=CCC2C(C)(C)C(=O)CCC2(C)C1COc3cccc4C=CC(=O)Oc34 JECGPMYZUFFYJW-UHFFFAOYSA-N 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 229960000632 dexamfetamine Drugs 0.000 description 2
- 229940099242 dexedrine Drugs 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 2
- 229950004794 dizocilpine Drugs 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- 230000021824 exploration behavior Effects 0.000 description 2
- MSNWSDPPULHLDL-UHFFFAOYSA-K ferric hydroxide Chemical compound [OH-].[OH-].[OH-].[Fe+3] MSNWSDPPULHLDL-UHFFFAOYSA-K 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000026781 habituation Effects 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910021506 iron(II) hydroxide Inorganic materials 0.000 description 2
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000010387 memory retrieval Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229960001785 mirtazapine Drugs 0.000 description 2
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 230000002474 noradrenergic effect Effects 0.000 description 2
- 150000002892 organic cations Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 229920001339 phlorotannin Polymers 0.000 description 2
- 229930182676 phlorotannins Natural products 0.000 description 2
- DJFBJKSMACBYBD-UHFFFAOYSA-N phosphane;hydrate Chemical compound O.P DJFBJKSMACBYBD-UHFFFAOYSA-N 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 208000012802 recumbency Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 229940075554 sorbate Drugs 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000004006 stereotypic behavior Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 229940127228 tetracyclic antidepressant Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- 238000007738 vacuum evaporation Methods 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- VOYCNOJFAJAILW-CAMHOICYSA-N (1r,4s,5s,6s)-4-[[(2s)-2-amino-4-methylsulfanylbutanoyl]amino]-2,2-dioxo-2$l^{6}-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@]1(C(O)=O)CS(=O)(=O)[C@H]2[C@H](C(O)=O)[C@@H]12 VOYCNOJFAJAILW-CAMHOICYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- KWTSXDURSIMDCE-UHFFFAOYSA-N 1-phenylpropan-2-amine Chemical compound CC(N)CC1=CC=CC=C1 KWTSXDURSIMDCE-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001274615 Andricus Species 0.000 description 1
- 241001275745 Andricus kollari Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 241001275723 Biorhiza pallida Species 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241001263559 Cynipidae Species 0.000 description 1
- 241001274616 Cynipini Species 0.000 description 1
- 241001226140 Cynips quercusfolii Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 241000407368 Floraphis choui Species 0.000 description 1
- 241000407382 Floraphis meitanensis Species 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000834713 Gogo Species 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 241000513230 Kaburagia rhusicola Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 241000513238 Meitanaphis elongallis Species 0.000 description 1
- 241000407320 Meitanaphis flavogallis Species 0.000 description 1
- 241000407319 Meitanaphis microgallis Species 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 241000776131 Neuroterus albipes Species 0.000 description 1
- 241001012882 Neuroterus numismalis Species 0.000 description 1
- 241001042995 Neuroterus quercusbaccarum Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N Rohrzucker Natural products OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 244000258044 Solanum gilo Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 229940047812 adderall Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960003036 amisulpride Drugs 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 230000000338 anxiogenic effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 239000007961 artificial flavoring substance Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005245 asenapine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229960002430 atomoxetine Drugs 0.000 description 1
- 230000009901 attention process Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 229950004068 brofaromine Drugs 0.000 description 1
- WZXHSWVDAYOFPE-UHFFFAOYSA-N brofaromine Chemical compound C=1C2=CC(OC)=CC(Br)=C2OC=1C1CCNCC1 WZXHSWVDAYOFPE-UHFFFAOYSA-N 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical compound CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
- 229950011318 cannabidiol Drugs 0.000 description 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940063628 catapres Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001552 chlorprothixene Drugs 0.000 description 1
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229960002925 clonidine hydrochloride Drugs 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 229940112502 concerta Drugs 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 229940098357 daytrana Drugs 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229940099340 desoxyn Drugs 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- DUGOZIWVEXMGBE-CHWSQXEVSA-N dexmethylphenidate Chemical compound C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-CHWSQXEVSA-N 0.000 description 1
- 229960001042 dexmethylphenidate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009459 flexible packaging Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960002419 flupentixol Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 229940053650 focalin Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960000647 gepirone Drugs 0.000 description 1
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960004746 guanfacine hydrochloride Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229920001461 hydrolysable tannin Polymers 0.000 description 1
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940070023 iproniazide Drugs 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- GJJFMKBJSRMPLA-DZGCQCFKSA-N levomilnacipran Chemical compound C=1C=CC=CC=1[C@]1(C(=O)N(CC)CC)C[C@H]1CN GJJFMKBJSRMPLA-DZGCQCFKSA-N 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229960000357 lisdexamfetamine dimesylate Drugs 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 1
- 229960005060 lorcaserin Drugs 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005056 memory consolidation Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 229960000300 mesoridazine Drugs 0.000 description 1
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229940042053 methotrimeprazine Drugs 0.000 description 1
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940060942 methylin Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Chemical group 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
- 229960001816 oxcarbazepine Drugs 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000761 pemoline Drugs 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 230000000858 peroxisomal effect Effects 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- VZPGINJWPPHRLS-UHFFFAOYSA-N phenazine-2,3-diamine Chemical compound C1=CC=C2N=C(C=C(C(N)=C3)N)C3=NC2=C1 VZPGINJWPPHRLS-UHFFFAOYSA-N 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 230000002385 psychotomimetic effect Effects 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229960003770 reboxetine Drugs 0.000 description 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 1
- 229960003015 rimonabant Drugs 0.000 description 1
- 229940106887 risperdal Drugs 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- 229940099204 ritalin Drugs 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009151 sensory gating Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 108010080511 serum sodium transport inhibitor Proteins 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 235000009561 snack bars Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940012488 strattera Drugs 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 239000001797 sucrose acetate isobutyrate Substances 0.000 description 1
- 235000010983 sucrose acetate isobutyrate Nutrition 0.000 description 1
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-O tacrine(1+) Chemical compound C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-O 0.000 description 1
- 229940065385 tenex Drugs 0.000 description 1
- 229960005333 tetrabenazine Drugs 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960005013 tiotixene Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- 229960003904 triflupromazine Drugs 0.000 description 1
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 229940013007 vyvanse Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
- 229960002911 zonisamide Drugs 0.000 description 1
- 229960004141 zuclopenthixol Drugs 0.000 description 1
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/0288—Applications, solvents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- Tannins are a group of naturally occurring compounds that exist in various plants, for example, Rhus chinensis, Rhus javanica, Rhus semialata, Rhus coriaria, Rhus potaninii, Rhus punjabensis var. sinica (Diels) Rehder &E.H. Wilson, Camellia sinensis, Berry, Bixa orellana, Vitis vinifera, Punica granatum, Quercus infectoria, Quercus cerris, Acacia mearnsii, Pseudotsuga menziesii, Caesalpinia spinosa, Fagus hayata Palib.
- tannins There are three major classes of tannins, including hydrolysable tannins (also known as tannic acids) , condensed tannins, and phlorotannins, which contain gallic acid, flavone, and phloroglucinol, respectively, as the base unit. Tannins are widely used as a type of industrial particleboard adhesive and for production of anti-corrosive primer or resins. It was also suggested that tannins may have various effects on human health.
- hydrolysable tannins also known as tannic acids
- condensed tannins condensed tannins
- phlorotannins which contain gallic acid, flavone, and phloroglucinol, respectively, as the base unit.
- Tannins are widely used as a type of industrial particleboard adhesive and for production of anti-corrosive primer or resins. It was also suggested that tannins may have various effects on human health.
- D-amino acid oxidase is a peroxisomal enzyme that oxidizes D-amino acids to the corresponding imino acids. It has been reported that DAAO is involved in the metabolism of brain D-amino acids, including D-serine, and the regulation of the glutamatergic neurotransmission. As such, DAAO is a target for treating central nervous system (CNS) disorders that are associated with D-serine and/or glutamatergic neurotransmission.
- CNS central nervous system
- the present disclosure is based at least on the development of improved enrichment methods for preparing tannic acid mixtures having enhanced bioactivity, safety, and purity profiles. Accordingly, provided herein are enrichment methods for producing tannic acid compositions and tannic acid compositions (e.g., produced by the enrichment methods disclosed herein) for use in inhibiting DAAO activity and alleviating CNS and obesity associated diseases and disorders.
- one aspect of the present disclosure features a method for preparing a tannic acid composition, the method comprising: (i) providing a composition containing tannic acids; (ii) incubating multiple batches of the composition at 20-80 °C with a first solvent sequentially to produce a first tannic acid extract; (iii) contacting the first tannic acid extract with one or more of charcoal, metal carbonate (e.g., lithium carbonate, sodium carbonate, or potassium carbonate) , and metal sulfate (e.g., calcium sulfate or magnesium sulfate) at 20-80 °C to remove substances absorbed to the charcoal and/or metal carbonate, or removed by the metal sulfate, thereby producing a first tannic acid composition; (iv) mixing the first tannic acid composition with a second solvent to form a solution; (v) contacting the solution with dichloromethane, dichloroethane, pentane, hex
- Suitable first solvents include, but are not limited to, comprises acetone, acetonitrile, methyl ethyl ketone, ethyl acetate, methyl acetate, ethanol, isopropanol, tetrahydrofuran, 1, 4-dioxane, heptane, hexane, water, or a combination thereof.
- Suitable second solvents include, but are not limited to, acetone acetonitrile, ethyl acetate, methyl acetate, methyl ethyl ketone, ethanol, isopropanol, 1, 4-dioxane, tetrahydrofuran, or a combination thereof.
- composition containing tannic acids of step (i) can be gallnut powder or gallnut chips obtained from gallnuts of a plant.
- Exemplary plants include, but not limited to, Rhus chinensis, Rhus javanica, Rhus semialata, Rhus coriaria, Rhus potaninii, Rhus punjabensis var. sinica (Diels) Rehder &E.H.
- Wilson Camellia sinensis, Berry, Bixa orellana, Vitis vinifera, Punica granatum, Quercus infectoria, Quercus cerris, Acacia mearnsii, Pseudotsuga menziesii, Caesalpinia spinosa, Fagus hayata Palib. ex Hayata, and Machilus thunbergii Sieb. &Zucc.
- the plant is Rhus chinensis, Rhus javanica, Rhus semialata, Rhus coriaria, Rhus potaninii, and Rhus punjabensis var. sinica (Diels) Rehder &E.H. Wilson.
- the gallnuts may have diameters ranging from 1-8 cm.
- the gallnuts can be Chinese belly-shaped gallnuts or horned gallnuts. When Chinese horned gallnuts are used, the diameters of such gallnuts may range from 1-8 cm, e.g., from 2-6 cm or from 3-5 cm.
- step (ii) can be performed by (a) incubating a first batch of the composition with the first solvent, (b) incubating a second batch of the composition with the mixture formed in (a) , and (c) incubating a third batch of the composition with the mixture formed in (b) to produce the first tannic acid extract.
- step (ii) can be performed at a temperature of 20-60 °C.
- step (iii) can be performed by (a) contacting the first tannic acid extract with metal carbonate at 20-60 °C to form a mixture, (b) extracting the mixture with ethyl acetate, methyl acetate, acetone, methyl ethyl ketone, acetonitrile, ethanol, isopropanol, 1, 4-dioxane, tetrahydrofuran, or a combination thereof at 20-50 °C to produce an organic solution, and (c) incubating the organic solution with the charcoal and metal sulfate at 20-60 °C simultaneously or sequentially.
- the method described herein may further comprise a step of removing dextrin, gum, and resin from the first or second tannic acid composition.
- This removing step may be performed by a process comprising (a) mixing the first tannic acid composition or the second tannic acid composition with a polar solvent and collecting the organic layer thus formed; and optionally (b) contacting the organic layer with an alkyl solvent, a chlorinated solvent, or a mixture thereof at 10-70 °C, and collecting the bottom oily layer thus formed.
- Exemplary polar solvents for use in this removing step include, but are not limited to, ethyl acetate, methyl acetate, acetone, methyl ethyl ketone, acetonitrile, ethanol, isopropanol, 1, 4-dioxane, or tetrahydrofuran.
- Exemplary alkyl solvents for use in this removing step include, but are not limited to, pentane, hexane, or heptane.
- Exemplary chlorinated solvents include, but are not limited to, dichloromethane, or dichloroethane.
- the method described herein may further comprise (a) mixing the second tannic acid composition with an alkyl solvent (e.g., pentane, hexane, or heptane) , a chlorinated solvent (e.g., dichloromethane, or dichloroethane) , or combination thereof, and (b) stirring the mixture thus formed to remove solvent residues at 10-70 °C.
- an alkyl solvent e.g., pentane, hexane, or heptane
- a chlorinated solvent e.g., dichloromethane, or dichloroethane
- the present disclosure provides a method for removing dextrin, gum, and/or resin from a tannic acid composition, comprising: (i) providing a tannic acid composition comprising dextrin, gum, resin, or a combination thereof; (ii) mixing the tannic acid composition with a polar solvent to form an organic layer; (iii) contacting the organic layer with an alkyl solvent, a chlorinated solvent, or a combination thereof at 10-70 °C; and (iv) collecting the bottom oily layer thus formed.
- the present disclosure provides a method for removing solvent residues from a tannic acid composition; comprising: (i) providing a tannic acid composition comprising residues of at least one solvent; (ii) mixing the tannic acid composition with an alkyl solvent, a chlorinated solvent, or a combination thereof to form a mixture, and (iii) stirring the mixture to remove residues of the at least one solvent at 10-70 °C.
- present disclosure features a composition
- a composition comprising (i) a mixture of tannic acids or an acceptable salt thereof, and (ii) a carrier, wherein ⁇ 98%of the tannic acids in the composition have 4-12 galloyl moieties, ⁇ 97%of the tannic acids in the composition have 5-12 galloyl moieties; ⁇ 90%of the tannic acids in the composition have 6-12 galloyl moieties; or ⁇ 60%of the tannic acids in the composition have 8-12 galloyl moieties.
- the composition contains about 4-20%of the tannic acids having 5 galloyl moieties, about 10-35%of the tannic acids having 6-7 galloyl moieties, and/or about 55-85%of the tannic acids having 8-12 galloyl moieties.
- tannic acid-containing compositions prepared by any of the enrichment methods described herein.
- composition described herein may be a pharmaceutical composition, a nutraceutical composition, a health food, or a medical food. It can be formulated as a tablet, a capsule, a soft chew, or gel.
- compositions described herein can be used in inhibiting D-amino acid oxidase (DAAO) in a subject or can be used in treating a central nervous system (CNS) disorder or a disorder associated with obesity in a subject.
- CNS disorders include, but are not limited toschizophrenia, psychotic disorders, Alzheimer’s disease, frontotemporal dementia, vascular dementia, dementia with Lewy bodies, senile dementia, mild cognitive impairment, benign forgetfulness, closed head injury, autistic spectrum disorder, Asperger’s disorder, fragile X syndrome, attention deficit hyperactivity disorders, attention deficit disorder, obsessive compulsive disorder, tic disorders, childhood learning disorders, premenstrual syndrome, depression, major depressive disorder, anhedonia, suicidal ideation and/or behaviors, bipolar disorder, anxiety disorders, panic disorder, post-traumatic stress disorder, chronic mild and unpredictable stress, eating disorders, addiction disorders, personality disorders, Parkinson’s disorder, Huntington’s disorder, multiple sclerosis, amyotrophic lateral s
- the disorder is associated with obesity, for example, eating disorders, anorexia nervosa, bulimia nervosa, stroke, coronary heart disease, heart attack, congestive heart failure, congenital heart disease, hypertension, non-alcoholic steatohepatitis, insulin resistance, hyperuricemia, hypothyroidism, osteoarthritis, gallstones, infertility, obesity hypoventilation syndrome, obstructive sleep apnea, chronic obstructed pulmonary disease, and asthma.
- Other examples include diabetes, hyperglycemia, hyperlipidemia, and hypercholesterolemia.
- composition as described herein can be formulated for administration at a frequency of three times a day to one time every two months to the subject in need of the treatment as described herein.
- the composition is for co-use with one or more additional pharmaceutical agents for treating the CNS disorder, or the disorder associated with obesity.
- the composition and the one or more additional pharmaceutical agent are administered to the subject concurrently or sequentially.
- Figure 1 is a chart showing that tannic acids as a group inhibit D-amino acid oxidase (DAAO) .
- DAAO D-amino acid oxidase
- Figure 2 is a chart showing the anti-DAAO activities of tannic acids with different numbers of galloyl moieties at 300 nM. 3 galloyl moieties showed low activity. Tannic acids with four or more 4 galloyl moieties showed higher activity in inhibiting DAAO as compared with tannic acids with 3 galloyl moieties. The higher the number of galloyl moieties, the stronger the potency in inhibiting DAAO.
- Figure 3 is a schematic illustration of an exemplary design for verifying the activity of tannic acids on improving basic behavioral functioning, anxiety, depression, memory, sensorimotor gating and cognitive behaviors.
- the mice received either a vehicle control or tannic acids at 10 mg/kg or 30 mg/kg by injection every other day. Body weights of the treated mice were measured every other day. The behavioral tests were performed on days that injections were not administered.
- FIG 4 is a chart showing the body weight changes of mice treated with a vehicle control and tannic acids at various doses as indicated during the course of the treatment. Tannic acid at 10 mg/kg arrests the weight gain while 30 mg/kg reduces the weight. This is an example for tannic acid for weight reduction and to treat obesity disorders
- Figure 5 is a chart showing dose-dependent reduction of the spontaneous locomotion activities of mice after repeated injections of tannic acids or a vehicle control.
- Figure 6 is a chart showing that tannic acids (Merck Millipore, Germany) by a single oral gavage at the various doses as indicated dose-dependently reduced locomotion activity in mice in a dose-dependent manner.
- Figure 7 includes diagrams showing the dose-dependent improvement of anxiety-like behaviors of the mice after repeated injections of tannic acids vs. vehicle control.
- Panel A aversive duration of each group.
- Panel B aversive distance ratio of each group.
- Panel C number of risk assessments of each group.
- Figure 8 is a chart showing the dose-dependent improved performance of spatial memory retrieval of mice after repeated injections of tannic acid vs. vehicle control. 30 mg/kg group of animals perform better than 10 mg/kg group.
- Figure 9 is a schematic illustration of an exemplary experimental design for verifying the effects of tannic acids in mice treating with MK-801 as described in Example 3.
- the spontaneous locomotion activity and sensorimotor function of each mouse treated either with tannic acids or vehicle control were tested by open field and prepulse inhibition, respectively, with at least 1-week interval between tests. 20 minutes prior to the MK-801 (or vehicle) administration, tannic acids (or the vehicle) were administrated to each mouse. Also, 20 minutes prior to the behavioral tests, the MK-801 (or the vehicle) was administrated to each mouse.
- Figure 10 is a chart showing the effect of tannic acids via a single oral administration in reducing MK-801-induced hyper-locomotion in a dose-dependent manner.
- Figure 11 is a chart showing the effects of tannic acids in improving prepulse inhibition in a dose-dependent manner. .
- the improvement of the prepulse inhibition is better than the controls.
- 10 mg/kg group shows less improvement of prepulse inhibition than the groups of 15, 20 and 30 mg/kg groups.
- FIG 12 is a chart showing the improving effects of tannic acids from different sources on prepulse inhibition. Tannic acid is from Sigma-Aldrich (source A) or Spectrum, USA (source B) . The improvement of the prepulse inhibition is better than the controls.
- Figure 13 is a schematic illustration of an exemplary experimental design for verifying the effects of tannic acids in mice treating with MK-801 as described in Example 3.
- the spontaneous locomotion activity and sensorimotor function of each mouse treated either with tannic acids or vehicle control in addition to MK-801 were tested by open field, prepulse inhibition, Barnes maze, sucrose preference respectively, with at least 1-week interval among tests. 20 minutes prior to the MK-801 (or vehicle) injection, tannic acid (or the vehicle) was administrated to each mouse by i.p. injection. Also, 20 minutes prior to the behavioral tests, the MK-801 (or the vehicle) was administrated to each mouse by i.p. injection.
- Figure 14 is a chart showing the effects of tannic acids in improving MK-801-induced hyperactivity in a dose-dependent manner.
- Figure 15 is a chart showing the effects of tannic acids in improving MK-801-disrupted prepulse inhibition in a dose-dependent manner.
- Figure 16 is a chart showing the effects of tannic acids in improving MK-801-disrupted working memory in a dose-dependent manner in Barnes maze.
- Figure 17 is a chart showing the effects of tannic acids in improving MK-801-disrupted sucrose preference in a dose-dependent manner.
- FIG 18 is a schematic illustration of an exemplary experimental design for verifying the effects of tannic acids in mice on von Frey test. Tannic acids (or the vehicle) were administrated to each mouse by i.p. injection.
- Figure 19 is a chart showing the improvement of paw withdrawal pain threshold over time after injection of tannic acids or vehicle control (PBS) . Tannic acid treatment much improves the pain threshold.
- Figure 20 is a diagram showing the HPLC chromatogram of the composition containing tannic acid from Ouercus infectoria. There are impurities and substantial amount of tannic acids with 1-4 galloyl moieties.
- Figure 21 includes two diagrams showing the HPLC chromatogram of the composition containing tannic acid from Rhus chinensis. There are impurities and substantial amount of tannic acids with 1-4 galloyl moieties.
- Figure 22 includes two diagrams showing the HPLC chromatogram of the composition containing tannic acid from Rhus chinensis. There are impurities and substantial amount of tannic acids with 1-4 galloyl moieties.
- FIG 23 is a diagram showing the inhibitory activities against DAAO of tannic acids extracted from gallnuts from various plant or botanic sources as indicated. Tannic acids extract from gallnut of Rhus chinensis have higher inhibitory activity than from Rhus potaninii or Quercus infectoria, and 3-4 cm diameter gallnut of Rhus chinensis have higher inhibitory activity than the 6-7 cm diameter ones.
- Figure 24 is a chart showing the effect of tannic acids from different sources, via a single oral administration, in reducing MK-801-induced hyper-locomotion. Tannic acids from Enrichment #10 method have the highest inhibitory activities.
- Figure 25 is a chart showing tannic acids extracted by Enrichment #10 method have high potency, with a ceiling effect that the 50 mg/kg group of animals performed as well as the 200 mg/kg group, in improving MK-801-disrupted prepulse inhibition.
- Figure 26 is the diagram showing the HPLC-MS chromatograms of the compositions of tannic acid from Enrichment Method #10, USP Standard, and Wenzhou Ouhai Fine Chemicals Corporation where that of Enrichment Method #10 contains less than 0.35%of non-tannic acid impurities while those of UPS Standard and Wenzhou Ouhai Fine Chemicals Corporation contain much higher quantities of non-tannic acid impurities, 15.99%and 6.46%, respectively.
- Figure 27 is a schematic illustration of an exemplary enrichment method for preparing the tannic acid compositions described herein. See also Enrichment method 11 described below.
- Tannic acids are a subfamily of tannins existing in various plants. Tannic acids extracted from plants are a mixture of polygalloyl glucoses or polygalloyl quinic acid esters containing 2-12 galloyl moieties. Provided below is the structure of an exemplary tannic acid molecule that contains 10 galloyl moieties linked to a glucose moiety.
- tannic acids have been used as an antidote to soak up poisons, and for treating short-term conditions, such as bleeding, rashes and other conditions of soreness.
- tannic acid compositions which are substantially free of small tannic acid molecules (e.g., containing ⁇ 2%by weight tannic acids having less than 4 galloyl moieties) , substantially free of dextrin, gum, and/or resin, and/or substantially free of residues of solvents used in extracting tannic acids from a suitable source (e.g., a plant source as described herein) .
- a suitable source e.g., a plant source as described herein
- substantially free of a component means that either no such component is present (i.e., undetectable by a routine method) or only minimal, trace amounts of the component are present such that it does not have any substantial impact on the properties of the composition containing such.
- substantially free of a component in a composition means less than 10%(e.g., less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1%or lower) by weight of the component based on the weight of the composition.
- tannic acid compositions containing a mixture of tannic acids which are substantially free of small tannic acid molecules, substantially free of dextrin, gum, and/or resin, and/or substantially free of residues of solvents used in extracting tannic acids from a suitable source (e.g., a plant source as described herein) .
- Such a mixture of tannic acids may be prepared by any of the methods described herein.
- the tannic acid mixtures described herein showed strong inhibitory activity against DAAO, which is known to be involved in various diseases and disorders, such as an obesity disorder, hyperlipidemia, hypercholesterolemia, hyperglycemia, diabetes, and CNS disorders.
- Such tannic acid mixtures also showed that tannic acids successfully reduced body weight and improved basic behavioral functioning, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory and cognitive behaviors in a mouse model. Further, tannic acids showed rescue and protective effects on mice treated with MK-801, an antagonist of the N-methyl-D-aspartate receptor (the NMDA receptor) .
- NMDA receptor is a glutamate receptor and ion channel protein expressed on nerve cells and plays an important role in controlling synaptic plasticity, repair, neurodevelopment, learning and memory function. Most CNS disorders have dysfunction of NMDA receptor. Accordingly, compositions containing the tannic acid mixtures described herein are expected to benefit treatment of CNS disorders associated with dysfunction of NMDA receptor. Such tannic acid compositions are also expected to benefit treatment of obesity and diseases and disorders associated with obesity.
- the improved enrichment methods described herein include one or more of the following features: (i) a multiple-batch extraction process; (ii) a dextrin/gum/resin removal process, and (iii) a solvent residue removal process.
- tannic acids can be extracted from a composition comprising tannic acids, for example, the gallnut power or chips described herein, using a suitable solvent.
- a tannic acid-containing composition may comprise a heterogeneous population of tannic acids.
- a suitable solvent can then be used in this extraction process.
- solvent refers to a liquid capable of dissolving one or more solutes.
- a solvent may comprise a pure population of a substance that dissolves a solute of interest.
- a solvent as used herein may be a mixture of multiple substances for dissolving the solute.
- a suitable solvent for extracting tannic acids comprise acetone, acetonitrile, methyl ethyl ketone, ethyl acetate, methyl acetate, ethanol, isopropanol, tetrahydrofuran, 1, 4-dioxane, pentane, hexane, heptane, water, or a combination thereof.
- the extraction process can be performed in a multiple-batch manner.
- multiple batches of the tannic acid-containing compositions may be placed into the suitable solvent sequentially, each being incubated (e.g., with stirring) in the suitable solvent for a suitable period, e.g., 1-6 hours.
- a first batch of the tannic acid-containing composition may be incubated with the suitable solvent for a suitable period, e.g., 1-6 hours or 2-4 hours.
- a second batch of the tannic acid-containing composition (which may be in substantially the same amount as the first batch) may then be placed into the suitable solvent (containing the first batch) and incubated for a suitable period, e.g., 1-6 or 2-4 hours.
- a third batch of the tannic acid-containing composition (which may also be in substantially the same amount as the first batch and/or second batch) may be placed in the same suitable solvent (containing the first and second batches) and incubate for a suitable period, e.g., 1-10 hours, 2-8 hours, or 3-6 hours. If needed, additional batches of the tannic acid-containing composition may be incubated with the suitable solvent in a similar manner. The soluble portion of the mixture then formed can then be filtered to remove insoluble substances and concentrated in vaccum to produce a crude tannic acid extract.
- the yield of tannic acids using the multiple-batch approach was found to be at least 2 fold higher than the yield of tannic acids using a single-batch approach (incubating the same total amount of the tannic acid-containing composition in the same amount of the solvent simultaneously) . See Enrichment method 11 below.
- Tannic acids extracted from a plant source such as those noted herein often contain dextrin, gum, and/or resin, which would limit therapeutic applications of the tannic acid compositions.
- the improved enrichment methods described herein may include a process that effectively removes dextrin, gum, and/or resin when needed.
- the dextrin/gum/resin removal process may be performed by mixing a tannic acid-containing composition with a suitable amount of an alkyl solvent and stirring the mixture thus formed at a suitable temperature (e.g., room temperature) for a suitable period (e.g., 1-4 hours or 2-3 hours) .
- the tannic acid-containing composition may be diluted in a suitable solvent (in which tannic acids can be dissolved, for example, acetone) if needed.
- Alkyl solvent refers to a solvent having an alkyl chain, for example, a C 1 -C 10 alkyl chain. Examples include, but are not limited to, hexane, pentane or heptane.
- the mixture can be kept for a while to allow for separation of two layers.
- the bottom oily layer thus formed can be collected. If needed, the resin-removal step can be repeated multiple times (e.g., 2-4 times) .
- the tannic acid-containing composition may be first mixed with a polar solvent for a suitable period to allow formation of an organic layer, which can be collected and subject to the following treatment with the alkyl solvent as described herein.
- a polar solvent contains molecules that are partially charges (have large dipole moments) and typically contain bonds between atoms with very different electronegativities, such as between oxygen and hydrogen.
- the polar solvent can be a protic solvent, which contains molecules having a hydrogen atom bound to an oxygen or nitrogen.
- Examples include formic acid, n-butanol, isopropanol (IPA) , nitromethane, ethanol (EtOH) , methanol (MeOH) , acetic acid, and water.
- the polar solvent can be an aprotic solvent, which lacks an acidic hydrogen. Examples include N-methylpyrrolidone, tetrahydrofuran (THF) , ethyl acetate (EtOAc) , acetone, dimethylformamide (DMF) , acetonitrile (MeCN) , dimethyl sulfoxide (DMSO) , and propylene carbonate (PC) .
- the resultant tannic acid compositions often contain solvent residues, which would also affect therapeutic applications and/or therapeutic efficacy of the tannic acid compositions.
- Provided herein is an effective approach for removing such solvent residues from tannic acid products, when needed.
- Solvent residues may be removed from tannic acid solids obtained following a routine method or the procedures described herein.
- tannic acid solids may be slurried using a suitable amount (e.g., 5-30x mL such as 20 x mL) of a suitable solvent at a suitable temperature (e.g., 40-70 °C such as 60 °C) for a suitable period (e.g., 12-24 hours, such as 16 hours) .
- the resultant mixture can then be filtered and evaporated in vacuum at a suitable temperature (e.g., 10-80 °C, preferably 60-80 °C such as 70 °C) to allow for removal of residues of solvents used in the preparation process.
- the solvent for use in this step may be an alkyl solvent (e.g., C 1 -C 10 alkyl solvent such as hexane) , a chlorinated solvent such as dichloromethane, or dichloroethane, or a combination thereof.
- this step can be repeated multiple times (e.g., 2-5 times) such that solvent residues can be removed substantially from the final tannic acid products. As shown in the table below, performing this step could significantly remove solvent residues from tannic acid compositions the preparation of which involves solvent extraction.
- tannic acid compositions that are substantially free of small tannic acid molecules (e.g., containing ⁇ 2% by weight tannic acids having less than 4 galloyl moieties) , substantially free of dextrin, gum, and/or resin, and/or substantially free of residues of solvents used in extracting tannic acids from a suitable source (e.g., a plant source as described herein) .
- a suitable source e.g., a plant source as described herein
- a tannic acid composition as described herein can be prepared as follows.
- Gallnuts from a suitable plant or botanic source e.g., those described herein, can be obtained via routine methods.
- the gallnuts can be grinded to form gallnut powers or gallnut chips.
- the gallnut power can be passed through a sieve having a suitable size (e.g., 20-mesh, 30-mesh, 40-mesh, 50-mesh, or 60-mesh) to form fine gallnut powers.
- Suitable plant sources include, but are not limited to, Rhus chinensis, Rhus javanica, Rhus semialata, Rhus coriaria, Rhus potaninii, Rhus punjabensis var. sinica (Diels) Rehder &E.H. Wilson, Camellia sinensis, Berry, Bixa orellana, Vitis vinifera, Punica granatum, Quercus infectoria, Quercus cerris, Acacia mearnsii, Pseudotsuga menziesii, Caesalpinia spinosa, Fagus hayata Palib. ex Hayata, or Machilus thunbergii Sieb.
- the tannic acid or tannic acid mixture contained in the composition herein are extracted from Rhus chinensis, Rhus javanica, Rhus semialata, Rhus coriaria, Rhus potaninii, or Rhus punjabensis var. sinica (Diels) Rehder &E.H. Wilson.
- the plant source described herein may require a nesting insect including but not limited to Andricus kollari, Andricus fecundatrix, Andricus quercuscalicis, Andricus quercuscalicis, Biorhiza pallida, Neuroterus quercusbaccarum, Neuroterus albipes, Neuroterus numismalis, Cynips quercusfolii, Melaphis chinensis (Bell) , Melaphis peitan Tsai et Tang, Nurudea sinica Tsai et Tang, Nurudea shiraiiMatsumura, Nurudea rosea Matsumura, Meitanaphis elongallis Tsai et Tang, Macrorhinarium ensigallis Tsai et Tang, Macrorhinariumovagallis Tsai et Tang, Floraphis meitanensis Tsai et Tang, Me
- the tannic acid or tannic acid mixture is extracted from gallnuts, including, but not limited to, Chinese belly-shaped gallnuts, horned gallnuts, hard ensiform gallnuts, egg-hard ensiform gallnuts, and inflorescence gallnuts of at least a plant or botanic source and requiring nesting insect described herein.
- the gallnut for use in preparing the tannic acids may have a diameter ranging from 1-8 cm (e.g., 1cm, 2cm, 3cm, 4cm, 5cm, 6cm, 7cm, or 8cm) .
- the gallnut may have a diameter ranging from 2-6 cm (e.g., 3-5 cm) .
- Crude tannic acid extracts may be extracted from the gallnut power and/or chips described herein using a conventional method or the multiple-batch approach described herein.
- the crude tannic acid extract can then be dissolved in water, an organic solvent, or a combination thereof, to form a tannic acid solution, which can be mixed with one or more of charcoal, metal carbonate (e.g., Na 2 CO 3 or K 2 CO 3 ) , and metal sulfate (e.g., CaSO 4 , MgSO 4 ) , simultaneously or sequentially, to remove undesired substances (e.g., substances that can be absorbed to the charcoal or precipitated/removed by the metal carbonate and/or metal sulfate) .
- Exemplary metal carbonates include, but are not limited to, lithium carbonate, sodium carbonate, or potassium carbonate.
- Exemplary metal sulfate can be calcium sulfate or magnesium sulfate.
- a crude tannic acid extract as described herein can be mixed with charcoal first for a suitable period of time (e.g., stirred at room temperature for 1-24 hours) .
- a metal carbonate and/or a metal sulfate e.g., Na 2 CO 3 , K 2 CO 3 , CaSO 4 and/or MgSO 4
- a suitable temperature e.g., room temperature
- a suitable period e.g., 30 minutes to 6 hours
- the mixture can then be filtered through, e.g., a bed of Celite, washed with a suitable solvent (e.g., acetone, acetonitrile, methyl ethyl ketone, ethyl acetate, ethanol, or a combination thereof) , and concentrated by a routine method to produce a tannic acid composition.
- a suitable solvent e.g., acetone, acetonitrile, methyl ethyl ketone, ethyl acetate, ethanol, or a combination thereof
- the crude tannic acid extract can be mixed with charcoal first for a suitable period of time (e.g., stirred at room temperature for 1-24 hours, for example, 6-12 hours or 12-18 hours) .
- the charcoal can then be removed from the mixture to form a solution.
- a metal carbonate and/or metal sulfate e.g., Na 2 CO 3 , K 2 CO 3 , CaSO 4 and/or MgSO 4
- a suitable temperature e.g., room temperature
- a suitable period e.g., 30 minutes to 6 hours, for example, 30 minutes to 2 hours or to 1 hour
- the mixture can then be filtered through, e.g., a bed of Celite, washed with a suitable solvent (e.g., acetone, acetonitrile, methyl ethyl ketone, ethyl acetate, methyl acetate, ethanol, or a combination thereof) , and concentrated by a routine method to produce a tannic acid composition.
- a suitable solvent e.g., acetone, acetonitrile, methyl ethyl ketone, ethyl acetate, methyl acetate, ethanol, or a combination thereof
- a tannic acid mixture formed in any of the steps described above may be placed in a suitable amount of ethyl acetate, methyl acetate, and/or methyl ethyl ketone (e.g., 3-8 x mL or 6x mL) and incubated at a suitable temperature (e.g., room temperature) for a suitable period (e.g., 1-2 hours) .
- a suitable temperature e.g., room temperature
- a suitable period e.g., 1-2 hours
- a crude tannic acid extract as described herein can be incubated with a metal carbonate at a suitable temperature (e.g., 20-60 °C such as 30-40 °C) for a suitable period.
- the mixture thus formed can then be extracted by a suitable amount of ethyl acetate, methyl acetate, and/or methyl ethyl ketone (e.g., 3-8 x mL or 6x mL) and incubated at a suitable temperature (e.g., room temperature or 20-50 °C) for a suitable period (e.g., 1-2 hours) to produce an organic solution.
- the organic solution can be incubated with charcoal and one or more metal sulfate, either simultaneously or sequentially, to remove substances absorbed to the charcoal and/or substances precipitated by the metal sulfate, thereby producing an enriched tannic acid mixture.
- the tannic acid mixture can be filtered through, e.g., a bed of Celite, washed with a suitable solvent (e.g., acetone, acetonitrile, methyl ethyl ketone, ethyl acetate, methyl acetate, ethanol, or a combination thereof) , and concentrated by a routine method to produce a tannic acid composition.
- a suitable solvent e.g., acetone, acetonitrile, methyl ethyl ketone, ethyl acetate, methyl acetate, ethanol, or a combination thereof
- any of the tannic acid mixtures described herein may also be incubated with silicon dioxide for a suitable period to further remove undesired substances.
- any of the crude tannic acid extracts or enriched tannic acid mixtures as described herein may be subject to the process of removing dextrin/gum/resin as described herein.
- the resultant oily residues may be diluted in a suitable solvent, for example, acetone, acetonitrile, methyl ethyl ketone, ethyl acetate, methyl acetate, pentane, hexane, heptane, or a combination thereof.
- the solution thus formed can be stirred and a chlorinated solvent such as CH 2 Cl 2 or dichloroethane can be added to the solution slowly in a dropwise manner to allow for precipitation of the desired tannic acids.
- the solids can then be collected by routine practice (e.g., filtration and/or drying) to produce an enriched tannic acid composition.
- the tannic acid solids thus prepared can then be subject to the solvent residual removal process described herein.
- a method comprising (i) grinding gallnuts of a suitable plant to form fine powder or small chips; (ii) extracting the find powder or small chips with a first solvent (e.g., those described herein) via the multiple-batch approach as described herein to produce a crude tannic acid extract; (iii) dissolving the crude tannic acid extract in water and mixing the tannic acid solution thus formed with K 2 CO 3 ; (iv) extracting the mixture formed in (iii) with a suitable solvent (e.g., ethyl acetate) and collecting the organic layer thus formed; (v) mixing the organic layer with charcoal and stirring the mixture thus formed for a suitable period (e.g., 0.5 hour) ; (vi) incubating the mixture with MgSO 4 for a suitable period; (vii) filtering the mixture formed in (vi) through Celite and collecting the filtrate; (viii) mixing the filtrate (which may be diluted) with an alkyl solvent (e.g.,
- compositions for example, pharmaceutical compositions, health food product such as nutraceutical compositions, and medical food that comprise one or more tannic acids and a carrier, e.g., a pharmaceutically acceptable carrier and/or an edible carrier.
- a carrier e.g., a pharmaceutically acceptable carrier and/or an edible carrier.
- Such carriers either naturally occurring or non-naturally occurring (synthetic) , may confer various benefits to the tannic acids in the composition, for example, improving in vitro and/or in vivo stability of the tannic acids, enhancing bioavailability of the tannic acids, increasing bioactivity of the tannic acids, and/or reducing side effects.
- Suitable carriers include, but are not limited to, diluents, fillers, salts, buffers, stabilizers, solubilizers, buffering agents, preservatives, or a combination thereof.
- the carrier may comprise benzoate such as sodium benzoate.
- the tannic acid populations in the compositions described herein may be substantially free of small tannic acid molecules (e.g., containing ⁇ 2%by weight tannic acids having less than 4 galloyl moieties) , substantially free of dextrin, gum, and/or resin, and/or substantially free of residues of solvents used in extracting tannic acids from a suitable source (e.g., a plant source as described herein) .
- a suitable source e.g., a plant source as described herein
- substantially free of a component means that either no such component is present (i.e., undetectable by a routine method) or only minimal, trace amounts of the component are present such that it does not have any substantial impact on the properties of the composition containing such.
- substantially free of a component in a composition means less than 10% (e.g., less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1%or lower) by weight of the component based on the weight of the composition.
- tannic acid populations may be prepared by any of the improved enrichment methods described herein.
- the tannic acid-containing composition described herein differs from the naturally-occurring tannic acid compositions in various aspects.
- the tannic acid mixture in the composition is substantially free of tannic acids having less than 4 galloyl moieties, which exist in naturally-occurring tannic acid mixtures. Removal of the tannic acids having a low number of galloyl moieties can enhance the biological activity (e.g., inhibiting DAAO) of the resultant tannic acid mixture.
- the composition described herein contain tannic acids having a high number of gallolyl moieties (e.g., 5-12, 6-12, 7-12, or 8-12) at a level substantially greater than such tannic acids in naturally-occurring tannic acid mixtures.
- the tannic acid populations contained in the composition described herein showed enhanced biological activity (e.g., inhibiting DAAO) as compared with tannic acids having lower numbers of gallolyl moieties.
- the composition may contain a substantially homogeneous population of tannic acids, as opposed to the heterogeneous population of tannic acids existing in nature.
- the composition described herein may contain ⁇ 98% (e.g., 98.5%, 99%, or 99.5%) of tannic acids that have 4-12 galloyl moieties.
- the composition may contain ⁇ 97% (e.g., 97.5%, 98%, 98.5%, 99%, or 99.5%) of tannic acids that have 5-12 galloyl moieties.
- the composition may contain ⁇ 90% (e.g., 92%, 95%, 97%, 98%, or higher) of tannic acids that have 6-12 galloyl moieties.
- the composition described herein may contain ⁇ 60% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, or higher) of tannic acids that have 8-12 galloyl moieties.
- the composition described herein may contain about 4-20%(e.g., about10-20%such as about 15%) of tannic acids having 5 galloyl moieties, about 10-35%(e.g., about 15-25%such as about 20%) of tannic acids having 6-7 galloyl moieties, and about 55-85% (e.g., about 55-65%such as about 60%or 65%) of tannic acids having 8-12 galloyl moieties.
- tannic acid populations described herein may be mixed with one or more carriers (e.g., pharmaceutically acceptable carriers) to form compositions.
- carriers e.g., pharmaceutically acceptable carriers
- pharmaceutically-acceptable salts refers to the relatively non-toxic, inorganic or organic base addition salts of tannic acids. These salts can be prepared in situ in the administration vehicle or the dosage form manufacturing process, or by separately reacting the one or more tannic acids with a suitable organic or inorganic base, and isolating the salt thus formed during subsequent purification.
- Suitable inorganic bases include, but are not limited to, sodium hydroxide, barium hydroxide, iron (ii) hydroxide, iron (III) hydroxide, magnesium hydroxide, calcium hydroxide, aluminium hydroxide, ammonium hydroxide, potassium hydroxide, caesium hydroxide, or lithium hydroxide.
- Suitable organic bases include, but are not limited to, pyridine, methyl amine, imidazole, benzimidazole, histidine, phosphazene bases, or a hydroxide of an organic cation such as quaternary ammonium hydroxide and phosphonium hydroxide. See, for example, Berge et al. (1977) J. Pharm. Sci. 66: 1-19.
- the tannic acid-containing compositions as described herein can be used for treating any of the target diseases as described herein.
- the tannic acid population in the composition is substantially free of condensed tannins and/or phlorotannins.
- “Acceptable” means that the carrier must be compatible with the active ingredient of the composition (and preferably, capable of stabilizing the active ingredient) and not deleterious to the subject to be treated.
- Pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers and other material which are well-known in the art. Exemplary pharmaceutically acceptable carriers for tannic acids or salts thereof in particular are described in U.S. Patent No. 5,211,657. Such preparations may routinely contain salt, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention.
- Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from a suitable inorganic base, (e.g., sodium hydroxide, barium hydroxide, iron (ii) hydroxide, iron (III) hydroxide, magnesium hydroxide, calcium hydroxide, aluminium hydroxide, ammonium hydroxide, potassium hydroxide, caesium hydroxide, or lithium hydroxide) or a suitable organic base (e.g., pyridine, methyl amine, imidazole, benzimidazole, histidine, phosphazene bases, or a hydroxide of an organic cation such as quaternary ammonium hydroxide and phosphonium hydroxide) .
- pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as lithium, sodium, potassium or calcium salts.
- the tannic acid-containing pharmaceutical compositions as described herein can comprise pharmaceutically acceptable carriers, excipients, or stabilizers in the form of lyophilized formulations or aqueous solutions.
- pharmaceutically acceptable carriers, excipients, or stabilizers in the form of lyophilized formulations or aqueous solutions.
- Remington The Science and Practice of Pharmacy 20th Ed. (2000) Lippincott Williams and Wilkins, Ed. K. E. Hoover.
- Such carriers, excipients or stabilizers may enhance one or more properties of the active ingredients (e.g., tannic acids) in the compositions described herein, e.g., bioactivity, stability, bioavailability, and other pharmacokinetics and/or bioactivities.
- Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations used, and may comprise buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; benzoates, sorbate and m-cresol) ; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine,
- sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing tannic acids, which matrices are in the form of shaped articles, e.g., films, or microcapsules.
- sustained-release matrices include polyesters, hydrogels (for example, poly (2-hydroxyethyl-methacrylate) , or poly (vinylalcohol) ) , polylactides (U.S. Pat. No.
- copolymers of L-glutamic acid and 7 ethyl-L-glutamate copolymers of L-glutamic acid and 7 ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT TM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate) , sucrose acetate isobutyrate, and poly-D- (-) -3-hydroxybutyric acid.
- LUPRON DEPOT TM injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate
- sucrose acetate isobutyrate sucrose acetate isobutyrate
- poly-D- (-) -3-hydroxybutyric acid poly-D- (-) -3-hydroxybutyric acid.
- compositions to be used for in vivo administration must be sterile. This is readily accomplished by, for example, filtration through sterile filtration membranes.
- Therapeutic compositions are generally placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
- compositions described herein can be in unit dosage forms such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal administration, or administration by inhalation or insufflation, or jntrathecal or intracerebral routes.
- the principal active ingredient can be mixed with a pharmaceutical carrier, e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g., water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof.
- a pharmaceutical carrier e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g., water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof.
- preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
- This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention.
- the tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
- Suitable surface-active agents include, in particular, non-ionic agents, such as polyoxyethylenesorbitans (e.g., Tween TM 20, 40, 60, 80 or 85) and other sorbitans (e.g., Span TM 20, 40, 60, 80 or 85) .
- Compositions with a surface-active agent will conveniently comprise between 0.05 and 5%surface-active agent, and can be between 0.1 and 2.5%. It will be appreciated that other ingredients may be added, for example mannitol or other pharmaceutically acceptable vehicles, if necessary.
- Suitable emulsions may be prepared using commercially available fat emulsions, such as Intralipid TM , Liposyn TM , Infonutrol TM , Lipofundin TM and Lipiphysan TM .
- the active ingredient may be either dissolved in a pre-mixed emulsion composition or alternatively it may be dissolved in an oil (e.g., soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil) and an emulsion formed upon mixing with a phospholipid (e.g. egg phospholipids, soybean phospholipids or soybean lecithin) and water.
- an oil e.g., soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil
- a phospholipid e.g. egg phospholipids, soybean phospholipids or soybean lecithin
- Suitable emulsions will typically contain up to 20%oil, for example, between 5 and 20%.
- the fat emulsion can comprise fat droplets between 0.1 and 1.0 ⁇ m, particularly 0.1 and 0.5 ⁇ m, and have a pH in the range of 5.5 to 8.0.
- compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
- the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as set out above.
- the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
- compositions in preferably sterile pharmaceutically acceptable solvents may be nebulized by use of gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device may be attached to a face mask, tent or intermittent positive pressure breathing machine. Solution, suspension or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.
- any of the tannic acid-containing pharmaceutical compositions may further comprise a second therapeutic agent based on the intended therapeutic uses of the composition.
- the second therapeutic agent is an anti-obesity agent, including, but not limited to, orlistat, lorcaserin, sibutramine, rimonabant, metformin, exenatide, pralintide, phentermine, fenfluramine, dexfenfluramine topiramate, dinitrophenol, bupropion, and zonisamide.
- an anti-obesity agent including, but not limited to, orlistat, lorcaserin, sibutramine, rimonabant, metformin, exenatide, pralintide, phentermine, fenfluramine, dexfenfluramine topiramate, dinitrophenol, bupropion, and zonisamide.
- the second therapeutic agent is an agent for treating a CNS disease/disorder.
- a therapeutic agent may be an antipsychotic drug.
- antipsychotic drugs include, but are not limited to, butyrophenone (e.g., haloperidol (HALDOL TM ) , phenothiazine (e.g., chlorpromazine (THORAZINE TM ) , fluphenazine (PROLIXIN TM ) , perphenazine (TRILAFON TM ) , prochlorperazine (COMPAZINE TM ) , thioridazine (MELLARIL TM ) , trifluoperazine (STELAZINE TM ) , mesoridazine, promazine, triflupromazine (VESPRIN TM ) , levomepromazine (NOZINAN TM ) , promethazine (PHENERGAN TM ) , thioxanthene
- the second therapeutic agent can be an antidepressant and/or mood stabilizer.
- the antidepressant comprises a monoamine oxidase inhibitor (MAOI) , a tricyclic antidepressant (TCA) , a tetracyclic antidepressant (TeCA) , a selective serotonin reuptake inhibitor (SSRI) , a noradrenergic and specific serotonergic antidepressant (NASSA) , a norepinephrine (noradrenaline) reuptake inhibitor, a norepinephrine-dopamine reuptake inhibitor, and/or a serotonin-norepinephrine reuptake inhibitor (SNRI) .
- MAOI monoamine oxidase inhibitor
- TCA tricyclic antidepressant
- TeCA tetracyclic antidepressant
- SSRI selective serotonin reuptake inhibitor
- NASSA noradrenergic and
- Exemplary SSRIs include fluoxetine (PROZAC TM ) , paroxetine (PAXIL TM , SEROXAT TM ) , escitalopram (LEXAPRO TM , ESIPRAM TM ) , citalopram (CELEXA TM ) , sertraline (ZOLOFT TM ) , fluvoxamine (LUVOX TM ) ) .
- Exemplary SNRIs include venlafaxine (EFFEXOR TM ) , milnacipram and duloxetine (CYMBALTA TM ) .
- Additional antidepressant include a noradrenergic and specific serotonergic antidepressant (NASSA) (e.g., mirtazapine (AVANZA TM , ZISPIN TM , REMERON TM ) , or mianserin, a norepinephrine (noradrenaline) reuptake inhibitor (NRI) (e.g., reboxetine (EDRONAX TM ) ) , a norepinephrine-dopamine reuptake inhibitors (e.g., bupropion (WELLBUTRIN TM , ZYBAN TM ) ) , amitriptyline, nortriptiline, protriptyline, desipramine, imipramine, trimipramine, amoxapine, bupropion, bupropion SR, clomipramine, doxepin, isocarboxazid, venlafaxine XR, tranylcypro
- the second therapeutic agent can be an agent for the treatment of ADD and/or ADHD.
- Suitable ADHD medications include, but are not limited to amphetamine, modafinil, desoxyn, methamphetamine, cocaine, arecoline, dexmethylphenidate (focalin, focalin XR) , dextroamphetamine (dexedrine, dexedrine spansules, dextroamphetamine ER, dextrostat) , methylphenidate (concerta, daytrana, metadate CD, metadate ER, methylin, methylin ER, ritalin, ritalin-LA, ritalin-SR) , lisdexamfetamine dimesylate (Vyvanse) , mixed salts amphetamine (Adderall, Adderall XR) , atomoxetine (Strattera) , clonidine hydrochloride (Catapres) , gua
- the second therapeutic agent may be an agent for use in treating a cognitive disorder, and/or a condition characterized by neurodegeneration (e.g., Alzheimer's disease, or Parkinson's disease) .
- Such therapeutic agents include, but are not limited to tacrine, rivastigmine, memantine (AXURA TM , AKATINOL TM , NAMENDA TM , EBIXA TM , ABIXA TM ) , donepezil (Aricept TM ) , physostigmine, nicotine, arecoline, huperzine alpha, selegiline, rilutek TM (riluzole) , vitamine c, vitamine e, carotenoids, ginkgo biloba, and the like.
- the tannic acid-containing compositions described herein can be a health food product, which can be any kinds of liquid and solid/semi-solid materials that are used for nourishing humans and animals, for improving basic behavioral functioning, hyperactivity, anxiety, depression, suicidal ideation and/or behavior, sensorimotor gating, pain threshold, memory and/or cognitive functioning, or for facilitating treatment of any of the target diseases noted herein (e.g., an obesity disorder, hyperlipidemia, hyperglycemia, diabetes, or a CNS disorder, including those described herein) .
- the target diseases noted herein e.g., an obesity disorder, hyperlipidemia, hyperglycemia, diabetes, or a CNS disorder, including those described herein.
- the health food product may be a food product (e.g., tea-based beverages, juice, soft drinks, coffee, milk, jelly, cookies, cereals, chocolates, snack bars, herbal extracts, dairy products (e.g., ice cream, and yogurt) ) , a food/dietary supplement, or a nutraceutical formulation.
- a food product e.g., tea-based beverages, juice, soft drinks, coffee, milk, jelly, cookies, cereals, chocolates, snack bars, herbal extracts, dairy products (e.g., ice cream, and yogurt)
- a food/dietary supplement e.g., a nutraceutical formulation.
- the health food product described herein containing one or more tannic acids (e.g., the tannic acid mixture described herein or the substantially homogenous population of a tannic acid having a defined number of galloyl moieties as also described herein) , may comprise one or more edible carriers, which confer one or more of the benefits to the tannic acids in the product as described herein.
- edible carriers include starch, cyclodextrin, maltodextrin, methylcellulose, carbonmethoxy cellulose, xanthan gum, and aqueous solutions thereof.
- the healthy food products described herein may further include neuroprotective foods, such as fish oil, flax seed oil, and/or benzoate.
- the healthy food product is a nutraceutical composition, which refers to compositions containing components from food sources and conferring extra health benefits in addition to the basic nutritional value found in foods.
- a nutraceutical composition as described herein comprises the tannic acid content described herein (e.g., the tannic acid mixture or the substantially homogenous tannic acid population as described herein) and additional ingredients and supplements that promote good health and/or enhance stability and bioactivity of the tannic acids.
- nutraceutical compositions may be fast or/and short-term or may help achieve long-term health objectives as those described herein, e.g., improving basic behavioral functioning, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory and/or cognitive functioning in, e.g., human subjects who have or are at risk for diseases associated with DAAO such as CNS disorders or human subjects who have or are at risk for an obesity disorder.
- the nutraceutical compositions may be contained in an edible material, for example, as a dietary supplement or a pharmaceutical formulation. As a dietary supplement, additional nutrients, such as vitamins, minerals or amino acids may be included.
- the composition can also be a drink or a food product, e.g., tea, soft drink, juice, milk, coffee, cookie, cereal, chocolate, and snack bar.
- a sweetener such as sorbitol, maltitol, hydrogenated glucose syrup and hydrogenated starch hydrolyzate, high fructose corn syrup, cane sugar, beet sugar, pectin, or sucralose.
- the nutraceutical composition disclosed herein can be in the form of a solution.
- the nutraceutical formulation can be provided in a medium, such as a buffer, a solvent, a diluent, an inert carrier, an oil, or a creme.
- the formulation is present in an aqueous solution that optionally contains a non-aqueous co-solvent, such as an alcohol.
- the nutraceutical composition can also be in the form of powder, paste, jelly, capsule, or tablet. Lactose and corn starch are commonly used as diluents for capsules and as carriers for tablets. Lubricating agents, such as magnesium stearate, are typically added to form tablets.
- the health food products may be formulated for a suitable administration route, for example, oral administration.
- the composition can take the form of, for example, tablets or capsules, prepared by conventional means with acceptable excipients such as binding agents (for example, pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose) ; fillers (for example, lactose, microcrystalline cellulose or calcium hydrogen phosphate) ; lubricants (for example, magnesium stearate, talc or silica) ; disintegrants (for example, potato starch or sodium starch glycolate) ; or wetting agents (for example, sodium lauryl sulphate) .
- binding agents for example, pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
- fillers for example, lactose, microcrystalline cellulose or calcium hydrogen phosphate
- lubricants for example, magnesium stearate, talc or silica
- the health food product can be in a liquid form and the one or more edible carriers can be a solvent or dispersion medium comprising but not limited to, ethanol, polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol) , lipids (e.g., triglycerides, vegetable oils, liposomes) or combinations thereof.
- the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin; by the maintenance of the required particle size by dispersion in carriers such as, for example liquid polyol or lipids; by the use of surfactants such as, for example hydroxypropylcellulose; or combinations thereof.
- an isotonic agent such as, for example, sugars, sodium chloride or combinations thereof.
- Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use.
- the liquid preparations can be formulated for administration with fruit juice.
- Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (for example, sorbitol syrup, cellulose derivatives or hydrogenated edible fats) ; emulsifying agents (for example, lecithin or acacia) ; non-aqueous vehicles (for example, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils) ; and preservatives (for example, methyl or propyl-p-hydroxybenzoates, benzoate or sorbate) .
- suspending agents for example, sorbitol syrup, cellulose derivatives or hydrogenated edible fats
- emulsifying agents for example, lecithin or acacia
- non-aqueous vehicles for example, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils
- preservatives for example, methyl or propyl-p-hydroxybenzoates, benzoate or sorbate
- the health food products described herein may further comprise one or more second therapeutic agents, including those described herein.
- the present disclosure also provides compositions of medical food products, use in improving basic behavioral functioning, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory and/or cognitive functioning, and/or for treating a target disease as described herein (e.g., an obesity disorder, hyperlipidemia, hyperglycemia, diabetes, or a CNS disorder) .
- a medical food product is a food product formulated to be consumed or administered enterally. Such a food product is usually used under the supervision of a physician for the specific dietary management of a target disease, such as those described herein.
- such a medical food composition is specially formulated and processed (as opposed to a naturally occurring foodstuff used in a natural state) for a patient in need of the treatment (e.g., human patients who suffer from illness or who requires use of the product as a major active agent for alleviating a disease or condition via specific dietary management. )
- a medical food composition described herein is not one of those that would be simply recommended by a physician as part of an overall diet to manage the symptoms or reduce the risk of a disease or condition.
- any of the medical food compositions described herein comprising one or more tannic acid molecules or salts thereof and at least one carrier (e.g., those described herein)
- at least one carrier e.g., those described herein
- the at least one carrier which can be either naturally-occurring or synthetic (non-naturally occurring) , would confer one or more benefits to the tannic acid content in the composition, for example, stability, bioavailability, and/or bioactivity.
- Any of the carriers described herein may be used for making the medical food composition.
- the medical food composition may further comprise one or more additional ingredients selected from the group including, but not limited to natural flavors, artificial flavors, major trace and ultra-trace minerals, minerals, vitamins, oats, nuts, spices, milk, egg, salt, flour, lecithin, xanthan gum and/or sweetening agents.
- the medical food composition may be placed in a suitable container, which may further comprise at least an additional therapeutic agent such as those described herein.
- kits for use in improving basic behavioral functioning, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory and/or cognitive functioning, and/or for treating a target disease as described herein (e.g., an obesity disorder, hyperlipidemia, hyperglycemia, diabetes, or a CNS disorder) .
- a target disease e.g., an obesity disorder, hyperlipidemia, hyperglycemia, diabetes, or a CNS disorder
- kits can include one or more containers comprising a tannic acid-containing composition as described herein and optionally one or more of the second therapeutic agents as also described herein.
- the kit can comprise instructions for use in accordance with any of the methods described herein.
- the included instructions can comprise, for example, a description of administration of the tannic acid-containing composition and optionally a description of administration of the second therapeutic agent (s) to improve basic behavioral functioning, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory and/or cognitive functioning, or to treat a target disease as described herein.
- the kit may further comprise a description of selecting an individual suitable for treatment based on identifying whether that individual has the disease or is at risk for the disease.
- the instructions comprise a description of administering one or more agents of the disclosure to an individual at risk of the disease or to an individual who is in need of improving basic behavioral functioning, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory and/or cognitive functioning.
- the instructions relating to the use of the tannic acid-containing composition to achieve the intended therapeutic effects generally include information as to dosage, dosing schedule, and route of administration for the intended treatment.
- the containers may be unit doses, bulk packages (e.g., multi-dose packages) or sub-unit doses.
- Instructions supplied in the kits of the invention are typically written instructions on a label or package insert (e.g., a paper sheet included in the kit) , but machine-readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.
- the label or package insert may indicate that the composition is used for the intended therapeutic utilities. Instructions may be provided for practicing any of the methods described herein.
- kits of this invention are in suitable packaging.
- suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags) , and the like.
- packages for use in combination with a specific device such as an inhaler, nasal administration device (e.g., an atomizer) or an infusion device such as a minipump.
- a kit may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle) .
- the container may also have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle) .
- Kits may optionally provide additional components such as buffers and interpretive information.
- the kit comprises a container and a label or package insert (s) on or associated with the container.
- the invention provides articles of manufacture comprising contents of the kits described above.
- compositions described herein may be used to improve basic behavioral functioning, weight reduction, hyperactivity, anxiety, depression, suicidal ideation and/or behavior, sensorimotor gating, pain threshold, memory, and/or cognitive functioning in a subject in need of the treatment.
- Such compositions may also be used to treating diseases or disorders associated with DAAO such as a central nervous disorder (e.g., those described herein) .
- the compositions may also be used to treating an obesity disorder.
- treating refers to the application or administration of a composition including one or more active agents to a subject, who is in need of the treatment, for example, having a target disease or disorder, a symptom of the disease/disorder, or a predisposition toward the disease/disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disorder, the symptom of the disease, or the predisposition toward the disease or disorder.
- Alleviating a target disease/disorder includes delaying the development or progression of the disease, or reducing disease severity. Alleviating the disease does not necessarily require curative results. As used therein, “delaying” the development of a target disease or disorder means to defer, hinder, slow, retard, stabilize, and/or postpone progression of the disease. This delay can be of varying lengths of time, depending on the history of the disease and/or individuals being treated.
- a method that “delays” or alleviates the development of a disease, or delays the onset of the disease is a method that reduces probability of developing one or more symptoms of the disease in a given time frame and/or reduces extent of the symptoms in a given time frame, when compared to not using the method. Such comparisons are typically based on clinical studies, using a number of subjects sufficient to give a statistically significant result.
- “Development” or “progression” of a disease means initial manifestations and/or ensuing progression of the disease. Development of the disease can be detectable and assessed using standard clinical techniques as well known in the art. However, development also refers to progression that may be undetectable. For purpose of this disclosure, development or progression refers to the biological course of the symptoms. “Development” includes occurrence, recurrence, and onset. As used herein “onset” or “occurrence” of a target disease or disorder includes initial onset and/or recurrence.
- an effective amount of a tannic acid-containing composition may be administered to a subject in need of the treatment via a suitable route.
- subject “individual, ” and “patient” are used interchangeably herein and refer to a mammal being assessed for treatment and/or being treated.
- Subjects may be human, but also include other mammals, particularly those mammals useful as laboratory models for human disease, e.g. mouse, rat, rabbit, dog, etc.
- a human subject who needs the treatment may be a human patient having, at risk for, or suspected of having a target disease/disorder, such as a CNS disorder, or a disease associated with obesity, e.g., diabetes, hyperglycemia, hypercholesterolemia or hyperlipidemia.
- a target disease/disorder such as a CNS disorder, or a disease associated with obesity, e.g., diabetes, hyperglycemia, hypercholesterolemia or hyperlipidemia.
- a subject having a target disease or disorder can be identified by routine medical examination, e.g., laboratory tests, organ functional tests, and/or behavior tests.
- a subject suspected of having any of such target disease/disorder might show one or more symptoms of the disease/disorder.
- a subject at risk for the disease/disorder can be a subject having one or more of the risk factors for that disease/disorder, for example, a genetic factor.
- the human subject is a child who has, is suspected of having, or is at risk for obesity or a CNS disorder associated with children, for example, attention deficit/hyperactivity disorder (ADHD) , autism, Asperger’s disorder, obsessive compulsive disorder, depression, psychosis, chronic pain, and learning disorder.
- ADHD attention deficit/hyperactivity disorder
- autism Asperger’s disorder
- obsessive compulsive disorder depression
- psychosis chronic pain
- chronic pain and learning disorder.
- CNS disorders that can be treated by the methods and compositions described herein include attention deficit/hyperactivity disorder (ADHD) , schizophrenia, pain, depression, suicidal ideation and/or behavior, bipolar disorder, tic disorder, post-traumatic stress disorder, anxiety, social anxiety disorder, panic disorder, autism, Asperger’s disorder, obsessive-compulsive disorder, learning disorder, Tourette’s syndrome, mild cognitive impairment, dementia, vascular dementia, a neurodegenerative disorder (e.g., Alzheimer’s disorder or Parkinson’s disease, frontotemporal dementia, Huntington’s disease) , nocturnal enuresis, blepharospasm, non-epileptic seizure, psychosis, mania, cerebral malaria and behavior and psychological symptoms of dementia (BPSD) .
- ADHD attention deficit/hyperactivity disorder
- BPSD neurodegenerative disorder
- a disease associated with obesity includes diseases and disorders that lead to obesity, as well as diseases and disorders that have a high occurrence rate in obesity patients.
- Obesity is a medical condition characterized by accumulation of excess body fat to the extent that it may have a negative effect on health.
- Obesity may be determined by body mass index (BMI) , a measurement obtained by dividing a person’s weight by the square of the person’s height. For example, BMI over 30 kg/m 2 may indicate obesity.
- BMI body mass index
- Exemplary diseases associated with obesity include, but are not limited to, eating disorders, anorexia nervosa, bulimia nervosa, stroke, coronary heart disease, heart attack, congestive heart failure, congenital heart disease, hypertension, non-alcoholic steatohepatitis, insulin resistance, hyperuricemia, hypothyroidism, osteoarthritis, gallstones, infertility, obesity hypoventilation syndrome, obstructive sleep apnea, chronic obstructed pulmonary disease, and asthma.
- an effective amount refers to the amount of each active agent (e.g., the tannic acid mixture or the substantially homogenous population of tannic acids as described herein) required to confer therapeutic effect on the subject, either alone or in combination with one or more other active agents, such as one or more of the second therapeutic agents described herein.
- the therapeutic effect is to inhibit the activity of DAAO (e.g., by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or higher) in the subject.
- the therapeutic effect is improvement of basic behavioral functioning, weight reduction, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory, and/or improvement of cognitive functioning.
- the therapeutic effect is alleviating one or more symptoms associated with any of the CNS disorders described herein. Alternatively or in addition, the therapeutic effect is maintaining or reducing body weight of the subject.
- Empirical considerations such as the half-life, generally will contribute to the determination of the dosage.
- Frequency of administration may be determined and adjusted over the course of therapy, and is generally, but not necessarily, based on treatment and/or suppression and/or amelioration and/or delay of a target disease/disorder.
- sustained continuous release formulations of a composition as described herein may be appropriate.
- Various formulations and devices for achieving sustained release are known in the art.
- an exemplary daily dosage might range from about any of 0.1 ⁇ g/kg to 3 ⁇ g/kg to 30 ⁇ g/kg to 300 ⁇ g/kg to 3 mg/kg, to 30 mg/kg to 100 mg/kg or more, depending on the factors mentioned above.
- the treatment is sustained until a desired suppression of symptoms occurs or until sufficient therapeutic levels are achieved to alleviate a target disease or disorder, or a symptom thereof.
- An exemplary dosing regimen comprises administering one or more initial doses at a suitable interval over a suitable period. If necessary, multiple maintenance doses can be given to the subject at a suitable interval over a suitable period of time.
- dosage regimens may be useful, depending on the pattern of pharmacokinetic decay that the practitioner wishes to achieve. For example, dosing from one to four times a day or a week is contemplated. In some embodiments, dosing ranging from about 3 ⁇ g/mg to about 2 mg/kg (such as about 3 ⁇ g/mg, about 10 ⁇ g/mg, about 30 ⁇ g/mg, about 100 ⁇ g/mg, about 300 ⁇ g/mg, about 1 mg/kg, and about 2 mg/kg) may be used.
- dosing frequency can be three times a day, twice a day, once a day, once every other day, once every week, once every 2 weeks, once every 4 weeks, once every 2 months, or once every 3 months.
- the dosing regimen can vary over time.
- doses ranging from about 0.3 to 50.00 mg/kg/day (e.g., 0.5 to 40 mg/kg/day, 1-30 mg/kg/day, 5-30 mg/kg/day, or 10-20 mg/kg/day) may be administered.
- the particular dosage regimen i.e., dose, timing and repetition, will depend on the particular individual and that individual's medical history, as well as the properties of the individual agents (such as the half-life of the agent, and other considerations well known in the art) .
- the appropriate dosage of a tannic acid-composition as described herein will depend on the specific tannic acid or tannic acid mixture, and/or other active ingredient employed, the type and severity of the disease/disorder, whether the composition is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the DAAO inhibitor, and the discretion of the attending physician. Typically the clinician will administer a composition, until a dosage is reached that achieves the desired result.
- compositions e.g., a pharmaceutical composition, a health food composition, a nutraceutical composition or a medical food composition
- This composition can also be administered via other conventional routes, e.g., administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
- parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques.
- it can be administered to the subject via injectable depot routes of administration such as using 1-week, half (or two week) -, 1-, 3-, or 6-month depot injectable or biodegradable materials and methods.
- the pharmaceutical composition is administered intraocularlly or intravitreally.
- Injectable compositions may contain various carriers such as vegetable oils, dimethylactamide, dimethyformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, and polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like) .
- water-soluble antibodies can be administered by the drip method, whereby a pharmaceutical formulation containing tannic acids and a physiologically acceptable excipient is infused.
- Physiologically acceptable excipients may include, for example, 5%dextrose, 0.9%saline, Ringer’s solution or other suitable excipients.
- Intramuscular preparations e.g., a sterile formulation of a suitable soluble salt form of tannic acids
- a pharmaceutical excipient such as Water-for-Injection, 0.9%saline, or 5%glucose solution.
- a tannic acid-containing composition is administered via a site-specific or targeted local delivery technique.
- site-specific or targeted local delivery techniques include various implantable depot sources of the tannic acid-containing compositions or local delivery catheters, such as infusion catheters, an indwelling catheter, or a needle catheter, synthetic grafts, adventitial wraps, shunts and stents or other implantable devices, site specific carriers, direct injection, or direct application. See, e.g., PCT Publication No. WO 00/53211 and U.S. Pat. No. 5,981,568.
- Treatment efficacy for a target disease/disorder can be assessed by methods well-known in the art.
- combination therapy embraces administration of these agents (e.g., a tannic acid-containing composition and an anti-CNS disorder or anti-obesity agent) in a sequential manner, that is, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or at least two of the agents, in a substantially simultaneous manner. Sequential or substantially simultaneous administration of each agent can be affected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular, subcutaneous routes, and direct absorption through mucous membrane tissues.
- the agents can be administered by the same route or by different routes.
- a first agent e.g., a tannic acid-containing composition
- a second agent e.g., an anti-CNS disorder agent or an anti-obesity agent
- intravenously e.g., intravenously.
- sequential means, unless otherwise specified, characterized by a regular sequence or order, e.g., if a dosage regimen includes the administration of a tannic acid-containing composition and an anti-CNS disorder or anti-obesity agent, a sequential dosage regimen could include administration of the tannic acid-containing composition before, simultaneously, substantially simultaneously, or after administration of the anti-CNS disorder or anti-obesity agent, but both agents will be administered in a regular sequence or order.
- the term “separate” means, unless otherwise specified, to keep apart one from the other.
- the term “simultaneously” means, unless otherwise specified, happening or done at the same time, i.e., the agents of the invention are administered at the same time.
- the term “substantially simultaneously” means that the agents are administered within minutes of each other (e.g., within 10 minutes of each other) and intends to embrace joint administration as well as consecutive administration, but if the administration is consecutive it is separated in time for only a short period (e.g., the time it would take a medical practitioner to administer two compounds separately) .
- concurrent administration and substantially simultaneous administration are used interchangeably. Sequential administration refers to temporally separated administration of the agents described herein.
- Combination therapy can also embrace the administration of the agents described herein (e.g., a tannic acid-containing composition and an anti-CNS disorder or anti-obesity agent) in further combination with other biologically active ingredients (e.g., a different anti-CNS disorder agent) and non-drug therapies (e.g., surgery) .
- agents described herein e.g., a tannic acid-containing composition and an anti-CNS disorder or anti-obesity agent
- other biologically active ingredients e.g., a different anti-CNS disorder agent
- non-drug therapies e.g., surgery
- any combination of a tannic acid-containing composition and a second therapeutic agent may be used in any sequence for treating a target disease.
- the combinations described herein may be selected on the basis of a number of factors, which include but are not limited to the effectiveness of inhibiting DAAO, improving basic behavioral functioning, weight reduction, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory or enhancing cognitive functioning, and/or alleviating at least one symptom associated with the target disease, or the effectiveness for mitigating the side effects of another agent of the combination.
- a combined therapy described herein may reduce any of the side effects associated with each individual members of the combination, for example, a side effect associated with the second therapeutic agent.
- DAAO D-amino acid oxidase
- DAAO The activity of DAAO was determined in vitro by measuring the inhibition of the catabolism of known substrate, D-proline.
- the cofactor FAD (40 M) was added to the DAAO stock solution first.
- potential inhibitors of tannic acid (s) were mixed with reaction mixture containing phosphate buffered saline (137 mM NaCl, 3 mM KCl, 10 mM Na 2 HPO 4 , 2 mM NaH 2 PO 4 , pH 7.4) , horseradish peroxidase (5 U/ml) , o-phenylendiamine (OPD, 0.03%) , and 0.6 ⁇ g human- (or porcine-) DAAO, and incubated for about 5 min.
- phosphate buffered saline 137 mM NaCl, 3 mM KCl, 10 mM Na 2 HPO 4 , 2 mM NaH 2 PO 4 , pH 7.4
- DAP 2, 3-diaminophenazine
- the DAAO inhibitory activities of subgroups of tannic acids were determined as follows. Tannic acid fractions having different numbers of galloyl moieties were separated by a reversed-phase column (RP-18) with a mobile phase of acetonitrile and distilled water in gradient elution. The DAAO inhibitory activity of each tannic acid fraction at 80 ⁇ M (Table 2) and 300 nM ( Figure 2, Table 2) was analyzed by the method described above, using distilled water and 10%DMSO aqueous solution as blank controls and sodium benzoate as a positive control.
- Table 2 shows the anti-DAAO activities of tannic acids with different numbers of galloyl moieties. Tannic acids with four or more 4 galloyl moieties showed much higher activity in inhibiting DAAO as compared with tannic acids with less than 4 galloyl moieties. All DAAO assays were done with 80 ⁇ M of tannic acids.
- Table 4 shows the IC 50 ( ⁇ M) of anti-DAAO activities of tannic acids with different numbers of galloyl moieties.
- the IC 50 were determined for each tannic acid with different numbers of galloyl moieties, which indicating potent tannic acids with more than 3 galloyl moieties.
- Tannic acid purification with 4-9 galloyl moieties (4-9 G) exhibits stronger potency than the tannic acid mixture.
- tannic acids having more than 3 galloyl moieties enriches the potency as indicated by the smaller IC 50 , as compared to the tannic acid mixture (Table 5) .
- the results show that tannic acids having more than 3 galloyl moieties (e.g., 4-10) exhibited higher DAAO inhibition potency than the tannic acids having 3 and less galloyl moieties.
- the objective of this study was to verify the effects of multiple doses of tannic acids on basic metabolism, behavioral functioning, and cognitive behaviors.
- the body weight, spontaneous locomotion activity, anxiety-like behaviors, spatial learning and memory, depressive-like behaviors and sensorimotor gating function of each mouse were examined following the repeated injections or oral administrations of tannic acids. These activities are known to be mediated by the NMDA receptor.
- mice C57BL/6J male mice were group housed (3-5 mice per cage) with food and water available ad libitum in polysulfone ventilated cages (Alternative Design, AR, USA) in the animal rooms. The colony was maintained on a 12/12-h light/dark cycle at the temperature of 22 ⁇ 2 °C and all behavioral studies were performed during the dark cycle. All animals used in this study were adult mice (at least 2.5 months of age) .
- Tannic acids were purchased from Sigma (Sigma-Aldrich, USA) .
- the adult mice were randomly assigned to three groups: (1) control, (2) tannic acid (10 mg/kg) , and (3) tannic acid (30 mg/kg) , which were treated, respectively, by a vehicle control (PBS) , tannic acid at 10 mg/kg, and tannic acid at 30 mg/kg.
- PBS vehicle control
- tannic acid tannic acid at 10 mg/kg
- tannic acid at 30 mg/kg.
- Two weeks prior to the behavioral tests all mice were injected intraperitoneally (i.p. ) with either the vehicle control or tannic acid every other day.
- the body weight of each mouse which served as an index of its physical development and metabolism, was recorded on the day of injection.
- mice treated with either the vehicle control or the tannic acids as described above were tested sequentially by 5 tasks: (1) open field task for spontaneous locomotion test, (2) anxiety-like behaviors test by elevated plus maze, (3) spatial learning and memory test by Barnes maze, (4) depressive-like behaviors test by tail suspension, and (5) sensorimotor function test by prepulse inhibition. At least a 1-week interval was made between different tasks. In order to minimize carryover effects, the tasks were arranged in the sequence to ensure that the more stressful task did not occur prior to a less stressful one. The procedures are described in Current protocol in Neuroscience (Developmental Editor: Eric Prager, Online ISBN: 9780471142300, DOI: 10.1002/0471142301) , the relevant disclosures of which are incorporated by reference herein for the intended purposes.
- mice were placed in a cage (37.5 cm ⁇ 21.5 cm ⁇ 18 cm) under 50-65 lux light intensity. Their spontaneous locomotor activities were measured for 60 minutes using the EthoVision video tracking system (Noldus Information Technology, the Netherlands) . The travel distance of each mouse was measured as an index of locomotion activity. As shown in Figure 5, tannic acids reduced the travel distances of the treated mice in a dose-dependent manner.
- mice were administered orally at 10 mg/kg, 30 mg/kg, 100 mg/kg, 300 mg/kg, and 600 mg/kg for a single dose and their locomotion activities were measured for 30 minutes, 60 minutes, 90 minutes, and 120 minutes. Tannic acids at all tested doses reduced the locomotion of the treated mice as compared with the mice treated with the vehicle control. The results are illustrated in Figure 6.
- An elevated plus maze consisting of two open arms and two closed arms was used to assess the instinctively anxious behavior.
- the maze was elevated 50 cm from the floor with two open arms (each 50 cm long ⁇ 10 cm wide) , two closed arms plus 45 cm high walls without a roof (each 50 cm long ⁇ 10 cm wide) , and a square shaped central platform (10 ⁇ 10 cm) .
- Each mouse was placed in the central platform and faced toward one of the closed arms for observation under 50-65 lux light intensity for 5 minutes.
- the time spent on each part of the maze and travel distance on each part of maze was recorded by the EthoVision tracking system (Noldus Information Technology, the Netherlands) .
- the aversive duration ratio of each group was shown in Figure 7, Panel A.
- the tannic acid (30 mg/kg) group displayed marginal higher aversive duration ratios whereas the tannic acid (10 mg/kg) group did not.
- the aversive distance ratio of each group was shown in Figure 7, Panel B.
- the tannic acid (30 mg/kg) group displayed significant higher aversive distance ratios as compared with the control group.
- the number of risk assessments of each group is displayed in Figure 7 Panel C. As compared to the control group, both tannic acid groups displayed significant lower risk assessments (all p ⁇ 0.05) .
- mice were tested in the Barnes maze to examine their spatial learning and memory as described previously (Barnes, J Comp Physiol Psychol, 93 (1) : 74-104 [1979] ) .
- This paradigm has been commonly examined in mouse models of CNS disorders, including, but not limited to schizophrenia, depressions, obsessive compulsive disorder, post-traumatic stress disorder, addiction disorders, Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease, Duchenne muscular dystrophy, stroke, and Fragile X syndrome (see Cook et al., 2014; and Ittner, 2008; Hendriksen and Vles, 2008; Conklin et al., 2000; Song et al., 2006; Lai et al., 2014; Vasterling et al., 2002; Hyman, 2005; Schaar et al., 2010; Santos et al., 2014; Zhu et al., 2007; Deckersbach et al., 2000) .
- the testing apparatus was an elevated (50 cm above the floor) circular plate (100 cm in diameter) with 20 holes (7 cm in diameter, 7 cm between holes) evenly spaced around the perimeter.
- the mice were trained on the plate to identify an escape box (25 ⁇ 8 ⁇ 6 cm) hidden behind the target hole, which was designated as an analog to the hidden platform in the Morris water maze task.
- the location of the target hole was selected for each mouse but randomized across mice. Mice were initially placed at the center of the plate covered by an opaque cylinder, and the cylinder was removed 10 seconds after the beginning of the trial with both an aversive tone (440 Hz, 85 dB) and the lights (100 lux) switched on.
- mice were trained to locate the target hole according to surrounding visual cues and escape from the aversive tone for three training trials per day over 3 consecutive days.
- the spatial memory was measured by the “probe test” . All of the training trials and the probe trials were videotaped for 3 minutes. Then, the escape latency for the training trials and the percentage of time in different quadrants (target, left, right, and opposite) during the probe test were analyzed.
- the tannic acid (30 mg/kg) group displayed a significant preference to the target zone whereas the other groups did not, as illustrated in Figure 8.
- mice treated with tannic acids with multiple injections at various doses were studied in the experiments described in Example 2. In summary, three main findings were noted.
- mice in the tannic acid (30 mg/kg) group decreased. This group of mice also displayed lower spontaneous locomotion in the open field.
- the open field tasks were used to test novelty-induced locomotor activity and general motor functions (Powell et al., Biol Psychiatry, 59 (12) : 1198-1207 [2006] ; van den Buuse, Schizophr Bull, 36 (2) : 246-270 [2010] ) .
- the decreased locomotion activity in mice with repeated tannic acid injections may be resulted from the faster habituation to the novel environment.
- mice treated with tannic acid were decreased in the elevated plus maze.
- the elevated plus maze task is a mouse model for putative anxiolytic or anxiogenic compounds screening (Rodgers et al., Braz J Med Biol Res, 30 (3) : 289-304 [1997] ; Steimer, Dialogues Clin Neurosci, 13 (4) : 495-506 [2011] ) .
- the increase in the proportion of time spent in open arms represents lower anxiety in the plus maze.
- mice with repeated injections displayed not only higher proportion of time spent in open arms but also higher proportion of travel distance in open arms and lower risk assessment.
- mice with repeated tannic acid injections displayed the enhancement of spatial memory retrieval in the Barnes maze.
- the Barnes maze is a task to evaluate the cognitive function in mice, especially the spatial learning and memory (Rosenfeld et al., J Vis Exp, (84) : e51194 [2014] ) .
- an increasing amount of clinical research emphasizes the impact of cognitive deficits in many mental illnesses including schizophrenia, dementia, Alzheimer’s disease, depression, and obsessive compulsive disorder (OCD) etc.
- tannic acids would be effective in weight reduction and improving basic behavioral functioning, hyperactivity, anxiety, memory and/or cognitive behavior. For example, a large percentage of children with ADHD have co-morbid learning disorder that can also be improved by tannic acid, given its effects on learning and memory.
- the objective of this experiment was to assess the potential mechanisms of action of tannic acids in treating CNS disorders, using MK-801, a well-known NMDA receptor antagonist. Tannic acids and MK-801 were administrated in mice by intraperitoneal (i.p. ) injections before the behavioral tests (i.e., open field and prepulse inhibition) , respectively.
- MK-801 also known as dizocilpine, is an antagonist of NMDA receptor (Kovacic et al., Oxid Med Cell Longev, 3 (1) : 13-22 [2010] ) .
- mice C57BL/6J male mice were group housed (3-5 mice per cage) with food and water available ad libitum in polysulfone ventilated cages (Alternative Design, AR, USA) in the animal rooms. The colony was maintained on a 12/12-h light/dark cycle at the temperature of 22 ⁇ 2 °C and all behavioral studies will be performed during the dark cycle. All animals used in this study were adult mice (at least 2.5 months of age) .
- mice were randomly assigned into six groups:
- Group 1 PBS + Saline control
- Group 2 PBS + MK-801;
- Group 3 tannic acid (10 mg/kg) + MK-801;
- Each mouse in Groups 2-6 received an acute administration of MK-801 (Sigma-Aldrich, USA) dissolved in normal saline, 0.1 mg/kg, i.p. ) 20 minutes prior to the behavioral tests.
- Each mouse in Groups 3-6 received an acute administration of tannic acids (Sigma-Aldrich, USA; dissolved in PBS, 10, 15, 20 or 30 mg/kg, i.p. ) 20 minutes prior to the MK-801 administration.
- mice in this study were tested with open field task and prepulse inhibition task with at least 1-week interval between two tasks.
- An additional cohort of mice was used to test the effect of different sources of tannic acid on prepulse inhibition.
- the MK-801 group (Group 2) displayed a hyper-locomotion activity.
- the tannic acid 10, 20, and 30 groups (Groups 3, 5, and 6) displayed a lower locomotion activity than the control group as illustrated in Figure 10.
- all tannic acid groups displayed lower locomotion activity, as shown in Figure 10.
- MK-801 generates hyperactivity which is frequently applied as animal models including, but not limited to schizophrenia, bipolar disorder, attention-deficit hyperactivity disorder, obsessive compulsive disorder, Tourette’s syndrome, autism spectrum disorders, Fragile X syndrome, Parkinson’s disease, dementia with Lewy bodies, and senile dementia (see Rubia et al., 2010; Sheppard and Bradshaw, 1999; Bent et al., 2014; Powell and Miyakawa, 2006; Nestler and Hyman, 2010; ′kova′ -Vales ⁇ ova et al., 2008; Gobira et al., 2013; Lai et al., 2014; Maio et al., 2014; Sontag et al., 2010; Ding et al., 2014; Walitza et al., 2007; Finestone et al., 1982; Golimstok et al., 2011) .
- Pre-attentive processes tend to be automatic and rapid, and to operate outside of conscious awareness, whereas deliberate attention processes have limited resources, require more efforts, and operate more slowly.
- a common measure of pre-attentive process is prepulse inhibition.
- This paradigm has been commonly examined in mouse models of several CNS disorders, including, but not limited to schizophrenia, major depressive disorder, bipolar disorder, attention deficit disorder, attention-deficit hyperactivity disorder, tic disorder, obsessive compulsive disorder, Tourette’s syndrome, blepharospasm, post-traumatic stress disorder, panic disorder, autism spectrum disorder, Asperger’s disorder, Alzheimer’s disease, mild dementia of Alzheimer, dementia with Lewy bodies, Huntington's disease, personality disorders, nocturnal enuresis, and non-epileptic seizures (see McAlonan et al., 2002; Braff et al., 2001; Giakoumaki et al., 2007; Ueki et al., 2006; Perriol et al., 2005
- Prepulse inhibition was used as an index of sensorimotor gating function using SR-LAB startle apparatus (San Diego Instruments, San Diego, CA, USA) . Under 72 dB background noise, each session was composed of 5 minutes accumulation period followed by 64 trials in four blocks. The pulse alone (PA) trial was a 40 ms, 120 dB white noise burst. In the prepulse (pp) + pulse trials, a 20 ms white noise prepulse stimuli of 78 dB (pp6) , 82 dB (pp10) , and 90 dB (pp18) were presented 100 ms before a 40 ms 120 dB pulse. The non-stimulus (NS) trials presented the background noise only.
- SR-LAB startle apparatus San Diego Instruments, San Diego, CA, USA
- the initial and the last blocks were composed of six PA trials, respectively.
- Two middle blocks consisted of PA, pp + pulse, and NS trials. These trials were presented pseudo-randomly and separated by intertribal intervals of 15 seconds on average (varying between 10 to 20 s) .
- the tannic acid (15 mg/kg) , tannic acid (20 mg/kg) and tannic acid (30 mg/kg) groups displayed significantly higher percentages of prepulse inhibition as compared with the control group, while no such results was observed in the MK-801 and tannic acid (10 mg/kg) groups, as depicted in Figure 11.
- Tannic acids purchased from Sigma-Aldrich (source A) and from Spectrum, USA (source B) at 15 mg/kg were used in this study.
- the IC 50 ( ⁇ M) of anti-DAAO activities of tannic acids of sources A and B are 0.291 and 0.636, respectively.
- psychosis symptoms are challenging to observe and measure in animal models, the psychosis-related behaviors can be tested include psychomotor agitation, excitement symptoms, sensory gating and sensitivity to psychotomimetic drugs, such as MK-801 (Arguello et al., Neuron, 52 (1) : 179-196 [2006] ; Lai et al., Curr Pharm Des, 20 (32) : 5139-5150 [2014] ) .
- mice parameters related to hyper-locomotion activity and alteration of novelty-induced locomotion activity (either impairment of habituation to novelty or increased exploration) in an open field task can be used to measure the psychomotor agitation and excitement symptoms, respectively (Lai et al., Curr Pharm Des, 20 (32) : 5139-5150 [2014] ; Powell et al., Biol Psychiatry, 59 (12) : 1198-1207 [2006] ; Vardigan et al., Pharmacol Biochem Behav, 95 (2) : 223-229 [2010] ) .
- the administration of tannic acid both by i.p. or per os (p.o.
- tannic acids are a potential therapeutic agent for treating psychosis symptoms (e.g., delusions and hallucinations) .
- the deficits of prepulse inhibition were also found in other central nerve system diseases, including autism spectrum disorder (McAlonan et al., Brain, 125 (Pt 7) : 1594-1606 [2002] ) , obsessive compulsive disorder, Huntington’s disease, nocturnal enuresis, attention deficit disorder, Tourette’s syndrome, blepharospasm, non-epileptic seizures, post-traumatic stress disorder (Braff et al., Psychopharmacology (Berl) , 156 (2-3) : 234-258 [2001] ) , panic disorder, bipolar disorder, mild dementia of Alzheimer’s , dementia with Lewy bodies, and combined attention-deficit hyperactivity disorder and tic disorder (Giakoumaki et al., Biol Psychiatry, 62 (12) : 1418-1422 [2007] ; Ludewig et al., Depress Anxiety, 15 (2) : 55-60 [2002] ; Perriol
- tannic acids are a promising therapeutic agent for various CNS disorders. Further, tannic acids reduce both spontaneous and MK-801-induced hyperlocomotion, indicating that tannic acids Tannic acid can serve as a therapeutic agent to improve symptoms of ADHD and its related disorders.
- tannic acids could maintain and/or reduce body weights in mice treated thereby, indicating that tannic acids would be effective in control body weight and/or treating obesity and its disorders including eating disorder, anorexia nervosa, bulimia nervosa, stroke, coronary heart disease, heart attack, congestive heart failure, congenital heart disease, hypertension, non-alcoholic steatohepatitis, insulin resistance, hyperuricemia, hypothyroidism, osteoarthritis, gallstones, infertility (hypogonadism and hyperandrogegism) , obesity hypoventilation syndrome, obstructive sleep apnea, chronic obstructed pulmonary disease, and asthma.
- the objective of this experiment was to assess the potential mechanisms of action of tannic acids in treating CNS disorders, using MK-801, a well-known NMDA receptor antagonist. Tannic acids and MK-801 were administrated in mice by oral gavage (p.o. ) and intraperitoneal (i.p. ) injections respectively before the behavioral tests (i.e., open field, prepulse inhibition, Barnes maze and sucrose preference) , respectively.
- MK-801 also known as dizocilpine, is an antagonist of NMDA receptor (Kovacic et al., Oxid Med Cell Longev, 3 (1) : 13-22 [2010] ) .
- mice C57BL/6J male mice were group housed (3-5 mice per cage) with food and water available ad libitum in polysulfone ventilated cages (Alternative Design, AR, USA) in the animal rooms. The colony was maintained on a 12/12-h light/dark cycle at the temperature of 22 ⁇ 2 °C and all behavioral studies will be performed during the dark cycle. All animals used in this study were adult mice (at least 2.5 months of age) .
- mice were randomly assigned into five groups:
- Group 1 PBS + Saline control
- Group 2 PBS + MK-801;
- Group 3 tannic acid (10 mg/kg) + MK-801;
- Each mouse in Groups 2-5 received an acute administration of MK-801 (Sigma-Aldrich, USA) dissolved in normal saline, 0.1 mg/kg for open field and Barnes maze tasks, and 0.2 mg/kg for prepulse inhibition and sucrose preference tasks by i.p. injection) 20 minutes prior to the behavioral tests.
- Each mouse in Groups 3-6 received an acute oral administration of tannic acids (Merck Millipore, Germany; dissolved in PBS, 10, 30, or 100 mg/kg, p.o. ) 20 minutes prior to the MK-801 administration.
- mice in this study were tested with open field task, prepulse inhibition task, Barnes maze and sucrose preference with at least 1-week interval between tasks.
- mice in MK-801 group did not show the preference toward the sucrose solution (2%) .
- mice with tannic acid 30 mg/kg and 100 mg/kg displayed rescue/protective effects on MK-801 induced depressive-like behavior (anhedonia) as shown in Figure 17.
- Sucrose preference test has been commonly examined in mouse models of several mental illnesses, including, but not limited to, depression, major depression disorder, anhedonia, negative symptoms of schizophrenia, chronic mild and unpredictable stress (see Anderson et al., 2006; Carvalho et al., 2013; Briones et al., 2011; Der-A vakian and Markou, 2012; Tye et al., 2013; Edwards and Koob, 2012; Brigman et al., 2010; Koo and Duman, 2007; Nestler and Hyman, 2010; Overstreet, 2012; Papp et al., 1991; Santiago et al., 2010; Skalisz et al., 2002; Szczypka et al., 2001; Taylor et al., 2010; Vardigan et al., 2010; Willner et al., 1987; You et al., 2011) .
- Tannic acids were administrated in mice by intraperitoneal (i.p. ) injections before the behavioral tests (i.e., von Frey test) .
- mice C57BL/6J male mice were group housed (5 mice per cage) with food and water available ad libitum in polysulfone ventilated cages (Alternative Design, AR, USA) in the animal rooms. The colony was maintained on a 12/12-h light/dark cycle at the temperature of 22 ⁇ 2 °C and all behavioral studies will be performed during the dark cycle. All animals used in this study were adult mice (at least 8 weeks of age) .
- mice were randomly assigned into two groups:
- Group 1 PBS control
- Each mouse in Groups 1 received an acute administration of PBS as a vehicle control by i.p. injection.
- Each mouse in Groups 2 received an acute administration of tannic acids (Merck Millipore, Germany; dissolved in PBS 15 mg/kg, i.p. ) .
- the von Frey test has been commonly examined in mouse models of several CNS disorders, including, but not limited to, neuropathic pain including hyperalgesia and allodynia, hypoesthesia in diabetic polyneuropathy, chronic pain syndromes (see Park et al., 2015; Savage and Ma, 2015; Caterha et al., 2000; Nicotra et al., 2014; Keizer et al., 2007; Chakrabarty et al., 2011; Obrosova et al., 2007; Orita et al., 2011; Reeve et al., 2000) .
- neuropathic pain including hyperalgesia and allodynia, hypoesthesia in diabetic polyneuropathy, chronic pain syndromes (see Park et al., 2015; Savage and Ma, 2015; Caterha et al., 2000; Nicotra et al., 2014; Keizer et al., 2007; Chakrabarty et al., 2011; Obrosova e
- compositions and inhibitory activities against D-amino acid oxidase (DAAO) of 3 commercial tannic acids from different suppliers were compared.
- compositions of 3 commercial tannic acids were determined by HPLC and the inhibitory activities against D-AAO were determined by the method illustrated in Example 1.
- compositions are Compositions:
- Tannic acidsextractted from Rhus chinensis have much higher percentage of 6-12G and much lower 2-5G percentage than tannic acids from Quercus infectoria, and therefore higher DAAO inhibitory potency than the other two.
- Tannic acids were extracted from gallnuts of different plant or botanic sources as indicated and their inhibitory activity against D-amino acid oxidase (DAAO) was investigated.
- DAAO D-amino acid oxidase
- Tannic acid producing gallnuts from a suitable plant or botanic source were milled by a mechanical grinder and passed through a 40-mesh sieve to produce fine gallnut powder.
- the fine gallnut powder (20.0 g) was placed in 200.0 mL of a suitable solvent (e.g., acetone, acetonitrile, methyl ethyl ketone (MEK) , ethyl acetate (EtOAc) , ethanol (EtOH) , isopropanol, tetrahydrofuran, or 1, 4-dioxane) .
- a suitable solvent e.g., acetone, acetonitrile, methyl ethyl ketone (MEK) , ethyl acetate (EtOAc) , ethanol (EtOH) , isopropanol, tetrahydrofuran, or 1, 4-dioxane
- Tannic acids extracted from gallnuts of each plant or botanic source noted herein were enriched as described below. Their inhibitory activities against DAAO were investigated.
- the fine gallnut powder (20.0 g) was placed in 200.0 mL of a suitable solvent (acetone, methyl ethyl ketone, ethyl acetate, or ethanol) and the mixture thus formed was stirred at either RT or 20-60°C for 12 hrs.
- the resultant solution was filtered, and the filtrate was concentrated in vacuum to form a composition containing tannic acids.
- the composition was mixed with 50.0 mL of 50 or 30%methyl ethyl ketone/hexane solution (50%or 30%methyl ethyl ketone in hexane) .
- the mixture thus formed was further stirred at RT for 12 hrs, and the resulting two organic layers were separated.
- the oilier layer (the lower layer) was concentrated in vacuum to produce a crude solid.
- the solid was dissolved in 50.0 mL of a suitable solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) , and the resulting solution was mixed with charcoal (1.6 g) .
- the resulting mixture was stirred at RT for 12 hrs and CaSO 4 or MgSO 4 (2.5 g) was added into the mixture.
- the mixture thus formed was further stirred at RT for 30 min and filtered through a bed of Celite, washed with a suitable solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) (100 mLx2) , and concentrated in vacuum.
- a suitable solvent acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol
- the resultant solid (containing tannic acids) was dissolved in acetone or ethyl acetate (12.0 mL) , and then the solution thus formed was stirred and mixed with CH 2 Cl 2 (72.0 mL) dropwise.
- the solid thus formed was collected by filtration and dried under vacuum at 40°C for 2 hrs to produce an enriched tannic acid solid.
- the fine gallnut power (20.0 g) was placed in 200.0 mL of a suitable solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, ethanol) was stirred at RT for 12 hrs.
- the solution thus formed was filtered, and the filtrate collected was mixed with 200.0 mL of hexane.
- the mixture was stirred at RT for 12 hrs, and the resulting two organic layers were separated.
- the oiler layer (lower layer) was concentrated in vacuum and the solid thus obtained was dissolved in 50.0 mL of a suitable solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, ethanol, etc. ) .
- the resulting solution was mixed with charcoal (1.6 g) and further stirred at RT for 12 hrs.
- the mixture thus obtained was further mixed with CaSO 4 or MgSO 4 (2.5 g) and stirred at RT for 30 min.
- the mixture was filtered through a bed of Celite, washed with (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, ethanol, etc. ) (100 mLx2) , and concentrated in vacuum.
- the crude residues thus obtained were dissolved in acetone or ethyl acetate (12.0 mL) , and the solution thus formed was stirred and mixed with CH 2 Cl 2 (72.0 mL) slowly.
- the solid thus formed was collected by filtration and dried under vacuum at 40°C for 2 hrs to produce an enriched tannic acid composition.
- the fine gallnut power (20.0 g) was placed in 200.0 mL of solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) was stirred at RTfor 12 hrs. The resultant solution was filtered, and the filtrate was collected. The filtrate was then added into 200.0 mL hexane. The mixture thus formed was stirred at RT for 12 hrs, and the resulting two organic layers were separated.
- solvent acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol
- the oilier layer (lower layer) was collected and mixed with 40.0 mL of solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) and charcoal (1.6 g) and the resulting mixture was stirred at RT for 12 hrs.
- the mixture was further mixed with CaSO 4 or MgSO 4 (2.5 g) and stirred at RT for 30 min, filtered through a bed of Celite, and washed with solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) (100 mLx2) .
- the filtrate thus collected was concentrated in vacuum and the resultant solid substances were dissolved in acetone or ethyl acetate (12.0 mL) .
- the solution thus formed was stirred and mixed with CH 2 Cl 2 (72.0 mL) dropwise.
- the solid thus formed was collected by filtration and dried under vacuum at 40°C for 2 hrs to form an enriched tannic acid composition.
- the fine gallnut power (20.0 g) was placed in 200.0 mL of solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) to form a mixture, which was stirred at RT for 12 hrs.
- the mixture was mixed with charcoal (1.6 g) and stirred at RT for 12 hrs.
- the resultant mixture was further mixed with CaSO 4 or MgSO 4 (2.5 g) and stirred at RT for 30 min, filtered through a bed of Celite, washed with solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) (100 mLx2) .
- the fine gallnut power (20.0 g) was placed in 200.0 mL of solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) and the mixture thus formed was stirred RTfor 12 hrs.
- the mixture was mixed with charcoal (1.6 g) and stirred at RT for 12s hrs.
- the mixture was further mixed with CaSO 4 or MgSO 4 (2.5 g) and stirred at RT for 30 min.
- the mixture was filtered through a bed of Celite, and washed with solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) (100 mLx2) .
- the filtrate was concentrated down to about 10 ⁇ 15 mL and the resulting solution was mixed with CH 2 Cl 2 (60 ⁇ 90 mL) dropwise.
- the solid thus formed was collected by filtration and dried under vacuum at 40°C for 2 hrs to form an enriched tannic acid composition.
- the fine gallnut power (20.0 g) was placed in 200.0 mL of solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) and the solution thus formed was stirred at RT for 12 hrs, and then filtered. The filtrate was collected and mixed with charcoal (1.6 g) and stirred at RT for 12 hrs. The mixture was further mixed with CaSO 4 or MgSO 4 (2.5 g) and stirred at RT for 30 min.
- solvent acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol
- the fine gallnut power (20.0 g) was placed in 50.0 mL of 50%or 30%methyl ethyl ketone/hexane and was stirred at RT for 12 hrs. The resultant mixture was filtered and solids were collected. The solids were then mixed with 200.0 mL solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) . The mixture thus formed was stirred at RTfor 12 hrs, filtered and the filtrate was collected. The filtrate was then mixed with charcoal (1.6 g) and stirred at RT for 12 hrs.
- solvent acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol
- the resulting mixture was further mixed with CaSO 4 or MgSO 4 (2.5 g) and stirred at RT for 30 min, filtered through a bed of Celite, washed with solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) (100 mLx2) , and the filtrate was concentrated by vacuum evaporation.
- solvent acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol
- the residue thus obtained was dissolved in acetone or ethyl acetate (12 mL) , and then the solution was stirred and mixed with CH 2 Cl 2 (72.0 mL) dropwise.
- the solid thus formed was collected by filtration and dried under vacuum at 40°C for 2 hrs to produce an enriched tannic acid composition.
- the fine gallnut power (20.0 g) was placed in 50 mL of 50 or 30%methyl ethyl ketone/hexane and was stirred at RT for 12 hrs.
- the solution was filtered and the solid collected was mixed with 200.0 mL of solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) .
- the mixture was stirred at RTfor 12 hrs and filtered, and the filtrate collected was mixed with charcoal (1.6 g) and stirred at RT for 12 hrs.
- the resulting mixture was further mixed with CaSO 4 or MgSO 4 (2.5 g) and stirred at RT for 30 min.
- the mixture was then filtered through a bed of Celite, washed with solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) (100 mLx2) , and the filtrate was concentrated down about 10 ⁇ 15 mL.
- the residual solution was mixed with CH 2 Cl 2 (60 ⁇ 90 mL) slowly and the solid thus formed was collected by filtration and dried under vacuum at 40°C for 2 hrs to produce an enriched tannic acid composition.
- the fine gallnut power (20.0 g) was placed in 200.0 mL of solvent (acetone, methyl ethyl ketone, ethyl acetate, or ethanol) and was stirred at 20 ⁇ 60°Cfor 12 hrs. The solution was filtered and the filtrate collected was placed in 200.0 mL of hexane. The mixture thus formed was stirred at RT for 12 hrs, and the two resulting organic layers were separated.
- solvent acetone, methyl ethyl ketone, ethyl acetate, or ethanol
- the oiler layer (lower layer) was collected and mixed with 40.0 mL of solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) , and the solution thus formed was mixed with charcoal (1.6 g) and stirred at RT for 12 hrs. The mixture was further mixed with CaSO 4 or MgSO 4 (2.5 g) and stirred at RT for 30 min. The mixture was then filtered through a bed of Celite, washed with solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) (100 mLx2) , and the filtrate was concentrated under vacuum. .
- solvent acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol
- the mixture was then filtered through a bed of Celite (20g) , washed with a solvent (including ethyl acetate, methyl acetate, or methyl ethyl ketone, 100 mL) , and the filtrate was concentrated in vacuo.
- the resulting residue was diluted with a solvent (including acetone, ethyl acetate, methyl acetate, or methyl ethyl ketone, 110 mL) , then 660 ml of another solvent was mixed with the resulting solution at RT and the resulting solution was stirred until the addition was completed.
- the mixture was stirred at RT for 12 ⁇ 18 hrs.
- the solid formed was collected by filtration and dried under vacuum at 45°C for 12hrs.
- the composition of tannic acid afforded was analyzed by HPLC-MS ( Figure 26) and 1 H-NMR.
- the HPLC- MSchromatogram ( Figure 26) of the composition of tannic acid from Enrichment Method #10 contains less than 0.35%of non-tannic acid impurities, compared to those of UPS Standard and Wenzhou Ouhai Fine Chemicals Corporation containing much higher quantities of non-tannic acid impurities, 15.99%and 6.46%, respectively.
- the 1 H-NMR spectrum of the composition of tannic acid from Enrichment Method #10 illustrates only peaks from gallolyl and glucose moieties while those of USP Standard and Wenzhou Ouhai Fine Chemicals Corporation show several peaks other than those from galloyl and glucose moieties.
- the solid afforded from any of the Enrichment Methods described above was slurried with 2000 mL of a solvent (including heptane, CH 2 Cl 2 , or heptane/CH 2 Cl 2 (1: 9 to 9: 1) ) at 35 ⁇ 60 °C for 8-16hrs, then the solid formed was filtered and evaporated in vacuo at 60 ⁇ 70 °C for 8hrs.
- the solids were then slurry with 2000 mL of a solvent (including heptane, CH 2 Cl 2 or heptane/CH 2 Cl 2 (1: 9 to 9: 1) ) at 35 ⁇ 60 °C for 8-16hr, then the solid was filtered and evaporated in vacuo at 60 ⁇ 70 °C for 8hrs.
- the solid was finally further slurried with 2000 mL of a solvent (including heptane, CH 2 Cl 2 or heptane/CH 2 Cl 2 (1: 9 to 9: 1) ) at 35 ⁇ 60 °C for 8-16hrs, then the solid generated was filtered and evaporated in vacuo at 60 ⁇ 70 °C for 8 hrs to give tannic acid solid (yield: 80%) .
- a solvent including heptane, CH 2 Cl 2 or heptane/CH 2 Cl 2 (1: 9 to 9: 1
- Gallnuts were either ground thoroughly to form fine powder or roughly to form small chips first.
- the solution of gallnut powder or small chips (10.0 g) in 60 ⁇ 100 mL of a solvent (including ethyl acetate, methyl acetate, methyl ethyl ketone, ethanol, or water) was stirred at 35-60°C for 3 hrs, then the second batch of 10.0 g of gallnut powder or small chips were added to the solution and continued to stir at 35-60°C for 3 hrs.
- the third batch of 10.0 g of gallnut powder or small chips were added to the solution followed by stirring at 35-60°C for 8 ⁇ 14 hrs. After the stirring period ended, the solution was filtered and the filtrate collected was concentrated in vacuo to give the crude tannic acid solid (yield: 54 ⁇ 60%) .
- the mixture was then filtered through a bed of Celite (16 g) , washed with a solvent (including ethyl acetate, methyl acetate, or methyl ethyl ketone, 80 mL) , and the filtrate was concentrated in vacuo.
- the residue was diluted with a solvent (including acetone, ethyl acetate, methyl acetate, or methyl ethyl ketone, 240 mL) , then the solution was added with hexanes (720 mL) and stirred at RT for 2 hrs, and then this organic layer was separated.
- the resulting oily residue was diluted with a solvent (including acetone, ethyl acetate, methyl acetate, or methyl ethyl ketone, 240 mL) , then the solution was added with hexanes (720 mL) and stirred at RT for 2 hrs, and then this organic layer was separated.
- the resulting oily residue was diluted with a solvent (including acetone, ethyl acetate, methyl acetate, or methyl ethyl ketone, 100 mL) , then 660 ml of another solvent was mixed with the resulting solution at RT and stirred until the addition was completed. The mixture was further stirred at RT for 12 ⁇ 18 hrs.
- the solid formed was collected by filtration and dried under vacuum at 45°C for 6 hrs.
- the solid was slurry with 1600 mL of a solvent (including heptane, CH 2 Cl 2 or heptane/CH 2 Cl 2 (1: 9 to 9: 1) ) at 35 ⁇ 60 °C for 16 hrs, then the solid was filtered and evaporated in vacuo at 60 ⁇ 70 °C for 8 hrs.
- the solid was then slurry with 1600 mL of a solvent (including heptane, CH 2 Cl 2 or heptane/CH 2 Cl 2 (1: 9 to 9: 1) ) at 35 ⁇ 60 °C for 8-16 hrs, then the solid was filtered and evaporated in vacuo at 60 ⁇ 70 °C for 8 hrs.
- the solid was further slurried with 1600 mL of a solvent (including heptane, CH 2 Cl 2 or heptane/CH 2 Cl 2 (1: 9 to 9: 1) ) at 35 ⁇ 60 °C for 8-16 hrs, then the solid was filtered and evaporated in vacuo at 60 ⁇ 70 °C for 8 hrs to give the desirable tannic acid (yield: 62%) .
- a solvent including heptane, CH 2 Cl 2 or heptane/CH 2 Cl 2 (1: 9 to 9: 1
- Table 12 below shows the content of tannic acids in the tannic acid composition prepared by Enrichment method 11 described herein as determined by HPLC.
- a tannic acid composition prepared by this method is substantially free of small tannic acids (e.g., having ⁇ 4 galloyl moieties and a substantial portion is large tannic acids (e.g., having >8 galloyl moieties) . As disclosed herein, such tannic acid compositions are expected to have superior therapeutic effects.
- tannic acid from Enrichment method 10 gave the lowest DAAO IC 50 with the compositions of lowest amount of 1-4G and highest amount of 5-12G as illustrated above.
- the objective of this experiment was to evaluate of Enrichment #10 tannic acids in treating CNS disorders, using MK-801 model, a well-known NMDA receptor antagonist. Tannic acids and MK-801 were administrated in mice by oral gavage (p.o. ) and intraperitoneal (i.p. ) injections respectively before the behavioral tests (i.e., open field and prepulse inhibition) , respectively.
- mice C57BL/6J male mice were group housed (3-5 mice per cage) with food and water available ad libitum in polysulfone ventilated cages (Alternative Design, AR, USA) in the animal rooms. The colony was maintained on a 12/12-hr light/dark cycle at the temperature of 22 ⁇ 2 °C and all behavioral studies will be performed during the dark cycle. All animals used in this study were adult mice (at least 2.5 months of age) .
- mice were randomly assigned into five groups:
- Group 3 Merck TA (50 mg/kg) + MK-801;
- Group 5 Enrichment #10 (50 mg/kg) + MK-801.
- Each mouse in Groups 2-5 received an acute administration of 0.2 mg/kg MK-801 (Sigma-Aldrich, USA) dissolved in normal saline by i.p. injection 20 minutes prior to the locomotion activity test.
- Each mouse in Groups 3-6 received an acute oral administration of 50 mg/kg tannic acids dissolved in ddH 2 O by p.o. 20 minutes prior to the MK-801 administration.
- Tannic acid purchased from Merch Millipore (Merck TA) and from Wufeng Chicheng Biotech (CCBiotech TA) , and tannic acid from Enrichment method 10 (Enrichment #10) at 50 mg/kg were used in this study.
- mice were randomly assigned into four groups:
- Group 3 Enrichment #10 (50 mg/kg) + MK-801;
- Each mouse in Groups 2-4 received an acute administration of 0.3 mg/kg MK-801 (Sigma-Aldrich, USA) dissolved in normal saline by i.p. injection 20 minutes prior to the prepulse inhibitin test.
- Each mouse in Groups 3-4 received an acute oral administration of 50 or 200 mg/kg Enrichment #10 tannic acids dissolved in ddH 2 O by p.o. 20 minutes prior to the MK-801 administration.
- mice were placed in a cage (37.5 cm ⁇ 21.5 cm ⁇ 18 cm) under 50-65 lux light intensity. Their spontaneous locomotor activities were measured for 30 minutes using the SMART video tracking system (Panlab, Harvard Apparatus) . The travel distance of each mouse was measured as an index of locomotion activity.
- the objective of this experiment was to evaluate the effects of different sources of tannic acids on locomotion activities.
- the MK-801 group (Group 2) displayed hyper-locomotion activity.
- both tannic acid from Wufeng Chicheng Biotech (CCBiotech TA; Group 4) and from Enrichment method 10 (Enrichment #10; Group 5) groups displayed a significant lower locomotion activity whereas tannic acid from Merck Millipore (Merck TA; Group 3) did not.
- Enrichment #10 (Group 5) displayed a lower locomotion activity than CCBiotech TA (Group 4) , as shown in Figure 24.
- Prepulse inhibition was used as an index of sensorimotor gating function using SR-LAB startle apparatus (San Diego Instruments, San Diego, CA, USA) .
- SR-LAB startle apparatus San Diego Instruments, San Diego, CA, USA
- the pulse alone (PA) trial was a 40 ms, 120 dB white noise burst.
- pp prepulse + pulse trials
- a 20 ms white noise prepulse stimuli of 71 dB (pp6) , 75 dB (pp10) , and 83 dB (pp18) were presented 100 ms before a 40 ms 120 dB pulse.
- the non-stimulus (NS) trials presented the background noise only.
- the initial and the last blocks were composed of six PA trials, respectively.
- Two middle blocks consisted of PA, pp + pulse, and NS trials. These trials were presented pseudo-randomly and separated by intertribal intervals of 15 seconds on average (varying between 10 to 20 s) .
- the objective of this example was to evaluate the adverse effects and to determine the maximum tolerated dose (MTD) of tannic acid purchased from Sigma (Sigma tannic acid) and tannic acid from Enrichment method 10 (Enrichment #10) after a single dose administration by oral gavage (p.o. ) following a 7-day observation period.
- MTD maximum tolerated dose
- mice C57BL/6J male mice were group housed (3-5 mice per cage) with food and water available ad libitum in polysulfone ventilated cages (Alternative Design, AR, USA) in the animal rooms. The colony was maintained on a 12/12-h light/dark cycle at the temperature of 22 ⁇ 2 °C and all behavioral studies will be performed during the dark cycle. All animals used in this study were adult mice (at least 2.5 months of age) .
- Tannic acids were purchased from Sigma (Sigma tannic acid) or made from Enrichment method 10 (Enrichment #10) .
- Sigma tannic acid the adult mice were randomly assigned to four groups: (1) control, (2) tannic acid (500 mg/kg) , (3) tannic acid (750 mg/kg) , and (4) tannic acid (1000 mg/kg) which were treated, respectively, by a vehicle control (ddH 2 O) , tannic acid at 500 mg/kg, tannic acid at 750 mg/kg and tannic acid at 1000 mg/kg.
- mice For Enrichment #10 tannic acid, the adult mice were randomly assigned to five groups: (1) control, (2) tannic acid (200 mg/kg) , (3) tannic acid (500 mg/kg) , (4) tannic acid (1000 mg/kg) , and (5) tannic acid (2000 mg/kg) which were treated, respectively, by a vehicle control (ddH 2 O) , tannic acid at 200 mg/kg, tannic acid at 500 mg/kg, tannic acid at 1000 mg/kg and tannic acid at 2000 mg/kg. All mice were administrated with either the vehicle control or tannic acid by oral gavage (p.o. ) . Animals will be observed twice daily (a.m.
- Enrichment #10 tannic acid was at least 2000 mg/kg. In conclusion, enrichment #10 tannic acid showed a much higher maximum tolerated dose than Sigma tannic acid and is safer to be used as treatment for CNS and obesity disorders.
- inventive embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed.
- inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein.
- a reference to “A and/or B” when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B) ; in another embodiment, to B only (optionally including elements other than A) ; in yet another embodiment, to both A and B (optionally including other elements) ; etc.
- the phrase “at least one, ” in reference to a list of one or more elements should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
- This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified.
- “at least one of A and B” can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B) ; in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A) ; in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements) ; etc.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Obesity (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
- Tannins are a group of naturally occurring compounds that exist in various plants, for example, Rhus chinensis, Rhus javanica, Rhus semialata, Rhus coriaria, Rhus potaninii, Rhus punjabensis var. sinica (Diels) Rehder &E.H. Wilson, Camellia sinensis, Berry, Bixa orellana, Vitis vinifera, Punica granatum, Quercus infectoria, Quercus cerris, Acacia mearnsii, Pseudotsuga menziesii, Caesalpinia spinosa, Fagus hayata Palib. ex Hayata, or Machilus thunbergii Sieb. &Zucc. etc. . There are three major classes of tannins, including hydrolysable tannins (also known as tannic acids) , condensed tannins, and phlorotannins, which contain gallic acid, flavone, and phloroglucinol, respectively, as the base unit. Tannins are widely used as a type of industrial particleboard adhesive and for production of anti-corrosive primer or resins. It was also suggested that tannins may have various effects on human health.
- D-amino acid oxidase (DAAO) is a peroxisomal enzyme that oxidizes D-amino acids to the corresponding imino acids. It has been reported that DAAO is involved in the metabolism of brain D-amino acids, including D-serine, and the regulation of the glutamatergic neurotransmission. As such, DAAO is a target for treating central nervous system (CNS) disorders that are associated with D-serine and/or glutamatergic neurotransmission.
- SUMMARY OF THE INVENTION
- The present disclosure is based at least on the development of improved enrichment methods for preparing tannic acid mixtures having enhanced bioactivity, safety, and purity profiles. Accordingly, provided herein are enrichment methods for producing tannic acid compositions and tannic acid compositions (e.g., produced by the enrichment methods disclosed herein) for use in inhibiting DAAO activity and alleviating CNS and obesity associated diseases and disorders.
- Accordingly, one aspect of the present disclosure features a method for preparing a tannic acid composition, the method comprising: (i) providing a composition containing tannic acids; (ii) incubating multiple batches of the composition at 20-80 ℃ with a first solvent sequentially to produce a first tannic acid extract; (iii) contacting the first tannic acid extract with one or more of charcoal, metal carbonate (e.g., lithium carbonate, sodium carbonate, or potassium carbonate) , and metal sulfate (e.g., calcium sulfate or magnesium sulfate) at 20-80 ℃ to remove substances absorbed to the charcoal and/or metal carbonate, or removed by the metal sulfate, thereby producing a first tannic acid composition; (iv) mixing the first tannic acid composition with a second solvent to form a solution; (v) contacting the solution with dichloromethane, dichloroethane, pentane, hexane, heptane, or a mixture thereof at 20-40 ℃ to allow for precipitation of tannic acids in solid form; and (vi) collecting the tannic acids in solid form, thereby producing a second tannic acid composition, wherein ≤ 2%of the tannic acids in the second tannic acid composition have 1-4 galloyl moieties. In some instances, step (iii) can further comprise contacting the mixture with silicon dioxide.
- Suitable first solvents include, but are not limited to, comprises acetone, acetonitrile, methyl ethyl ketone, ethyl acetate, methyl acetate, ethanol, isopropanol, tetrahydrofuran, 1, 4-dioxane, heptane, hexane, water, or a combination thereof. Suitable second solvents include, but are not limited to, acetone acetonitrile, ethyl acetate, methyl acetate, methyl ethyl ketone, ethanol, isopropanol, 1, 4-dioxane, tetrahydrofuran, or a combination thereof.
- The composition containing tannic acids of step (i) can be gallnut powder or gallnut chips obtained from gallnuts of a plant. Exemplary plants include, but not limited to, Rhus chinensis, Rhus javanica, Rhus semialata, Rhus coriaria, Rhus potaninii, Rhus punjabensis var. sinica (Diels) Rehder &E.H. Wilson, Camellia sinensis, Berry, Bixa orellana, Vitis vinifera, Punica granatum, Quercus infectoria, Quercus cerris, Acacia mearnsii, Pseudotsuga menziesii, Caesalpinia spinosa, Fagus hayata Palib. ex Hayata, and Machilus thunbergii Sieb. &Zucc. In some instances, the plant is Rhus chinensis, Rhus javanica, Rhus semialata, Rhus coriaria, Rhus potaninii, and Rhus punjabensis var. sinica (Diels) Rehder &E.H. Wilson.
- In some embodiments, the gallnuts may have diameters ranging from 1-8 cm. In some examples, the gallnuts can be Chinese belly-shaped gallnuts or horned gallnuts. When Chinese horned gallnuts are used, the diameters of such gallnuts may range from 1-8 cm, e.g., from 2-6 cm or from 3-5 cm.
- In some embodiments, step (ii) can be performed by (a) incubating a first batch of the composition with the first solvent, (b) incubating a second batch of the composition with the mixture formed in (a) , and (c) incubating a third batch of the composition with the mixture formed in (b) to produce the first tannic acid extract. In some examples, step (ii) can be performed at a temperature of 20-60 ℃.
- In some embodiments, step (iii) can be performed by (a) contacting the first tannic acid extract with metal carbonate at 20-60 ℃ to form a mixture, (b) extracting the mixture with ethyl acetate, methyl acetate, acetone, methyl ethyl ketone, acetonitrile, ethanol, isopropanol, 1, 4-dioxane, tetrahydrofuran, or a combination thereof at 20-50 ℃ to produce an organic solution, and (c) incubating the organic solution with the charcoal and metal sulfate at 20-60 ℃ simultaneously or sequentially.
- In some embodiments, the method described herein may further comprise a step of removing dextrin, gum, and resin from the first or second tannic acid composition. This removing step may be performed by a process comprising (a) mixing the first tannic acid composition or the second tannic acid composition with a polar solvent and collecting the organic layer thus formed; and optionally (b) contacting the organic layer with an alkyl solvent, a chlorinated solvent, or a mixture thereof at 10-70 ℃, and collecting the bottom oily layer thus formed. Exemplary polar solvents for use in this removing step include, but are not limited to, ethyl acetate, methyl acetate, acetone, methyl ethyl ketone, acetonitrile, ethanol, isopropanol, 1, 4-dioxane, or tetrahydrofuran. Exemplary alkyl solvents for use in this removing step include, but are not limited to, pentane, hexane, or heptane. Exemplary chlorinated solvents include, but are not limited to, dichloromethane, or dichloroethane.
- Alternatively or in addition, the method described herein may further comprise (a) mixing the second tannic acid composition with an alkyl solvent (e.g., pentane, hexane, or heptane) , a chlorinated solvent (e.g., dichloromethane, or dichloroethane) , or combination thereof, and (b) stirring the mixture thus formed to remove solvent residues at 10-70 ℃.
- In another aspect, the present disclosure provides a method for removing dextrin, gum, and/or resin from a tannic acid composition, comprising: (i) providing a tannic acid composition comprising dextrin, gum, resin, or a combination thereof; (ii) mixing the tannic acid composition with a polar solvent to form an organic layer; (iii) contacting the organic layer with an alkyl solvent, a chlorinated solvent, or a combination thereof at 10-70 ℃; and (iv) collecting the bottom oily layer thus formed.
- In yet another aspect, the present disclosure provides a method for removing solvent residues from a tannic acid composition; comprising: (i) providing a tannic acid composition comprising residues of at least one solvent; (ii) mixing the tannic acid composition with an alkyl solvent, a chlorinated solvent, or a combination thereof to form a mixture, and (iii) stirring the mixture to remove residues of the at least one solvent at 10-70 ℃.
- Further, present disclosure features a composition comprising (i) a mixture of tannic acids or an acceptable salt thereof, and (ii) a carrier, wherein ≥ 98%of the tannic acids in the composition have 4-12 galloyl moieties, ≥ 97%of the tannic acids in the composition have 5-12 galloyl moieties; ≥ 90%of the tannic acids in the composition have 6-12 galloyl moieties; or ≥ 60%of the tannic acids in the composition have 8-12 galloyl moieties. In some embodiments, the composition contains about 4-20%of the tannic acids having 5 galloyl moieties, about 10-35%of the tannic acids having 6-7 galloyl moieties, and/or about 55-85%of the tannic acids having 8-12 galloyl moieties. Also within the scope of the present disclosure are tannic acid-containing compositions prepared by any of the enrichment methods described herein.
- The composition described herein may be a pharmaceutical composition, a nutraceutical composition, a health food, or a medical food. It can be formulated as a tablet, a capsule, a soft chew, or gel.
- Any of the compositions described herein can be used in inhibiting D-amino acid oxidase (DAAO) in a subject or can be used in treating a central nervous system (CNS) disorder or a disorder associated with obesity in a subject. Exemplary CNS disorders include, but are not limited toschizophrenia, psychotic disorders, Alzheimer’s disease, frontotemporal dementia, vascular dementia, dementia with Lewy bodies, senile dementia, mild cognitive impairment, benign forgetfulness, closed head injury, autistic spectrum disorder, Asperger’s disorder, fragile X syndrome, attention deficit hyperactivity disorders, attention deficit disorder, obsessive compulsive disorder, tic disorders, childhood learning disorders, premenstrual syndrome, depression, major depressive disorder, anhedonia, suicidal ideation and/or behaviors, bipolar disorder, anxiety disorders, panic disorder, post-traumatic stress disorder, chronic mild and unpredictable stress, eating disorders, addiction disorders, personality disorders, Parkinson’s disorder, Huntington’s disorder, multiple sclerosis, amyotrophic lateral sclerosis, Tourette’s syndrome, nocturnal enuresis, non-epileptic seizures, blepharospasm, Duchenne muscular dystrophy, stroke, chronic pain, neuropathic pain including hyperalgesia and allodynia, diabetic polyneuropathy, and chronic pain syndromes. In some instances, the disorder is associated with obesity, for example, eating disorders, anorexia nervosa, bulimia nervosa, stroke, coronary heart disease, heart attack, congestive heart failure, congenital heart disease, hypertension, non-alcoholic steatohepatitis, insulin resistance, hyperuricemia, hypothyroidism, osteoarthritis, gallstones, infertility, obesity hypoventilation syndrome, obstructive sleep apnea, chronic obstructed pulmonary disease, and asthma. Other examples include diabetes, hyperglycemia, hyperlipidemia, and hypercholesterolemia.
- The composition as described herein can be formulated for administration at a frequency of three times a day to one time every two months to the subject in need of the treatment as described herein. In some instances, the composition is for co-use with one or more additional pharmaceutical agents for treating the CNS disorder, or the disorder associated with obesity. The composition and the one or more additional pharmaceutical agent are administered to the subject concurrently or sequentially.
- The details of one or more embodiments of the invention are set forth in the description below. Other features or advantages of the present invention will be apparent from the following drawings and detailed description of several embodiments, and also from the appended claims.
- The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure, which can be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
- Figure 1 is a chart showing that tannic acids as a group inhibit D-amino acid oxidase (DAAO) .
- Figure 2 is a chart showing the anti-DAAO activities of tannic acids with different numbers of galloyl moieties at 300 nM. 3 galloyl moieties showed low activity. Tannic acids with four or more 4 galloyl moieties showed higher activity in inhibiting DAAO as compared with tannic acids with 3 galloyl moieties. The higher the number of galloyl moieties, the stronger the potency in inhibiting DAAO.
- Figure 3 is a schematic illustration of an exemplary design for verifying the activity of tannic acids on improving basic behavioral functioning, anxiety, depression, memory, sensorimotor gating and cognitive behaviors. The mice received either a vehicle control or tannic acids at 10 mg/kg or 30 mg/kg by injection every other day. Body weights of the treated mice were measured every other day. The behavioral tests were performed on days that injections were not administered.
- Figure 4 is a chart showing the body weight changes of mice treated with a vehicle control and tannic acids at various doses as indicated during the course of the treatment. Tannic acid at 10 mg/kg arrests the weight gain while 30 mg/kg reduces the weight. This is an example for tannic acid for weight reduction and to treat obesity disorders
- Figure 5 is a chart showing dose-dependent reduction of the spontaneous locomotion activities of mice after repeated injections of tannic acids or a vehicle control.
- Figure 6 is a chart showing that tannic acids (Merck Millipore, Germany) by a single oral gavage at the various doses as indicated dose-dependently reduced locomotion activity in mice in a dose-dependent manner.
- Figure 7 includes diagrams showing the dose-dependent improvement of anxiety-like behaviors of the mice after repeated injections of tannic acids vs. vehicle control. Panel A: aversive duration of each group. Panel B: aversive distance ratio of each group. Panel C: number of risk assessments of each group.
- Figure 8 is a chart showing the dose-dependent improved performance of spatial memory retrieval of mice after repeated injections of tannic acid vs. vehicle control. 30 mg/kg group of animals perform better than 10 mg/kg group.
- Figure 9 is a schematic illustration of an exemplary experimental design for verifying the effects of tannic acids in mice treating with MK-801 as described in Example 3. The spontaneous locomotion activity and sensorimotor function of each mouse treated either with tannic acids or vehicle control were tested by open field and prepulse inhibition, respectively, with at least 1-week interval between tests. 20 minutes prior to the MK-801 (or vehicle) administration, tannic acids (or the vehicle) were administrated to each mouse. Also, 20 minutes prior to the behavioral tests, the MK-801 (or the vehicle) was administrated to each mouse.
- Figure 10 is a chart showing the effect of tannic acids via a single oral administration in reducing MK-801-induced hyper-locomotion in a dose-dependent manner.
- Figure 11 is a chart showing the effects of tannic acids in improving prepulse inhibition in a dose-dependent manner. . The improvement of the prepulse inhibition is better than the controls. 10 mg/kg group shows less improvement of prepulse inhibition than the groups of 15, 20 and 30 mg/kg groups.
- Figure 12 is a chart showing the improving effects of tannic acids from different sources on prepulse inhibition. Tannic acid is from Sigma-Aldrich (source A) or Spectrum, USA (source B) . The improvement of the prepulse inhibition is better than the controls.
- Figure 13 is a schematic illustration of an exemplary experimental design for verifying the effects of tannic acids in mice treating with MK-801 as described in Example 3.The spontaneous locomotion activity and sensorimotor function of each mouse treated either with tannic acids or vehicle control in addition to MK-801 were tested by open field, prepulse inhibition, Barnes maze, sucrose preference respectively, with at least 1-week interval among tests. 20 minutes prior to the MK-801 (or vehicle) injection, tannic acid (or the vehicle) was administrated to each mouse by i.p. injection. Also, 20 minutes prior to the behavioral tests, the MK-801 (or the vehicle) was administrated to each mouse by i.p. injection.
- Figure 14 is a chart showing the effects of tannic acids in improving MK-801-induced hyperactivity in a dose-dependent manner.
- Figure 15 is a chart showing the effects of tannic acids in improving MK-801-disrupted prepulse inhibition in a dose-dependent manner.
- Figure 16 is a chart showing the effects of tannic acids in improving MK-801-disrupted working memory in a dose-dependent manner in Barnes maze.
- Figure 17 is a chart showing the effects of tannic acids in improving MK-801-disrupted sucrose preference in a dose-dependent manner.
- Figure 18 is a schematic illustration of an exemplary experimental design for verifying the effects of tannic acids in mice on von Frey test. Tannic acids (or the vehicle) were administrated to each mouse by i.p. injection.
- Figure 19 is a chart showing the improvement of paw withdrawal pain threshold over time after injection of tannic acids or vehicle control (PBS) . Tannic acid treatment much improves the pain threshold.
- Figure 20 is a diagram showing the HPLC chromatogram of the composition containing tannic acid from Ouercus infectoria. There are impurities and substantial amount of tannic acids with 1-4 galloyl moieties.
- Figure 21 includes two diagrams showing the HPLC chromatogram of the composition containing tannic acid from Rhus chinensis. There are impurities and substantial amount of tannic acids with 1-4 galloyl moieties.
- Figure 22 includes two diagrams showing the HPLC chromatogram of the composition containing tannic acid from Rhus chinensis. There are impurities and substantial amount of tannic acids with 1-4 galloyl moieties.
- Figure 23 is a diagram showing the inhibitory activities against DAAO of tannic acids extracted from gallnuts from various plant or botanic sources as indicated. Tannic acids extract from gallnut of Rhus chinensis have higher inhibitory activity than from Rhus potaninii or Quercus infectoria, and 3-4 cm diameter gallnut of Rhus chinensis have higher inhibitory activity than the 6-7 cm diameter ones.
- Figure 24 is a chart showing the effect of tannic acids from different sources, via a single oral administration, in reducing MK-801-induced hyper-locomotion. Tannic acids from Enrichment #10 method have the highest inhibitory activities.
- Figure 25 is a chart showing tannic acids extracted by Enrichment #10 method have high potency, with a ceiling effect that the 50 mg/kg group of animals performed as well as the 200 mg/kg group, in improving MK-801-disrupted prepulse inhibition.
- Figure 26 is the diagram showing the HPLC-MS chromatograms of the compositions of tannic acid from Enrichment Method #10, USP Standard, and Wenzhou Ouhai Fine Chemicals Corporation where that of Enrichment Method #10 contains less than 0.35%of non-tannic acid impurities while those of UPS Standard and Wenzhou Ouhai Fine Chemicals Corporation contain much higher quantities of non-tannic acid impurities, 15.99%and 6.46%, respectively.
- Figure 27 is a schematic illustration of an exemplary enrichment method for preparing the tannic acid compositions described herein. See also Enrichment method 11 described below.
- Tannic acids are a subfamily of tannins existing in various plants. Tannic acids extracted from plants are a mixture of polygalloyl glucoses or polygalloyl quinic acid esters containing 2-12 galloyl moieties. Provided below is the structure of an exemplary tannic acid molecule that contains 10 galloyl moieties linked to a glucose moiety.
-
- Historically, tannic acids have been used as an antidote to soak up poisons, and for treating short-term conditions, such as bleeding, rashes and other conditions of soreness.
- Provided herein are improved enrichment methods for preparing tannic acid compositions, which are substantially free of small tannic acid molecules (e.g., containing <2%by weight tannic acids having less than 4 galloyl moieties) , substantially free of dextrin, gum, and/or resin, and/or substantially free of residues of solvents used in extracting tannic acids from a suitable source (e.g., a plant source as described herein) . The term “substantially free” of a component means that either no such component is present (i.e., undetectable by a routine method) or only minimal, trace amounts of the component are present such that it does not have any substantial impact on the properties of the composition containing such. In some instances, “substantially free” of a component in a composition means less than 10%(e.g., less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1%or lower) by weight of the component based on the weight of the composition. Also provided herein are tannic acid compositions containing a mixture of tannic acids which are substantially free of small tannic acid molecules, substantially free of dextrin, gum, and/or resin, and/or substantially free of residues of solvents used in extracting tannic acids from a suitable source (e.g., a plant source as described herein) . Such a mixture of tannic acids may be prepared by any of the methods described herein. The tannic acid mixtures described herein showed strong inhibitory activity against DAAO, which is known to be involved in various diseases and disorders, such as an obesity disorder, hyperlipidemia, hypercholesterolemia, hyperglycemia, diabetes, and CNS disorders. Such tannic acid mixtures also showed that tannic acids successfully reduced body weight and improved basic behavioral functioning, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory and cognitive behaviors in a mouse model. Further, tannic acids showed rescue and protective effects on mice treated with MK-801, an antagonist of the N-methyl-D-aspartate receptor (the NMDA receptor) . NMDA receptor is a glutamate receptor and ion channel protein expressed on nerve cells and plays an important role in controlling synaptic plasticity, repair, neurodevelopment, learning and memory function. Most CNS disorders have dysfunction of NMDA receptor. Accordingly, compositions containing the tannic acid mixtures described herein are expected to benefit treatment of CNS disorders associated with dysfunction of NMDA receptor. Such tannic acid compositions are also expected to benefit treatment of obesity and diseases and disorders associated with obesity.
- I. Improved Enrichment Methods for Preparing Tannic Acid Compositions
- The improved enrichment methods described herein include one or more of the following features: (i) a multiple-batch extraction process; (ii) a dextrin/gum/resin removal process, and (iii) a solvent residue removal process.
- (a) Multiple-Batch Extraction
- In some embodiment, tannic acids can be extracted from a composition comprising tannic acids, for example, the gallnut power or chips described herein, using a suitable solvent. Such a tannic acid-containing composition may comprise a heterogeneous population of tannic acids. A suitable solvent can then be used in this extraction process. As used herein, the term “solvent” refers to a liquid capable of dissolving one or more solutes. A solvent may comprise a pure population of a substance that dissolves a solute of interest. Alternatively, a solvent as used herein may be a mixture of multiple substances for dissolving the solute. A suitable solvent for extracting tannic acids comprise acetone, acetonitrile, methyl ethyl ketone, ethyl acetate, methyl acetate, ethanol, isopropanol, tetrahydrofuran, 1, 4-dioxane, pentane, hexane, heptane, water, or a combination thereof.
- The extraction process can be performed in a multiple-batch manner. Briefly, multiple batches of the tannic acid-containing compositions may be placed into the suitable solvent sequentially, each being incubated (e.g., with stirring) in the suitable solvent for a suitable period, e.g., 1-6 hours. For example, a first batch of the tannic acid-containing composition may be incubated with the suitable solvent for a suitable period, e.g., 1-6 hours or 2-4 hours. A second batch of the tannic acid-containing composition (which may be in substantially the same amount as the first batch) may then be placed into the suitable solvent (containing the first batch) and incubated for a suitable period, e.g., 1-6 or 2-4 hours. Afterwards, a third batch of the tannic acid-containing composition (which may also be in substantially the same amount as the first batch and/or second batch) may be placed in the same suitable solvent (containing the first and second batches) and incubate for a suitable period, e.g., 1-10 hours, 2-8 hours, or 3-6 hours. If needed, additional batches of the tannic acid-containing composition may be incubated with the suitable solvent in a similar manner. The soluble portion of the mixture then formed can then be filtered to remove insoluble substances and concentrated in vaccum to produce a crude tannic acid extract. Surprisingly, the yield of tannic acids using the multiple-batch approach was found to be at least 2 fold higher than the yield of tannic acids using a single-batch approach (incubating the same total amount of the tannic acid-containing composition in the same amount of the solvent simultaneously) . See Enrichment method 11 below.
- (b) Dextrin/Gum/Resin Removal
- Tannic acids extracted from a plant source such as those noted herein often contain dextrin, gum, and/or resin, which would limit therapeutic applications of the tannic acid compositions. The improved enrichment methods described herein may include a process that effectively removes dextrin, gum, and/or resin when needed.
- The dextrin/gum/resin removal process may be performed by mixing a tannic acid-containing composition with a suitable amount of an alkyl solvent and stirring the mixture thus formed at a suitable temperature (e.g., room temperature) for a suitable period (e.g., 1-4 hours or 2-3 hours) . The tannic acid-containing composition may be diluted in a suitable solvent (in which tannic acids can be dissolved, for example, acetone) if needed. Alkyl solvent refers to a solvent having an alkyl chain, for example, a C1-C10 alkyl chain. Examples include, but are not limited to, hexane, pentane or heptane. After the stirring process, the mixture can be kept for a while to allow for separation of two layers. The bottom oily layer thus formed can be collected. If needed, the resin-removal step can be repeated multiple times (e.g., 2-4 times) .
- Prior to the treatment with the alkyl solvent, the tannic acid-containing composition may be first mixed with a polar solvent for a suitable period to allow formation of an organic layer, which can be collected and subject to the following treatment with the alkyl solvent as described herein. A polar solvent contains molecules that are partially charges (have large dipole moments) and typically contain bonds between atoms with very different electronegativities, such as between oxygen and hydrogen. In some instances, the polar solvent can be a protic solvent, which contains molecules having a hydrogen atom bound to an oxygen or nitrogen. Examples include formic acid, n-butanol, isopropanol (IPA) , nitromethane, ethanol (EtOH) , methanol (MeOH) , acetic acid, and water. In other instances, the polar solvent can be an aprotic solvent, which lacks an acidic hydrogen. Examples include N-methylpyrrolidone, tetrahydrofuran (THF) , ethyl acetate (EtOAc) , acetone, dimethylformamide (DMF) , acetonitrile (MeCN) , dimethyl sulfoxide (DMSO) , and propylene carbonate (PC) .
- Results from this study showed that performing the resin removal step noted above twice led to significantly enhanced resin removal efficiency as compared with using MgSO4, Na2CO3, and/or K2CO3 treatment. See Examples below.
- (c) Solvent Residue Removal
- As solvents are typically used in extracting tannic acids from a natural source, the resultant tannic acid compositions often contain solvent residues, which would also affect therapeutic applications and/or therapeutic efficacy of the tannic acid compositions. Provided herein is an effective approach for removing such solvent residues from tannic acid products, when needed.
- Solvent residues may be removed from tannic acid solids obtained following a routine method or the procedures described herein. To perform this removal step, tannic acid solids may be slurried using a suitable amount (e.g., 5-30x mL such as 20 x mL) of a suitable solvent at a suitable temperature (e.g., 40-70 ℃ such as 60 ℃) for a suitable period (e.g., 12-24 hours, such as 16 hours) . The resultant mixture can then be filtered and evaporated in vacuum at a suitable temperature (e.g., 10-80 ℃, preferably 60-80 ℃ such as 70 ℃) to allow for removal of residues of solvents used in the preparation process. The solvent for use in this step may be an alkyl solvent (e.g., C1-C10 alkyl solvent such as hexane) , a chlorinated solvent such as dichloromethane, or dichloroethane, or a combination thereof. When needed, this step can be repeated multiple times (e.g., 2-5 times) such that solvent residues can be removed substantially from the final tannic acid products. As shown in the table below, performing this step could significantly remove solvent residues from tannic acid compositions the preparation of which involves solvent extraction.
- Table 1. Efficiency of Solvent Residue Removal
-
- (d) Exemplary Enrichment Methods
- Provided below are exemplary enrichment methods for producing tannic acid compositions that are substantially free of small tannic acid molecules (e.g., containing <2% by weight tannic acids having less than 4 galloyl moieties) , substantially free of dextrin, gum, and/or resin, and/or substantially free of residues of solvents used in extracting tannic acids from a suitable source (e.g., a plant source as described herein) .
- In some embodiments, a tannic acid composition as described herein can be prepared as follows. Gallnuts from a suitable plant or botanic source, e.g., those described herein, can be obtained via routine methods. The gallnuts can be grinded to form gallnut powers or gallnut chips. In some examples, the gallnut power can be passed through a sieve having a suitable size (e.g., 20-mesh, 30-mesh, 40-mesh, 50-mesh, or 60-mesh) to form fine gallnut powers.
- Suitable plant sources include, but are not limited to, Rhus chinensis, Rhus javanica, Rhus semialata, Rhus coriaria, Rhus potaninii, Rhus punjabensis var. sinica (Diels) Rehder &E.H. Wilson, Camellia sinensis, Berry, Bixa orellana, Vitis vinifera, Punica granatum, Quercus infectoria, Quercus cerris, Acacia mearnsii, Pseudotsuga menziesii, Caesalpinia spinosa, Fagus hayata Palib. ex Hayata, or Machilus thunbergii Sieb. &Zucc. . In some embodiments, the tannic acid or tannic acid mixture contained in the composition herein are extracted from Rhus chinensis, Rhus javanica, Rhus semialata, Rhus coriaria, Rhus potaninii, or Rhus punjabensis var. sinica (Diels) Rehder &E.H. Wilson.
- The plant source described herein may require a nesting insect including but not limited to Andricus kollari, Andricus fecundatrix, Andricus quercuscalicis, Andricus quercuscalicis, Biorhiza pallida, Neuroterus quercusbaccarum, Neuroterus albipes, Neuroterus numismalis, Cynips quercusfolii, Melaphis chinensis (Bell) , Melaphis peitan Tsai et Tang, Nurudea sinica Tsai et Tang, Nurudea shiraiiMatsumura, Nurudea rosea Matsumura, Meitanaphis elongallis Tsai et Tang, Macrorhinarium ensigallis Tsai et Tang, Macrorhinariumovagallis Tsai et Tang, Floraphis meitanensis Tsai et Tang, Meitanaphis flavogallis Tang, Kaburagia rhusicola Takagi, Kaburagia ovatihuicola Xiang, Kaburagia ensigallis Tsai et Tang, Kaburagia ovogallis, Kaburagia thusicola Takagi, Meitanaphis microgallis Xiang, and Floraphis choui Xiang.
- In some embodiments, the tannic acid or tannic acid mixture is extracted from gallnuts, including, but not limited to, Chinese belly-shaped gallnuts, horned gallnuts, hard ensiform gallnuts, egg-hard ensiform gallnuts, and inflorescence gallnuts of at least a plant or botanic source and requiring nesting insect described herein. The gallnut for use in preparing the tannic acids may have a diameter ranging from 1-8 cm (e.g., 1cm, 2cm, 3cm, 4cm, 5cm, 6cm, 7cm, or 8cm) . In some examples, the gallnut may have a diameter ranging from 2-6 cm (e.g., 3-5 cm) .
-
Plant Nesting insect Gallnuts Quercus infectoria Andricus kollari Oak gallnuts1 Rhus chinensis Melaphis chinensis (Bell) Chinese horned gallnuts2 Rhus potaninii Melaphis peitan Tsai et Tang Chinese belly-shaped gallnuts2 - 1The population biology of oak gall wasps (Hymenoptera: Cynipidae) , Annual Review of Entomology. 2002; 47: 633-68
- 2Study on Chinese Gallnut, Forest Research, 2003, 16 (6) : 760-767
- Crude tannic acid extracts may be extracted from the gallnut power and/or chips described herein using a conventional method or the multiple-batch approach described herein. The crude tannic acid extract can then be dissolved in water, an organic solvent, or a combination thereof, to form a tannic acid solution, which can be mixed with one or more of charcoal, metal carbonate (e.g., Na2CO3 or K2CO3) , and metal sulfate (e.g., CaSO4, MgSO4) , simultaneously or sequentially, to remove undesired substances (e.g., substances that can be absorbed to the charcoal or precipitated/removed by the metal carbonate and/or metal sulfate) . Exemplary metal carbonates include, but are not limited to, lithium carbonate, sodium carbonate, or potassium carbonate. Exemplary metal sulfate can be calcium sulfate or magnesium sulfate.
- In some examples, a crude tannic acid extract as described herein can be mixed with charcoal first for a suitable period of time (e.g., stirred at room temperature for 1-24 hours) . A metal carbonate and/or a metal sulfate (e.g., Na2CO3, K2CO3, CaSO4 and/or MgSO4) can then be added to the mixture, which can be stirred under a suitable temperature (e.g., room temperature) for a suitable period (e.g., 30 minutes to 6 hours) . The mixture can then be filtered through, e.g., a bed of Celite, washed with a suitable solvent (e.g., acetone, acetonitrile, methyl ethyl ketone, ethyl acetate, ethanol, or a combination thereof) , and concentrated by a routine method to produce a tannic acid composition.
- In other examples, the crude tannic acid extract can be mixed with charcoal first for a suitable period of time (e.g., stirred at room temperature for 1-24 hours, for example, 6-12 hours or 12-18 hours) . The charcoal can then be removed from the mixture to form a solution. A metal carbonate and/or metal sulfate (e.g., Na2CO3, K2CO3, CaSO4 and/or MgSO4) can then added to the solution, which can be stirred under a suitable temperature (e.g., room temperature) for a suitable period (e.g., 30 minutes to 6 hours, for example, 30 minutes to 2 hours or to 1 hour) . The mixture can then be filtered through, e.g., a bed of Celite, washed with a suitable solvent (e.g., acetone, acetonitrile, methyl ethyl ketone, ethyl acetate, methyl acetate, ethanol, or a combination thereof) , and concentrated by a routine method to produce a tannic acid composition.
- In some examples, a tannic acid mixture formed in any of the steps described above may be placed in a suitable amount of ethyl acetate, methyl acetate, and/or methyl ethyl ketone (e.g., 3-8 x mL or 6x mL) and incubated at a suitable temperature (e.g., room temperature) for a suitable period (e.g., 1-2 hours) . The organic layer thus formed can be collected, which contains tannic acids.
- In some examples, a crude tannic acid extract as described herein can be incubated with a metal carbonate at a suitable temperature (e.g., 20-60 ℃ such as 30-40 ℃) for a suitable period. The mixture thus formed can then be extracted by a suitable amount of ethyl acetate, methyl acetate, and/or methyl ethyl ketone (e.g., 3-8 x mL or 6x mL) and incubated at a suitable temperature (e.g., room temperature or 20-50 ℃) for a suitable period (e.g., 1-2 hours) to produce an organic solution. The organic solution can be incubated with charcoal and one or more metal sulfate, either simultaneously or sequentially, to remove substances absorbed to the charcoal and/or substances precipitated by the metal sulfate, thereby producing an enriched tannic acid mixture. When needed, the tannic acid mixture can be filtered through, e.g., a bed of Celite, washed with a suitable solvent (e.g., acetone, acetonitrile, methyl ethyl ketone, ethyl acetate, methyl acetate, ethanol, or a combination thereof) , and concentrated by a routine method to produce a tannic acid composition.
- Any of the tannic acid mixtures described herein may also be incubated with silicon dioxide for a suitable period to further remove undesired substances.
- Any of the crude tannic acid extracts or enriched tannic acid mixtures as described herein may be subject to the process of removing dextrin/gum/resin as described herein. The resultant oily residues may be diluted in a suitable solvent, for example, acetone, acetonitrile, methyl ethyl ketone, ethyl acetate, methyl acetate, pentane, hexane, heptane, or a combination thereof. The solution thus formed can be stirred and a chlorinated solvent such as CH2Cl2 or dichloroethane can be added to the solution slowly in a dropwise manner to allow for precipitation of the desired tannic acids. The solids can then be collected by routine practice (e.g., filtration and/or drying) to produce an enriched tannic acid composition.
- The tannic acid solids thus prepared can then be subject to the solvent residual removal process described herein.
- Some examples follow, which are merely illustrative and by no means limit the present disclosures to these specific examples.
- - A method comprising (i) grinding gallnuts of a suitable plant to form fine powder or small chips; (ii) extracting the find powder or small chips with a first solvent (e.g., those described herein) via the multiple-batch approach as described herein to produce a crude tannic acid extract; (iii) dissolving the crude tannic acid extract in water and mixing the tannic acid solution thus formed with K2CO3; (iv) extracting the mixture formed in (iii) with a suitable solvent (e.g., ethyl acetate) and collecting the organic layer thus formed; (v) mixing the organic layer with charcoal and stirring the mixture thus formed for a suitable period (e.g., 0.5 hour) ; (vi) incubating the mixture with MgSO4 for a suitable period; (vii) filtering the mixture formed in (vi) through Celite and collecting the filtrate; (viii) mixing the filtrate (which may be diluted) with an alkyl solvent (e.g., hexane) and collecting the oily residues thus formed; (ix) optionally repeating step (viii) ; (x) collecting the resultant oily residues, which is optionally diluted in acetone, and mixing the oily residues with CH2Cl2; (xi) stirring the mixture thus formed for a suitable period allowing for precipitation of solid tannic acids; (xii) collecting the solid tannic acids, which can be dried under vacuum if needed; (xiii) slurrying the solid tannic acids with an alkyl solvent, a chlorinated solvent, or a combination thereof; (xiv) optionally repeating step (xiii) ; and (xv) evaporating the mixture thus formed in vacuum, thereby producing a tannic acid composition.
- A schematic illustration of the above-described preparation method is provided in Figure 27.
- II. Tannic Acid-Containing Compositions and Kits Containing Such
- One aspect of the present disclosure relates to compositions, for example, pharmaceutical compositions, health food product such as nutraceutical compositions, and medical food that comprise one or more tannic acids and a carrier, e.g., a pharmaceutically acceptable carrier and/or an edible carrier. Such carriers, either naturally occurring or non-naturally occurring (synthetic) , may confer various benefits to the tannic acids in the composition, for example, improving in vitro and/or in vivo stability of the tannic acids, enhancing bioavailability of the tannic acids, increasing bioactivity of the tannic acids, and/or reducing side effects. Suitable carriers include, but are not limited to, diluents, fillers, salts, buffers, stabilizers, solubilizers, buffering agents, preservatives, or a combination thereof. In some examples, the carrier may comprise benzoate such as sodium benzoate.
- (A) Tannic Acid Contents
- The tannic acid populations in the compositions described herein may be substantially free of small tannic acid molecules (e.g., containing <2%by weight tannic acids having less than 4 galloyl moieties) , substantially free of dextrin, gum, and/or resin, and/or substantially free of residues of solvents used in extracting tannic acids from a suitable source (e.g., a plant source as described herein) . The term “substantially free” of a component means that either no such component is present (i.e., undetectable by a routine method) or only minimal, trace amounts of the component are present such that it does not have any substantial impact on the properties of the composition containing such. In some instances, “substantially free” of a component in a composition means less than 10% (e.g., less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1%or lower) by weight of the component based on the weight of the composition. Such tannic acid populations may be prepared by any of the improved enrichment methods described herein.
- While the tannic acid population, either heterogeneous or substantially homogeneous, can be purified from a suitable natural source, the tannic acid-containing composition described herein differs from the naturally-occurring tannic acid compositions in various aspects. In some examples, the tannic acid mixture in the composition is substantially free of tannic acids having less than 4 galloyl moieties, which exist in naturally-occurring tannic acid mixtures. Removal of the tannic acids having a low number of galloyl moieties can enhance the biological activity (e.g., inhibiting DAAO) of the resultant tannic acid mixture. In other examples, the composition described herein contain tannic acids having a high number of gallolyl moieties (e.g., 5-12, 6-12, 7-12, or 8-12) at a level substantially greater than such tannic acids in naturally-occurring tannic acid mixtures. As provided herein, the tannic acid populations contained in the composition described herein showed enhanced biological activity (e.g., inhibiting DAAO) as compared with tannic acids having lower numbers of gallolyl moieties. In yet other examples, the composition may contain a substantially homogeneous population of tannic acids, as opposed to the heterogeneous population of tannic acids existing in nature.
- In some embodiments, the composition described herein may contain ≥ 98% (e.g., 98.5%, 99%, or 99.5%) of tannic acids that have 4-12 galloyl moieties. In other embodiments, the composition may contain ≥ 97% (e.g., 97.5%, 98%, 98.5%, 99%, or 99.5%) of tannic acids that have 5-12 galloyl moieties. In yet other embodiments, the composition may contain ≥ 90% (e.g., 92%, 95%, 97%, 98%, or higher) of tannic acids that have 6-12 galloyl moieties. Alternatively, the composition described herein may contain ≥ 60% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, or higher) of tannic acids that have 8-12 galloyl moieties.
- In particular examples, the composition described herein may contain about 4-20%(e.g., about10-20%such as about 15%) of tannic acids having 5 galloyl moieties, about 10-35%(e.g., about 15-25%such as about 20%) of tannic acids having 6-7 galloyl moieties, and about 55-85% (e.g., about 55-65%such as about 60%or 65%) of tannic acids having 8-12 galloyl moieties.
- The tannic acid populations described herein (e.g., prepared by any of the improved enrichment methods also described herein) , or pharmaceutically acceptable salts thereof, may be mixed with one or more carriers (e.g., pharmaceutically acceptable carriers) to form compositions. The term “pharmaceutically-acceptable salts” refers to the relatively non-toxic, inorganic or organic base addition salts of tannic acids. These salts can be prepared in situ in the administration vehicle or the dosage form manufacturing process, or by separately reacting the one or more tannic acids with a suitable organic or inorganic base, and isolating the salt thus formed during subsequent purification. Suitable inorganic bases include, but are not limited to, sodium hydroxide, barium hydroxide, iron (ii) hydroxide, iron (III) hydroxide, magnesium hydroxide, calcium hydroxide, aluminium hydroxide, ammonium hydroxide, potassium hydroxide, caesium hydroxide, or lithium hydroxide. Suitable organic bases include, but are not limited to, pyridine, methyl amine, imidazole, benzimidazole, histidine, phosphazene bases, or a hydroxide of an organic cation such as quaternary ammonium hydroxide and phosphonium hydroxide. See, for example, Berge et al. (1977) J. Pharm. Sci. 66: 1-19.
- (B) Pharmaceutical Compositions
- The tannic acid-containing compositions as described herein, e.g., a pharmaceutical composition comprising a pharmaceutically acceptable carrier, can be used for treating any of the target diseases as described herein. In some embodiments, the tannic acid population in the composition is substantially free of condensed tannins and/or phlorotannins. “Acceptable” means that the carrier must be compatible with the active ingredient of the composition (and preferably, capable of stabilizing the active ingredient) and not deleterious to the subject to be treated. Pharmaceutically acceptable excipients (carriers) including buffers, which are well known in the art. See, e.g., Remington: The Science and Practice of Pharmacy 20th Ed. (2000) Lippincott Williams and Wilkins, Ed. K.E. Hoover.
- Pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers and other material which are well-known in the art. Exemplary pharmaceutically acceptable carriers for tannic acids or salts thereof in particular are described in U.S. Patent No. 5,211,657. Such preparations may routinely contain salt, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from a suitable inorganic base, (e.g., sodium hydroxide, barium hydroxide, iron (ii) hydroxide, iron (III) hydroxide, magnesium hydroxide, calcium hydroxide, aluminium hydroxide, ammonium hydroxide, potassium hydroxide, caesium hydroxide, or lithium hydroxide) or a suitable organic base (e.g., pyridine, methyl amine, imidazole, benzimidazole, histidine, phosphazene bases, or a hydroxide of an organic cation such as quaternary ammonium hydroxide and phosphonium hydroxide) . Also, pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as lithium, sodium, potassium or calcium salts.
- The tannic acid-containing pharmaceutical compositions as described herein can comprise pharmaceutically acceptable carriers, excipients, or stabilizers in the form of lyophilized formulations or aqueous solutions. Remington: The Science and Practice of Pharmacy 20th Ed. (2000) Lippincott Williams and Wilkins, Ed. K. E. Hoover. Such carriers, excipients or stabilizers may enhance one or more properties of the active ingredients (e.g., tannic acids) in the compositions described herein, e.g., bioactivity, stability, bioavailability, and other pharmacokinetics and/or bioactivities.
- Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations used, and may comprise buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; benzoates, sorbate and m-cresol) ; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, serine, alanine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes) ; and/or non-ionic surfactants such as TWEENTM (polysorbate) , PLURONICSTM (nonionic surfactants) , or polyethylene glycol (PEG) .
- In other examples, the pharmaceutical composition described herein can be formulated in sustained-release format. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing tannic acids, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly (2-hydroxyethyl-methacrylate) , or poly (vinylalcohol) ) , polylactides (U.S. Pat. No. 3,773,919) , copolymers of L-glutamic acid and 7 ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOTTM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate) , sucrose acetate isobutyrate, and poly-D- (-) -3-hydroxybutyric acid.
- The pharmaceutical compositions to be used for in vivo administration must be sterile. This is readily accomplished by, for example, filtration through sterile filtration membranes. Therapeutic compositions are generally placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
- The pharmaceutical compositions described herein can be in unit dosage forms such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal administration, or administration by inhalation or insufflation, or jntrathecal or intracerebral routes.
- For preparing solid compositions such as tablets, the principal active ingredient can be mixed with a pharmaceutical carrier, e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g., water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
- Suitable surface-active agents include, in particular, non-ionic agents, such as polyoxyethylenesorbitans (e.g., TweenTM 20, 40, 60, 80 or 85) and other sorbitans (e.g., SpanTM 20, 40, 60, 80 or 85) . Compositions with a surface-active agent will conveniently comprise between 0.05 and 5%surface-active agent, and can be between 0.1 and 2.5%. It will be appreciated that other ingredients may be added, for example mannitol or other pharmaceutically acceptable vehicles, if necessary.
- Suitable emulsions may be prepared using commercially available fat emulsions, such as IntralipidTM, LiposynTM, InfonutrolTM, LipofundinTM and LipiphysanTM. The active ingredient may be either dissolved in a pre-mixed emulsion composition or alternatively it may be dissolved in an oil (e.g., soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil) and an emulsion formed upon mixing with a phospholipid (e.g. egg phospholipids, soybean phospholipids or soybean lecithin) and water. It will be appreciated that other ingredients may be added, for example glycerol or glucose, to adjust the tonicity of the emulsion. Suitable emulsions will typically contain up to 20%oil, for example, between 5 and 20%. The fat emulsion can comprise fat droplets between 0.1 and 1.0 μm, particularly 0.1 and 0.5 μm, and have a pH in the range of 5.5 to 8.0.
- Pharmaceutical compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as set out above. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
- Compositions in preferably sterile pharmaceutically acceptable solvents may be nebulized by use of gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device may be attached to a face mask, tent or intermittent positive pressure breathing machine. Solution, suspension or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.
- In some embodiments, any of the tannic acid-containing pharmaceutical compositions may further comprise a second therapeutic agent based on the intended therapeutic uses of the composition.
- In some examples, the second therapeutic agent is an anti-obesity agent, including, but not limited to, orlistat, lorcaserin, sibutramine, rimonabant, metformin, exenatide, pralintide, phentermine, fenfluramine, dexfenfluramine topiramate, dinitrophenol, bupropion, and zonisamide.
- In other examples, the second therapeutic agent is an agent for treating a CNS disease/disorder. Such a therapeutic agent may be an antipsychotic drug. Exemplary antipsychotic drugs include, but are not limited to, butyrophenone (e.g., haloperidol (HALDOLTM) , phenothiazine (e.g., chlorpromazine (THORAZINETM) , fluphenazine (PROLIXINTM) , perphenazine (TRILAFONTM) , prochlorperazine (COMPAZINETM) , thioridazine (MELLARILTM) , trifluoperazine (STELAZINETM) , mesoridazine, promazine, triflupromazine (VESPRINTM) , levomepromazine (NOZINANTM) , promethazine (PHENERGANTM) , thioxanthene (e.g., chlorprothixene, flupenthixol (DEPIXOLTM, FLUANXOLTM) , thiothixene (NAVANETM) , zuclopenthixol (CLOPIXOLTM, ACUPHASETM) , clozapine (CLOZARILTM) , olanzapine (ZYPREXATM) , risperidone (RISPERDALTM, RISPERDAL CONSTATM) , quetiapine (SEROQUELTM) , ziprasidone (GEODONTM) , amisulpride (SOLIANTM) , asenapine, paliperidonearipiprazole (ABILIFYTM) , dopamine partial agonists (BIFEPRUNOXTM, NORCLOZAPINETM (ACP-104) ) , lamotrigine (LAMICTALTM) , , tetrabenazine (NITOMANTM, XENAZINETM) , cannabidiol, LY2140023, and the like) .
- Alternatively, the second therapeutic agent can be an antidepressant and/or mood stabilizer. In certain embodiments the antidepressant comprises a monoamine oxidase inhibitor (MAOI) , a tricyclic antidepressant (TCA) , a tetracyclic antidepressant (TeCA) , a selective serotonin reuptake inhibitor (SSRI) , a noradrenergic and specific serotonergic antidepressant (NASSA) , a norepinephrine (noradrenaline) reuptake inhibitor, a norepinephrine-dopamine reuptake inhibitor, and/or a serotonin-norepinephrine reuptake inhibitor (SNRI) . Exemplary SSRIs include fluoxetine (PROZACTM) , paroxetine (PAXILTM, SEROXATTM) , escitalopram (LEXAPROTM, ESIPRAMTM) , citalopram (CELEXATM) , sertraline (ZOLOFTTM) , fluvoxamine (LUVOXTM) ) . Exemplary SNRIs include venlafaxine (EFFEXORTM) , milnacipram and duloxetine (CYMBALTATM) . Additional antidepressant include a noradrenergic and specific serotonergic antidepressant (NASSA) (e.g., mirtazapine (AVANZATM, ZISPINTM, REMERONTM) , or mianserin, a norepinephrine (noradrenaline) reuptake inhibitor (NRI) (e.g., reboxetine (EDRONAXTM) ) , a norepinephrine-dopamine reuptake inhibitors (e.g., bupropion (WELLBUTRINTM, ZYBANTM) ) , amitriptyline, nortriptiline, protriptyline, desipramine, imipramine, trimipramine, amoxapine, bupropion, bupropion SR, clomipramine, doxepin, isocarboxazid, venlafaxine XR, tranylcypromine, trazodone, nefazodone, phenelzine, lamatrogine, lithium, topiramate, gabapentin, carbamazepine, oxacarbazepine, valporate, maprotiline, mirtazapine, brofaromine, gepirone, moclobemide, isoniazid, iproniazid, and the like.
- In other examples, the second therapeutic agent can be an agent for the treatment of ADD and/or ADHD. Suitable ADHD medications include, but are not limited to amphetamine, modafinil, desoxyn, methamphetamine, cocaine, arecoline, dexmethylphenidate (focalin, focalin XR) , dextroamphetamine (dexedrine, dexedrine spansules, dextroamphetamine ER, dextrostat) , methylphenidate (concerta, daytrana, metadate CD, metadate ER, methylin, methylin ER, ritalin, ritalin-LA, ritalin-SR) , lisdexamfetamine dimesylate (Vyvanse) , mixed salts amphetamine (Adderall, Adderall XR) , atomoxetine (Strattera) , clonidine hydrochloride (Catapres) , guanfacine hydrochloride (Tenex) , arecoline, and pemoline.
- Further, the second therapeutic agent may be an agent for use in treating a cognitive disorder, and/or a condition characterized by neurodegeneration (e.g., Alzheimer's disease, or Parkinson's disease) . Such therapeutic agents include, but are not limited to tacrine, rivastigmine, memantine (AXURATM, AKATINOLTM, NAMENDATM, EBIXATM, ABIXATM) , donepezil (AriceptTM) , physostigmine, nicotine, arecoline, huperzine alpha, selegiline, rilutekTM (riluzole) , vitamine c, vitamine e, carotenoids, ginkgo biloba, and the like.
- (C) Health Food Product
- In some embodiments, the tannic acid-containing compositions described herein can be a health food product, which can be any kinds of liquid and solid/semi-solid materials that are used for nourishing humans and animals, for improving basic behavioral functioning, hyperactivity, anxiety, depression, suicidal ideation and/or behavior, sensorimotor gating, pain threshold, memory and/or cognitive functioning, or for facilitating treatment of any of the target diseases noted herein (e.g., an obesity disorder, hyperlipidemia, hyperglycemia, diabetes, or a CNS disorder, including those described herein) . The health food product may be a food product (e.g., tea-based beverages, juice, soft drinks, coffee, milk, jelly, cookies, cereals, chocolates, snack bars, herbal extracts, dairy products (e.g., ice cream, and yogurt) ) , a food/dietary supplement, or a nutraceutical formulation.
- The health food product described herein, containing one or more tannic acids (e.g., the tannic acid mixture described herein or the substantially homogenous population of a tannic acid having a defined number of galloyl moieties as also described herein) , may comprise one or more edible carriers, which confer one or more of the benefits to the tannic acids in the product as described herein. Examples of edible carriers include starch, cyclodextrin, maltodextrin, methylcellulose, carbonmethoxy cellulose, xanthan gum, and aqueous solutions thereof. Other examples include solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents) , isotonic agents, absorption delaying agents, stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art. In some examples, the healthy food products described herein may further include neuroprotective foods, such as fish oil, flax seed oil, and/or benzoate.
- In some examples, the healthy food product is a nutraceutical composition, which refers to compositions containing components from food sources and conferring extra health benefits in addition to the basic nutritional value found in foods. A nutraceutical composition as described herein comprises the tannic acid content described herein (e.g., the tannic acid mixture or the substantially homogenous tannic acid population as described herein) and additional ingredients and supplements that promote good health and/or enhance stability and bioactivity of the tannic acids.
- The actions of nutraceutical compositions may be fast or/and short-term or may help achieve long-term health objectives as those described herein, e.g., improving basic behavioral functioning, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory and/or cognitive functioning in, e.g., human subjects who have or are at risk for diseases associated with DAAO such as CNS disorders or human subjects who have or are at risk for an obesity disorder. The nutraceutical compositions may be contained in an edible material, for example, as a dietary supplement or a pharmaceutical formulation. As a dietary supplement, additional nutrients, such as vitamins, minerals or amino acids may be included. The composition can also be a drink or a food product, e.g., tea, soft drink, juice, milk, coffee, cookie, cereal, chocolate, and snack bar. If desired, the composition can be sweetened by adding a sweetener such as sorbitol, maltitol, hydrogenated glucose syrup and hydrogenated starch hydrolyzate, high fructose corn syrup, cane sugar, beet sugar, pectin, or sucralose.
- The nutraceutical composition disclosed herein can be in the form of a solution. For example, the nutraceutical formulation can be provided in a medium, such as a buffer, a solvent, a diluent, an inert carrier, an oil, or a creme. In some examples, the formulation is present in an aqueous solution that optionally contains a non-aqueous co-solvent, such as an alcohol. The nutraceutical composition can also be in the form of powder, paste, jelly, capsule, or tablet. Lactose and corn starch are commonly used as diluents for capsules and as carriers for tablets. Lubricating agents, such as magnesium stearate, are typically added to form tablets.
- The health food products may be formulated for a suitable administration route, for example, oral administration. For oral administration, the composition can take the form of, for example, tablets or capsules, prepared by conventional means with acceptable excipients such as binding agents (for example, pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose) ; fillers (for example, lactose, microcrystalline cellulose or calcium hydrogen phosphate) ; lubricants (for example, magnesium stearate, talc or silica) ; disintegrants (for example, potato starch or sodium starch glycolate) ; or wetting agents (for example, sodium lauryl sulphate) . The tablets can be coated by methods well known in the art. Also included are bars and other chewable formulations.
- In some examples, the health food product can be in a liquid form and the one or more edible carriers can be a solvent or dispersion medium comprising but not limited to, ethanol, polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol) , lipids (e.g., triglycerides, vegetable oils, liposomes) or combinations thereof. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin; by the maintenance of the required particle size by dispersion in carriers such as, for example liquid polyol or lipids; by the use of surfactants such as, for example hydroxypropylcellulose; or combinations thereof. In many cases, it will be advisable to include an isotonic agent, such as, for example, sugars, sodium chloride or combinations thereof.
- Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use. In one embodiment, the liquid preparations can be formulated for administration with fruit juice. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (for example, sorbitol syrup, cellulose derivatives or hydrogenated edible fats) ; emulsifying agents (for example, lecithin or acacia) ; non-aqueous vehicles (for example, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils) ; and preservatives (for example, methyl or propyl-p-hydroxybenzoates, benzoate or sorbate) .
- The health food products described herein may further comprise one or more second therapeutic agents, including those described herein.
- (D) Medical Food Products
- The present disclosure also provides compositions of medical food products, use in improving basic behavioral functioning, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory and/or cognitive functioning, and/or for treating a target disease as described herein (e.g., an obesity disorder, hyperlipidemia, hyperglycemia, diabetes, or a CNS disorder) . A medical food product is a food product formulated to be consumed or administered enterally. Such a food product is usually used under the supervision of a physician for the specific dietary management of a target disease, such as those described herein. In some instances, such a medical food composition is specially formulated and processed (as opposed to a naturally occurring foodstuff used in a natural state) for a patient in need of the treatment (e.g., human patients who suffer from illness or who requires use of the product as a major active agent for alleviating a disease or condition via specific dietary management. ) In some examples, a medical food composition described herein is not one of those that would be simply recommended by a physician as part of an overall diet to manage the symptoms or reduce the risk of a disease or condition.
- Any of the medical food compositions described herein, comprising one or more tannic acid molecules or salts thereof and at least one carrier (e.g., those described herein) , can be in the form of a liquid solution; powder, bar, wafer, a suspension in an appropriate liquid or in a suitable emulsion, as detailed below. The at least one carrier, which can be either naturally-occurring or synthetic (non-naturally occurring) , would confer one or more benefits to the tannic acid content in the composition, for example, stability, bioavailability, and/or bioactivity. Any of the carriers described herein may be used for making the medical food composition. In some embodiments, the medical food composition may further comprise one or more additional ingredients selected from the group including, but not limited to natural flavors, artificial flavors, major trace and ultra-trace minerals, minerals, vitamins, oats, nuts, spices, milk, egg, salt, flour, lecithin, xanthan gum and/or sweetening agents. The medical food composition may be placed in a suitable container, which may further comprise at least an additional therapeutic agent such as those described herein.
- (E) Kits
- The present disclosure also provides kits for use in improving basic behavioral functioning, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory and/or cognitive functioning, and/or for treating a target disease as described herein (e.g., an obesity disorder, hyperlipidemia, hyperglycemia, diabetes, or a CNS disorder) . Such kits can include one or more containers comprising a tannic acid-containing composition as described herein and optionally one or more of the second therapeutic agents as also described herein.
- In some embodiments, the kit can comprise instructions for use in accordance with any of the methods described herein. The included instructions can comprise, for example, a description of administration of the tannic acid-containing composition and optionally a description of administration of the second therapeutic agent (s) to improve basic behavioral functioning, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory and/or cognitive functioning, or to treat a target disease as described herein. The kit may further comprise a description of selecting an individual suitable for treatment based on identifying whether that individual has the disease or is at risk for the disease. In still other embodiments, the instructions comprise a description of administering one or more agents of the disclosure to an individual at risk of the disease or to an individual who is in need of improving basic behavioral functioning, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory and/or cognitive functioning.
- The instructions relating to the use of the tannic acid-containing composition to achieve the intended therapeutic effects generally include information as to dosage, dosing schedule, and route of administration for the intended treatment. The containers may be unit doses, bulk packages (e.g., multi-dose packages) or sub-unit doses. Instructions supplied in the kits of the invention are typically written instructions on a label or package insert (e.g., a paper sheet included in the kit) , but machine-readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.
- The label or package insert may indicate that the composition is used for the intended therapeutic utilities. Instructions may be provided for practicing any of the methods described herein.
- The kits of this invention are in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags) , and the like. Also contemplated are packages for use in combination with a specific device, such as an inhaler, nasal administration device (e.g., an atomizer) or an infusion device such as a minipump. A kit may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle) . The container may also have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle) .
- Kits may optionally provide additional components such as buffers and interpretive information. Normally, the kit comprises a container and a label or package insert (s) on or associated with the container. In some embodiments, the invention provides articles of manufacture comprising contents of the kits described above.
- III. Applications of Tannic Acid-Containing Compositions
- Any of the tannic acid-containing compositions described herein may be used to improve basic behavioral functioning, weight reduction, hyperactivity, anxiety, depression, suicidal ideation and/or behavior, sensorimotor gating, pain threshold, memory, and/or cognitive functioning in a subject in need of the treatment. Such compositions may also be used to treating diseases or disorders associated with DAAO such as a central nervous disorder (e.g., those described herein) . The compositions may also be used to treating an obesity disorder.
- As used herein, the term “treating” refers to the application or administration of a composition including one or more active agents to a subject, who is in need of the treatment, for example, having a target disease or disorder, a symptom of the disease/disorder, or a predisposition toward the disease/disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disorder, the symptom of the disease, or the predisposition toward the disease or disorder.
- Alleviating a target disease/disorder includes delaying the development or progression of the disease, or reducing disease severity. Alleviating the disease does not necessarily require curative results. As used therein, “delaying” the development of a target disease or disorder means to defer, hinder, slow, retard, stabilize, and/or postpone progression of the disease. This delay can be of varying lengths of time, depending on the history of the disease and/or individuals being treated. A method that “delays” or alleviates the development of a disease, or delays the onset of the disease, is a method that reduces probability of developing one or more symptoms of the disease in a given time frame and/or reduces extent of the symptoms in a given time frame, when compared to not using the method. Such comparisons are typically based on clinical studies, using a number of subjects sufficient to give a statistically significant result.
- “Development” or “progression” of a disease means initial manifestations and/or ensuing progression of the disease. Development of the disease can be detectable and assessed using standard clinical techniques as well known in the art. However, development also refers to progression that may be undetectable. For purpose of this disclosure, development or progression refers to the biological course of the symptoms. “Development” includes occurrence, recurrence, and onset. As used herein “onset” or “occurrence” of a target disease or disorder includes initial onset and/or recurrence.
- To achieve any of the intended therapeutic effects described herein, an effective amount of a tannic acid-containing composition may be administered to a subject in need of the treatment via a suitable route.
- The terms “subject, ” “individual, ” and “patient” are used interchangeably herein and refer to a mammal being assessed for treatment and/or being treated. Subjects may be human, but also include other mammals, particularly those mammals useful as laboratory models for human disease, e.g. mouse, rat, rabbit, dog, etc.
- A human subject who needs the treatment may be a human patient having, at risk for, or suspected of having a target disease/disorder, such as a CNS disorder, or a disease associated with obesity, e.g., diabetes, hyperglycemia, hypercholesterolemia or hyperlipidemia. A subject having a target disease or disorder can be identified by routine medical examination, e.g., laboratory tests, organ functional tests, and/or behavior tests. A subject suspected of having any of such target disease/disorder might show one or more symptoms of the disease/disorder. A subject at risk for the disease/disorder can be a subject having one or more of the risk factors for that disease/disorder, for example, a genetic factor. In some instances, the human subject is a child who has, is suspected of having, or is at risk for obesity or a CNS disorder associated with children, for example, attention deficit/hyperactivity disorder (ADHD) , autism, Asperger’s disorder, obsessive compulsive disorder, depression, psychosis, chronic pain, and learning disorder.
- The methods and compositions described herein may be used to treat a CNS disorder. Exemplary CNS disorders that can be treated by the methods and compositions described herein include attention deficit/hyperactivity disorder (ADHD) , schizophrenia, pain, depression, suicidal ideation and/or behavior, bipolar disorder, tic disorder, post-traumatic stress disorder, anxiety, social anxiety disorder, panic disorder, autism, Asperger’s disorder, obsessive-compulsive disorder, learning disorder, Tourette’s syndrome, mild cognitive impairment, dementia, vascular dementia, a neurodegenerative disorder (e.g., Alzheimer’s disorder or Parkinson’s disease, frontotemporal dementia, Huntington’s disease) , nocturnal enuresis, blepharospasm, non-epileptic seizure, psychosis, mania, cerebral malaria and behavior and psychological symptoms of dementia (BPSD) .
- A disease associated with obesity includes diseases and disorders that lead to obesity, as well as diseases and disorders that have a high occurrence rate in obesity patients. Obesity is a medical condition characterized by accumulation of excess body fat to the extent that it may have a negative effect on health. Obesity may be determined by body mass index (BMI) , a measurement obtained by dividing a person’s weight by the square of the person’s height. For example, BMI over 30 kg/m2 may indicate obesity. Exemplary diseases associated with obesity include, but are not limited to, eating disorders, anorexia nervosa, bulimia nervosa, stroke, coronary heart disease, heart attack, congestive heart failure, congenital heart disease, hypertension, non-alcoholic steatohepatitis, insulin resistance, hyperuricemia, hypothyroidism, osteoarthritis, gallstones, infertility, obesity hypoventilation syndrome, obstructive sleep apnea, chronic obstructed pulmonary disease, and asthma.
- As used herein, “an effective amount” refers to the amount of each active agent (e.g., the tannic acid mixture or the substantially homogenous population of tannic acids as described herein) required to confer therapeutic effect on the subject, either alone or in combination with one or more other active agents, such as one or more of the second therapeutic agents described herein. In some embodiment, the therapeutic effect is to inhibit the activity of DAAO (e.g., by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or higher) in the subject. In some embodiments, the therapeutic effect is improvement of basic behavioral functioning, weight reduction, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory, and/or improvement of cognitive functioning. In some embodiments, the therapeutic effect is alleviating one or more symptoms associated with any of the CNS disorders described herein. Alternatively or in addition, the therapeutic effect is maintaining or reducing body weight of the subject.
- Determination of whether an amount of the composition as described herein achieved the therapeutic effect would be evident to one of skill in the art. Effective amounts vary, as recognized by those skilled in the art, depending on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size, gender and weight, the duration of the treatment, the nature of concurrent therapy (if any) , the specific route of administration, genetic factors and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is generally preferred that a maximum dose of the individual components or combinations thereof be used, that is, the highest safe dose according to sound medical judgment.
- Empirical considerations, such as the half-life, generally will contribute to the determination of the dosage. Frequency of administration may be determined and adjusted over the course of therapy, and is generally, but not necessarily, based on treatment and/or suppression and/or amelioration and/or delay of a target disease/disorder. Alternatively, sustained continuous release formulations of a composition as described herein may be appropriate. Various formulations and devices for achieving sustained release are known in the art.
- Generally, for administration of any of the compositions, an exemplary daily dosage might range from about any of 0.1 μg/kg to 3 μg/kg to 30 μg/kg to 300 μg/kg to 3 mg/kg, to 30 mg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of symptoms occurs or until sufficient therapeutic levels are achieved to alleviate a target disease or disorder, or a symptom thereof. An exemplary dosing regimen comprises administering one or more initial doses at a suitable interval over a suitable period. If necessary, multiple maintenance doses can be given to the subject at a suitable interval over a suitable period of time. However, other dosage regimens may be useful, depending on the pattern of pharmacokinetic decay that the practitioner wishes to achieve. For example, dosing from one to four times a day or a week is contemplated. In some embodiments, dosing ranging from about 3 μg/mg to about 2 mg/kg (such as about 3 μg/mg, about 10 μg/mg, about 30 μg/mg, about 100 μg/mg, about 300 μg/mg, about 1 mg/kg, and about 2 mg/kg) may be used. In some embodiments, dosing frequency can be three times a day, twice a day, once a day, once every other day, once every week, once every 2 weeks, once every 4 weeks, once every 2 months, or once every 3 months. The dosing regimen can vary over time.
- In some embodiments, for an adult patient of normal weight, doses ranging from about 0.3 to 50.00 mg/kg/day (e.g., 0.5 to 40 mg/kg/day, 1-30 mg/kg/day, 5-30 mg/kg/day, or 10-20 mg/kg/day) may be administered. The particular dosage regimen, i.e., dose, timing and repetition, will depend on the particular individual and that individual's medical history, as well as the properties of the individual agents (such as the half-life of the agent, and other considerations well known in the art) .
- For the purpose of the present disclosure, the appropriate dosage of a tannic acid-composition as described herein will depend on the specific tannic acid or tannic acid mixture, and/or other active ingredient employed, the type and severity of the disease/disorder, whether the composition is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the DAAO inhibitor, and the discretion of the attending physician. Typically the clinician will administer a composition, until a dosage is reached that achieves the desired result.
- Conventional methods, known to those of ordinary skill in the art of medicine, can be used to administer the composition (e.g., a pharmaceutical composition, a health food composition, a nutraceutical composition or a medical food composition) to the subject, depending upon the type of disease to be treated or the site of the disease. This composition can also be administered via other conventional routes, e.g., administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term “parenteral” as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques. In addition, it can be administered to the subject via injectable depot routes of administration such as using 1-week, half (or two week) -, 1-, 3-, or 6-month depot injectable or biodegradable materials and methods. In some examples, the pharmaceutical composition is administered intraocularlly or intravitreally.
- Injectable compositions may contain various carriers such as vegetable oils, dimethylactamide, dimethyformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, and polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like) . For intravenous injection, water-soluble antibodies can be administered by the drip method, whereby a pharmaceutical formulation containing tannic acids and a physiologically acceptable excipient is infused. Physiologically acceptable excipients may include, for example, 5%dextrose, 0.9%saline, Ringer’s solution or other suitable excipients. Intramuscular preparations, e.g., a sterile formulation of a suitable soluble salt form of tannic acids, can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injection, 0.9%saline, or 5%glucose solution.
- In one embodiment, a tannic acid-containing composition is administered via a site-specific or targeted local delivery technique. Examples of site-specific or targeted local delivery techniques include various implantable depot sources of the tannic acid-containing compositions or local delivery catheters, such as infusion catheters, an indwelling catheter, or a needle catheter, synthetic grafts, adventitial wraps, shunts and stents or other implantable devices, site specific carriers, direct injection, or direct application. See, e.g., PCT Publication No. WO 00/53211 and U.S. Pat. No. 5,981,568.
- Treatment efficacy for a target disease/disorder can be assessed by methods well-known in the art.
- IV. Combined Therapy
- Also provided herein are combined therapies using any of the tannic acid-containing compositions described herein and a second therapeutic agent, such as those described herein. The term combination therapy, as used herein, embraces administration of these agents (e.g., a tannic acid-containing composition and an anti-CNS disorder or anti-obesity agent) in a sequential manner, that is, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or at least two of the agents, in a substantially simultaneous manner. Sequential or substantially simultaneous administration of each agent can be affected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular, subcutaneous routes, and direct absorption through mucous membrane tissues. The agents can be administered by the same route or by different routes. For example, a first agent (e.g., a tannic acid-containing composition) can be administered orally, and a second agent (e.g., an anti-CNS disorder agent or an anti-obesity agent) can be administered intravenously.
- As used herein, the term “sequential” means, unless otherwise specified, characterized by a regular sequence or order, e.g., if a dosage regimen includes the administration of a tannic acid-containing composition and an anti-CNS disorder or anti-obesity agent, a sequential dosage regimen could include administration of the tannic acid-containing composition before, simultaneously, substantially simultaneously, or after administration of the anti-CNS disorder or anti-obesity agent, but both agents will be administered in a regular sequence or order. The term “separate” means, unless otherwise specified, to keep apart one from the other. The term “simultaneously” means, unless otherwise specified, happening or done at the same time, i.e., the agents of the invention are administered at the same time. The term “substantially simultaneously” means that the agents are administered within minutes of each other (e.g., within 10 minutes of each other) and intends to embrace joint administration as well as consecutive administration, but if the administration is consecutive it is separated in time for only a short period (e.g., the time it would take a medical practitioner to administer two compounds separately) . As used herein, concurrent administration and substantially simultaneous administration are used interchangeably. Sequential administration refers to temporally separated administration of the agents described herein.
- Combination therapy can also embrace the administration of the agents described herein (e.g., a tannic acid-containing composition and an anti-CNS disorder or anti-obesity agent) in further combination with other biologically active ingredients (e.g., a different anti-CNS disorder agent) and non-drug therapies (e.g., surgery) .
- It should be appreciated that any combination of a tannic acid-containing composition and a second therapeutic agent (e.g., an anti-CNS disorder or anti-obesity agent) may be used in any sequence for treating a target disease. The combinations described herein may be selected on the basis of a number of factors, which include but are not limited to the effectiveness of inhibiting DAAO, improving basic behavioral functioning, weight reduction, hyperactivity, anxiety, depression, sensorimotor gating, pain threshold, memory or enhancing cognitive functioning, and/or alleviating at least one symptom associated with the target disease, or the effectiveness for mitigating the side effects of another agent of the combination. For example, a combined therapy described herein may reduce any of the side effects associated with each individual members of the combination, for example, a side effect associated with the second therapeutic agent.
- V. General Techniques
- The practice of the present invention will employ, unless otherwise indicated, conventional techniques of neuroscience, molecular biology (including recombinant techniques) , microbiology, cell biology, biochemistry and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as, Current protocol in Neuroscience (Developmental Editor: Eric Prager, Online ISBN: 9780471142300, DOI: 10.1002/0471142301) . Molecular Cloning: A Laboratory Manual, second edition (Sambrook, et al., 1989) Cold Spring Harbor Press; Oligonucleotide Synthesis (M.J. Gait, ed., 1984) ; Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (J.E. Cellis, ed., 1998) Academic Press; Animal Cell Culture (R.I. Freshney, ed., 1987) ; Introduction to Cell and Tissue Culture (J.P. Mather and P.E. Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (A. Doyle, J.B. Griffiths, and D.G. Newell, eds., 1993-8) J. Wiley and Sons; Methods in Enzymology (Academic Press, Inc. ) ; Handbook of Experimental Immunology (D.M. Weir and C.C. Blackwell, eds. ) ; Gene Transfer Vectors for Mammalian Cells (J.M. Miller and M.P. Calos, eds., 1987) ; Current Protocols in Molecular Biology (F.M. Ausubel, et al., eds., 1987) ; PCR: The Polymerase Chain Reaction, (Mullis, et al., eds., 1994) ; Current Protocols in Immunology (J.E. Coligan et al., eds., 1991) ; Short Protocols in Molecular Biology (Wiley and Sons, 1999) ; Immunobiology (C.A. Janeway and P. Travers, 1997) ; Antibodies (P. Finch, 1997) ; Antibodies: a practical approach (D. Catty., ed., IRL Press, 1988-1989) ; Monoclonal antibodies: a practical approach (P. Shepherd and C. Dean, eds., Oxford University Press, 2000) ; Using antibodies: a laboratory manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999) ; The Antibodies (M. Zanetti and J. D. Capra, eds., Harwood Academic Publishers, 1995) .
- Without further elaboration, it is believed that one skilled in the art can, based on the above description, utilize the present invention to its fullest extent. The specific embodiments provided herein are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. All publications cited herein are incorporated by reference for the purposes or subject matter referenced herein.
- Example 1. Identification of Potent Moieties of Tannic Acid and Determination of Its Effectiveness for Treating Central Nervous System (CNS) Disorders
- The activity of tannic acids for inhibiting D-amino acid oxidase (DAAO) was determined as follows.
- The activity of DAAO was determined in vitro by measuring the inhibition of the catabolism of known substrate, D-proline. The cofactor FAD (40 M) was added to the DAAO stock solution first. For the assay, potential inhibitors of tannic acid (s) were mixed with reaction mixture containing phosphate buffered saline (137 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 2 mM NaH2PO4, pH 7.4) , horseradish peroxidase (5 U/ml) , o-phenylendiamine (OPD, 0.03%) , and 0.6 μg human- (or porcine-) DAAO, and incubated for about 5 min. After the pre-incubation period, 40 mM D-proline were added as substrate and the reaction continued for 10 min. OPD was oxidized to form 2, 3-diaminophenazine (DAP) by horseradish peroxidase. The absorbance of DAP was measured at 453 nm by a spectrophotometry. Assay was done in serial dilutions of the inhibitors to generate IC50and analyzed by Prism (Graphpad Software) . In the analysis, the spectrophotometry readings were fit to a standard equation to determine the concentration of 50 %inhibition (IC50) . All enzymatic assays were conducted at room temperature in 96-well plate format.
- As shown in Figure 1, crude tannic acids as a group showed a strong D-amino acid oxidase (DAAO) inhibitory activity with an IC50 value of 5.47 μM.
- The DAAO inhibitory activities of subgroups of tannic acids (having a particular number of galloyl moieties) were determined as follows. Tannic acid fractions having different numbers of galloyl moieties were separated by a reversed-phase column (RP-18) with a mobile phase of acetonitrile and distilled water in gradient elution. The DAAO inhibitory activity of each tannic acid fraction at 80 μM (Table 2) and 300 nM (Figure 2, Table 2) was analyzed by the method described above, using distilled water and 10%DMSO aqueous solution as blank controls and sodium benzoate as a positive control.
- Table 2. DAAO-inhibitory Activities of Individual Tannic Acids
-
- Table 2 shows the anti-DAAO activities of tannic acids with different numbers of galloyl moieties. Tannic acids with four or more 4 galloyl moieties showed much higher activity in inhibiting DAAO as compared with tannic acids with less than 4 galloyl moieties. All DAAO assays were done with 80μM of tannic acids.
- Table 3. DAAO-inhibitory Activities of Individual Tannic Acids
-
-
- Table 3 shows the anti-DAAO activities of tannic acids with different numbers of galloyl moieties at 300 nM. 3 galloyl moieties showed weak activity, while the higher numbers of galloyl moieties showed significantly higher inhibition of DAAO activities. (G=number of galloyl group)
- Table 4. Potency of Individual Tannic Acids
-
- Table 4 below shows the IC50 (μM) of anti-DAAO activities of tannic acids with different numbers of galloyl moieties. The IC50 were determined for each tannic acid with different numbers of galloyl moieties, which indicating potent tannic acids with more than 3 galloyl moieties. Tannic acids with four or more 4 galloyl moieties showed much smaller IC50 and more potent in inhibiting DAAO as compared with tannic acids with less than 4 galloyl moieties. (G=number of galloyl group) .
- Table 5, Tannic acid purification with 4-9 galloyl moieties (4-9 G) exhibits stronger potency than the tannic acid mixture.
-
Sample Tannic Acids 4-9 G IC50 (μg/ml) 0.515 0.361 Std. Error 0.020 0.017 - Therefore, purification of tannic acids with more than 3 galloyl moieties enriches the potency as indicated by the smaller IC50, as compared to the tannic acid mixture (Table 5) . The results show that tannic acids having more than 3 galloyl moieties (e.g., 4-10) exhibited higher DAAO inhibition potency than the tannic acids having 3 and less galloyl moieties.
- Example 2. The Effects of Tannic Acid on Basic Behavioral Functioning and Cognitive Behaviors
- The objective of this study was to verify the effects of multiple doses of tannic acids on basic metabolism, behavioral functioning, and cognitive behaviors. In this experiment, the body weight, spontaneous locomotion activity, anxiety-like behaviors, spatial learning and memory, depressive-like behaviors and sensorimotor gating function of each mouse were examined following the repeated injections or oral administrations of tannic acids. These activities are known to be mediated by the NMDA receptor. (Wu et al., PNAS; 110 (36) : 14765-70 (2013) ; Furuya et al., Eur J Pharmacol, 364 (2-3) : 133-140 [1999] ; Lai et al., Curr Pharm Des, 20 (32) : 5139-5150 [2014] ; McLamb et al., Pharmacol Biochem Behav, 37 (1) : 41-45 [1990] ; Vardigan et al., Pharmacol Biochem Behav, 95 (2) : 223-229 [2010] ; Wiley et al, Eur J Pharmacol, 294 (1) : 101-107 [1995] ; Wu et al., Psychopharmacology (Berl) , 177 (3) : 256-263 [2005] ) . An exemplary illustration of this study is shown in Figure 3.
- Methods and Materials
- Animal and housing conditions
- C57BL/6J male mice were group housed (3-5 mice per cage) with food and water available ad libitum in polysulfone ventilated cages (Alternative Design, AR, USA) in the animal rooms. The colony was maintained on a 12/12-h light/dark cycle at the temperature of 22 ± 2 ℃ and all behavioral studies were performed during the dark cycle. All animals used in this study were adult mice (at least 2.5 months of age) .
- Repeated injections of tannic acid
- Tannic acids were purchased from Sigma (Sigma-Aldrich, USA) . The adult mice were randomly assigned to three groups: (1) control, (2) tannic acid (10 mg/kg) , and (3) tannic acid (30 mg/kg) , which were treated, respectively, by a vehicle control (PBS) , tannic acid at 10 mg/kg, and tannic acid at 30 mg/kg. Two weeks prior to the behavioral tests, all mice were injected intraperitoneally (i.p. ) with either the vehicle control or tannic acid every other day. The body weight of each mouse, which served as an index of its physical development and metabolism, was recorded on the day of injection.
- Examination the effects of repeated injections of tannic acid on mouse basic behavior functioning and cognitive behaviors
- All mice treated with either the vehicle control or the tannic acids as described above were tested sequentially by 5 tasks: (1) open field task for spontaneous locomotion test, (2) anxiety-like behaviors test by elevated plus maze, (3) spatial learning and memory test by Barnes maze, (4) depressive-like behaviors test by tail suspension, and (5) sensorimotor function test by prepulse inhibition. At least a 1-week interval was made between different tasks. In order to minimize carryover effects, the tasks were arranged in the sequence to ensure that the more stressful task did not occur prior to a less stressful one. The procedures are described in Current protocol in Neuroscience (Developmental Editor: Eric Prager, Online ISBN: 9780471142300, DOI: 10.1002/0471142301) , the relevant disclosures of which are incorporated by reference herein for the intended purposes.
- Results
- Physical Development and Weight Reduction
- During the period of repeated injections, the body weight of the tannic acid (10 mg/kg) group were increased at a level lower than that of the control group, while the body weight of the tannic acid (30 mg/kg) was much lighter than the controls. See Figure 4.
- Spontaneous Locomotor Activity
- The open field task is a common measurement of novelty induced exploratory behavior and general activity in both mice and rats. In this study, the mice were placed in a cage (37.5 cm × 21.5 cm × 18 cm) under 50-65 lux light intensity. Their spontaneous locomotor activities were measured for 60 minutes using the EthoVision video tracking system (Noldus Information Technology, the Netherlands) . The travel distance of each mouse was measured as an index of locomotion activity. As shown in Figure 5, tannic acids reduced the travel distances of the treated mice in a dose-dependent manner.
- A similar experiment was carried out, in which mice were administered orally at 10 mg/kg, 30 mg/kg, 100 mg/kg, 300 mg/kg, and 600 mg/kg for a single dose and their locomotion activities were measured for 30 minutes, 60 minutes, 90 minutes, and 120 minutes. Tannic acids at all tested doses reduced the locomotion of the treated mice as compared with the mice treated with the vehicle control. The results are illustrated in Figure 6.
- Anxiety-like Behaviors
- An elevated plus maze consisting of two open arms and two closed arms was used to assess the instinctively anxious behavior. The maze was elevated 50 cm from the floor with two open arms (each 50 cm long × 10 cm wide) , two closed arms plus 45 cm high walls without a roof (each 50 cm long ×10 cm wide) , and a square shaped central platform (10 ×10 cm) . Each mouse was placed in the central platform and faced toward one of the closed arms for observation under 50-65 lux light intensity for 5 minutes. The time spent on each part of the maze and travel distance on each part of maze was recorded by the EthoVision tracking system (Noldus Information Technology, the Netherlands) .
- The aversive duration ratio of each group was shown in Figure 7, Panel A. In comparison to the control group, the tannic acid (30 mg/kg) group displayed marginal higher aversive duration ratios whereas the tannic acid (10 mg/kg) group did not. The aversive distance ratio of each group was shown in Figure 7, Panel B. The tannic acid (30 mg/kg) group displayed significant higher aversive distance ratios as compared with the control group. The number of risk assessments of each group is displayed in Figure 7 Panel C. As compared to the control group, both tannic acid groups displayed significant lower risk assessments (all p < 0.05) .
- Spatial Learning and Memory
- Mice were tested in the Barnes maze to examine their spatial learning and memory as described previously (Barnes, J Comp Physiol Psychol, 93 (1) : 74-104 [1979] ) . This paradigm has been commonly examined in mouse models of CNS disorders, including, but not limited to schizophrenia, depressions, obsessive compulsive disorder, post-traumatic stress disorder, addiction disorders, Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease, Duchenne muscular dystrophy, stroke, and Fragile X syndrome (see Cook et al., 2014; and Ittner, 2008; Hendriksen and Vles, 2008; Conklin et al., 2000; Song et al., 2006; Lai et al., 2014; Vasterling et al., 2002; Hyman, 2005; Schaar et al., 2010; Santos et al., 2014; Zhu et al., 2007; Deckersbach et al., 2000) . The testing apparatus was an elevated (50 cm above the floor) circularplate (100 cm in diameter) with 20 holes (7 cm in diameter, 7 cm between holes) evenly spaced around the perimeter. The mice were trained on the plate to identify an escape box (25 × 8 × 6 cm) hidden behind the target hole, which was designated as an analog to the hidden platform in the Morris water maze task. The location of the target hole was selected for each mouse but randomized across mice. Mice were initially placed at the center of the plate covered by an opaque cylinder, and the cylinder was removed 10 seconds after the beginning of the trial with both an aversive tone (440 Hz, 85 dB) and the lights (100 lux) switched on. The mice were trained to locate the target hole according to surrounding visual cues and escape from the aversive tone for three training trials per day over 3 consecutive days. The spatial memory was measured by the “probe test” . All of the training trials and the probe trials were videotaped for 3 minutes. Then, the escape latency for the training trials and the percentage of time in different quadrants (target, left, right, and opposite) during the probe test were analyzed. In the probe test, the tannic acid (30 mg/kg) group displayed a significant preference to the target zone whereas the other groups did not, as illustrated in Figure 8.
- The basic metabolism, behavior functioning, and cognitive behaviors characteristics of mice treated with tannic acids with multiple injections at various doses were studied in the experiments described in Example 2. In summary, three main findings were noted.
- First, the body weight of mice in the tannic acid (30 mg/kg) group decreased. This group of mice also displayed lower spontaneous locomotion in the open field. The open field tasks were used to test novelty-induced locomotor activity and general motor functions (Powell et al., Biol Psychiatry, 59 (12) : 1198-1207 [2006] ; van den Buuse, Schizophr Bull, 36 (2) : 246-270 [2010] ) . Without being bound by theory, the decreased locomotion activity in mice with repeated tannic acid injections may be resulted from the faster habituation to the novel environment.
- Second, the anxiety–like behaviors of mice treated with tannic acid were decreased in the elevated plus maze. The elevated plus maze task is a mouse model for putative anxiolytic or anxiogenic compounds screening (Rodgers et al., Braz J Med Biol Res, 30 (3) : 289-304 [1997] ; Steimer, Dialogues Clin Neurosci, 13 (4) : 495-506 [2011] ) . The increase in the proportion of time spent in open arms represents lower anxiety in the plus maze. In the experiment, mice with repeated injections displayed not only higher proportion of time spent in open arms but also higher proportion of travel distance in open arms and lower risk assessment. These results support that repeated injections of tannic acid reduced the anxiety-like behaviors in the elevated plus maze.
- Third, mice with repeated tannic acid injections displayed the enhancement of spatial memory retrieval in the Barnes maze. The Barnes maze is a task to evaluate the cognitive function in mice, especially the spatial learning and memory (Rosenfeld et al., J Vis Exp, (84) : e51194 [2014] ) . Based on the advancement of the understanding of specific cognitive functional domains, an increasing amount of clinical research emphasizes the impact of cognitive deficits in many mental illnesses including schizophrenia, dementia, Alzheimer’s disease, depression, and obsessive compulsive disorder (OCD) etc. (Kirova et al., Biomed Res Int, 748212 [2015] ; Lai et al., Curr Pharm Des, 20 (32) : 5139-5150 [2014] ; Okasha et al., Acta Psychiatr Scand, 101 (4) : 281-285 [2000] ; Rosenblat et al., Int J Neuropsychopharmacol, pii: pyv082 [2015] ; Terry et al., Ann Neurol, 30 (4) : 572-580 [1991] ) . In the probe test (memory retrieval phase) , the tannic acid (30 group) displayed preference to the target zone. This evidence indicated that repeated injections of a high dose tannic acid were capable of enhancing the cognitive function in normal mice. Furthermore, NMDA receptor signaling is considered as an important role in the learning process and memory consolidation (Newcomer et al., Hippocampus, 11 (5) : 529-542 [2001] ; Rezvani, Animal Models of Cognitive Impairment, 1 (4) [2006] ) . Therefore, repeated injections of tannic acid may enhance the cognitive function through NMDA signaling in mice.
- Thus, the results of this study indicate that tannic acids would be effective in weight reduction and improving basic behavioral functioning, hyperactivity, anxiety, memory and/or cognitive behavior. For example, a large percentage of children with ADHD have co-morbid learning disorder that can also be improved by tannic acid, given its effects on learning and memory.
- Example 3. Rescue and Protective Effects of Tannic Acid Injection on MK-801-treated Mice
- The objective of this experiment was to assess the potential mechanisms of action of tannic acids in treating CNS disorders, using MK-801, a well-known NMDA receptor antagonist. Tannic acids and MK-801 were administrated in mice by intraperitoneal (i.p. ) injections before the behavioral tests (i.e., open field and prepulse inhibition) , respectively.
- Experimental design
- This experimentwas designed to characterize the mechanism of action of tannic acid. MK-801, also known as dizocilpine, is an antagonist of NMDA receptor (Kovacic et al., Oxid Med Cell Longev, 3 (1) : 13-22 [2010] ) . It has been used in many aspects of NMDA hypo-function induced symptoms of central nerve system diseases, including stereotypic behaviors, anhedonia, learning and memory deficits, working memory impairment and sensorimotor function abnormalities (Furuya et al., Eur J Pharmacol, 364 (2-3) : 133-140 [1999] ; McLamb et al., Pharmacol Biochem Behav, 37 (1) : 41-45 [1990] ; Vardigan et al., Pharmacol Biochem Behav, 95 (2) : 223-229 [2010] ; White et al., Pharmacol Biochem Behav, 59 (3) : 613-617 [1998] ; Wu et al., Psychopharmacology (Berl) , 177 (3) : 256-263 [2005] ) . The objective of these experiments was to assess the effects of tannic acids on mice with hypo-function NMDA receptor. An exemplary experimental design is illustrated in Figure 9.
- Methods and Materials
- Animal and housing conditions
- C57BL/6J male mice were group housed (3-5 mice per cage) with food and water available ad libitum in polysulfone ventilated cages (Alternative Design, AR, USA) in the animal rooms. The colony was maintained on a 12/12-h light/dark cycle at the temperature of 22 ± 2 ℃ and all behavioral studies will be performed during the dark cycle. All animals used in this study were adult mice (at least 2.5 months of age) .
- Drug Administration
- The mice were randomly assigned into six groups:
- Group 1: PBS + Saline control;
- Group 2: PBS + MK-801;
- Group 3: tannic acid (10 mg/kg) + MK-801;
- Group 4: tannic acid (15 mg/kg) + MK-801;
- Group 5: tannic acid (20 mg/kg) + MK-801; and
- Group 6: tannic acid (30 mg/kg) + MK-801.
- Each mouse in Groups 2-6 received an acute administration of MK-801 (Sigma-Aldrich, USA) dissolved in normal saline, 0.1 mg/kg, i.p. ) 20 minutes prior to the behavioral tests. Each mouse in Groups 3-6 received an acute administration of tannic acids (Sigma-Aldrich, USA; dissolved in PBS, 10, 15, 20 or 30 mg/kg, i.p. ) 20 minutes prior to the MK-801 administration.
- Examination of the effects of tannic acid administration on MK-801 treated mice
- All mice in this study were tested with open field task and prepulse inhibition task with at least 1-week interval between two tasks. An additional cohort of mice was used to test the effect of different sources of tannic acid on prepulse inhibition.
- Results
- The effects of tannic acid on locomotion in MK-801 treated mice
- Compared to the control group (Group 1) , the MK-801 group (Group 2) displayed a hyper-locomotion activity. The tannic acid 10, 20, and 30 groups (Groups 3, 5, and 6) displayed a lower locomotion activity than the control group as illustrated in Figure 10. In comparison to the MK-801 group (Group 2) , all tannic acid groups displayed lower locomotion activity, as shown in Figure 10.
- MK-801 generates hyperactivity which is frequently applied as animal models including, but not limited to schizophrenia, bipolar disorder, attention-deficit hyperactivity disorder, obsessive compulsive disorder, Tourette’s syndrome, autism spectrum disorders, Fragile X syndrome, Parkinson’s disease, dementia with Lewy bodies, and senile dementia (see Rubia et al., 2010; Sheppard and Bradshaw, 1999; Bent et al., 2014; Powell and Miyakawa, 2006; Nestler and Hyman, 2010; ′kova′ -Valesˇova et al., 2008; Gobira et al., 2013; Lai et al., 2014; Maio et al., 2014; Sontag et al., 2010; Ding et al., 2014; Walitza et al., 2007; Finestone et al., 1982; Golimstok et al., 2011) .
- The effects of tannic acids on prepulse inhibition in MK-801-treated mice--Sensorimotor Function
- Pre-attentive processes tend to be automatic and rapid, and to operate outside of conscious awareness, whereas deliberate attention processes have limited resources, require more efforts, and operate more slowly. A common measure of pre-attentive process is prepulse inhibition. This paradigm has been commonly examined in mouse models of several CNS disorders, including, but not limited to schizophrenia, major depressive disorder, bipolar disorder, attention deficit disorder, attention-deficit hyperactivity disorder, tic disorder, obsessive compulsive disorder, Tourette’s syndrome, blepharospasm, post-traumatic stress disorder, panic disorder, autism spectrum disorder, Asperger’s disorder, Alzheimer’s disease, mild dementia of Alzheimer, dementia with Lewy bodies, Huntington's disease, personality disorders, nocturnal enuresis, and non-epileptic seizures (see McAlonan et al., 2002; Braff et al., 2001; Giakoumaki et al., 2007; Ueki et al., 2006; Perriol et al., 2005; Ludewig et al., 2002; Castellanos et al., 1996; Cadenhead et al., 2000; Matsuo et al., 2017; Lai et al., 2014; McCool et al., 2003; Arguello &Gogos, 2006) because the deficit manifests in a similar manner to the human symptom.
- Prepulse inhibition was used as an index of sensorimotor gating function using SR-LAB startle apparatus (San Diego Instruments, San Diego, CA, USA) . Under 72 dB background noise, each session was composed of 5 minutes accumulation period followed by 64 trials in four blocks. The pulse alone (PA) trial was a 40 ms, 120 dB white noise burst. In the prepulse (pp) + pulse trials, a 20 ms white noise prepulse stimuli of 78 dB (pp6) , 82 dB (pp10) , and 90 dB (pp18) were presented 100 ms before a 40 ms 120 dB pulse. The non-stimulus (NS) trials presented the background noise only. The initial and the last blocks were composed of six PA trials, respectively. Two middle blocks consisted of PA, pp + pulse, and NS trials. These trials were presented pseudo-randomly and separated by intertribal intervals of 15 seconds on average (varying between 10 to 20 s) . The percentage of prepulse inhibition was evaluated by the following formula: %PPI = 100 × [ (PA score) - (pp-P score) ] / (PA score) , where the PA score was the average of the PA value in the middle blocks. Tannic acid improved the prepulse inhibition as in Figures 11&12 and dose-dependently, as demonstrated in Figure 11.
- In 78 dB prepulse intensity, no significant difference was found among the 6 groups. In 82 dB prepulse intensity, MK-801 and tannic acid (10 mg/kg) groups did not show the difference relative to the control group. As compared to the control group, the tannic acid (15 mg/kg) group displayed a marginally higher percentage of prepulse inhibition, and the tannic acid (20 mg/kg) and tannic acid (30 mg/kg) groups displayed significantly higher percentages of prepulse inhibition. In terms of the 90 dB prepulse intensity, compared to the control group, the tannic acid (15 mg/kg) , tannic acid (20 mg/kg) and tannic acid (30 mg/kg) groups displayed significantly higher percentages of prepulse inhibition as compared with the control group, while no such results was observed in the MK-801 and tannic acid (10 mg/kg) groups, as depicted in Figure 11.
- The effects of different tannic acid source on prepulse inhibition in MK-801-treated mice
- The objective of this experiment was to evaluate the effects of different sources of tannic acids on prepulse inhibition. Tannic acids purchased from Sigma-Aldrich (source A) and from Spectrum, USA (source B) at 15 mg/kg were used in this study. The IC50 (μM) of anti-DAAO activities of tannic acids of sources A and B are 0.291 and 0.636, respectively.
- With respect to the 78 dB and 82 dB prepulse intensities, no significant difference was observed between the mice treated with tannic acids of the two sources and the control group or the MK-801 group. In terms of the 90 dB prepulse intensity, both tannic acid groups displayed significantly higher percentages of prepulse inhibition as compared with the control group whereas no such results were observed in the MK-801 group. The results obtained from the mice treated with source A (Sigma-Aldrich) tannic acids and source B (Spectrum, USA) tannic acids were similar, as shown in Figure 12.
- Though psychosis symptoms are challenging to observe and measure in animal models, the psychosis-related behaviors can be tested include psychomotor agitation, excitement symptoms, sensory gating and sensitivity to psychotomimetic drugs, such as MK-801 (Arguello et al., Neuron, 52 (1) : 179-196 [2006] ; Lai et al., Curr Pharm Des, 20 (32) : 5139-5150 [2014] ) . In mice, parameters related to hyper-locomotion activity and alteration of novelty-induced locomotion activity (either impairment of habituation to novelty or increased exploration) in an open field task can be used to measure the psychomotor agitation and excitement symptoms, respectively (Lai et al., Curr Pharm Des, 20 (32) : 5139-5150 [2014] ; Powell et al., Biol Psychiatry, 59 (12) : 1198-1207 [2006] ; Vardigan et al., Pharmacol Biochem Behav, 95 (2) : 223-229 [2010] ) . In the present study, the administration of tannic acid, both by i.p. or per os (p.o. ) routes, reversed/protected MK-801 induced hyper-locomotion activity in the open field. The result indicated that the tannic acids are a potential therapeutic agent for treating psychosis symptoms (e.g., delusions and hallucinations) .
- In the prepulse inhibition task, 15 mg/kg of tannic acid was sufficient to enhance the sensorimotor gating function in mice treated with MK-801. In addition, different sources of tannic acid did not affect the enhancement of sensorimotor function in the prepulse inhibition task. Deficits in prepulse inhibition has been commonly considered as a schizophrenic endophenotype in mouse models because the deficit manifests can be identified similarly in humans (Arguello et al., Neuron, 52 (1) : 179-196 [2006] ; Geyer et al., Schizophr Bull, 13 (4) : 643-668 [1987] ; Lai et al., Curr Pharm Des, 20 (32) : 5139-5150 [2014] ) . The deficits of prepulse inhibition were also found in other central nerve system diseases, including autism spectrum disorder (McAlonan et al., Brain, 125 (Pt 7) : 1594-1606 [2002] ) , obsessive compulsive disorder, Huntington’s disease, nocturnal enuresis, attention deficit disorder, Tourette’s syndrome, blepharospasm, non-epileptic seizures, post-traumatic stress disorder (Braff et al., Psychopharmacology (Berl) , 156 (2-3) : 234-258 [2001] ) , panic disorder, bipolar disorder, mild dementia of Alzheimer’s , dementia with Lewy bodies, and combined attention-deficit hyperactivity disorder and tic disorder (Giakoumaki et al., Biol Psychiatry, 62 (12) : 1418-1422 [2007] ; Ludewig et al., Depress Anxiety, 15 (2) : 55-60 [2002] ; Perriol et al., J Neurol Neurosurg Psychiatry, 76 (1) : 106-108 [2005] ; Ueki et al., Psychiatry Clin Neurosci, 60 (1) : 55-62 [2006] ) .
- As such, tannic acids are a promising therapeutic agent for various CNS disorders. Further, tannic acids reduce both spontaneous and MK-801-induced hyperlocomotion, indicating that tannic acids Tannic acid can serve as a therapeutic agent to improve symptoms of ADHD and its related disorders.
- Moreover, it was observed that tannic acids could maintain and/or reduce body weights in mice treated thereby, indicating that tannic acids would be effective in control body weight and/or treating obesity and its disorders including eating disorder, anorexia nervosa, bulimia nervosa, stroke, coronary heart disease, heart attack, congestive heart failure, congenital heart disease, hypertension, non-alcoholic steatohepatitis, insulin resistance, hyperuricemia, hypothyroidism, osteoarthritis, gallstones, infertility (hypogonadism and hyperandrogegism) , obesity hypoventilation syndrome, obstructive sleep apnea, chronic obstructed pulmonary disease, and asthma.
- Example 4. Rescue and Protective Effects of Tannic Acid oral administration on MK-801 Treated Mice
- The objective of this experiment was to assess the potential mechanisms of action of tannic acids in treating CNS disorders, using MK-801, a well-known NMDA receptor antagonist. Tannic acids and MK-801 were administrated in mice by oral gavage (p.o. ) and intraperitoneal (i.p. ) injections respectively before the behavioral tests (i.e., open field, prepulse inhibition, Barnes maze and sucrose preference) , respectively.
- Experimental design
- This experiment was designed to characterize the mechanism of action of tannic acid. MK-801, also known as dizocilpine, is an antagonist of NMDA receptor (Kovacic et al., Oxid Med Cell Longev, 3 (1) : 13-22 [2010] ) . It has been used in many aspects of NMDA hypo-function induced symptoms of central nerve system diseases, including stereotypic behaviors, anhedonia, learning and memory deficits, working memory impairment and sensorimotor function abnormalities (Furuya et al., Eur J Pharmacol, 364 (2-3) : 133-140 [1999] ; McLamb et al., Pharmacol Biochem Behav, 37 (1) : 41-45 [1990] ; Vardigan et al., Pharmacol Biochem Behav, 95 (2) : 223-229 [2010] ; White et al., Pharmacol Biochem Behav, 59 (3) : 613-617 [1998] ; Wu et al., Psychopharmacology (Berl) , 177 (3) : 256-263 [2005] ) . The objective of these experiments was to assess the effects of tannic acids on mice with hypo-function NMDA receptor. An exemplary experimental design is illustrated in Figure 13.
- Methods and Materials
- Animal and housing conditions
- C57BL/6J male mice were group housed (3-5 mice per cage) with food and water available ad libitum in polysulfone ventilated cages (Alternative Design, AR, USA) in the animal rooms. The colony was maintained on a 12/12-h light/dark cycle at the temperature of 22 ± 2 ℃ and all behavioral studies will be performed during the dark cycle. All animals used in this study were adult mice (at least 2.5 months of age) .
- Drug Administration
- The mice were randomly assigned into five groups:
- Group 1: PBS + Saline control;
- Group 2: PBS + MK-801;
- Group 3: tannic acid (10 mg/kg) + MK-801;
- Group 4: tannic acid (30 mg/kg) + MK-801; and
- Group 5: tannic acid (100 mg/kg) + MK-801.
- Each mouse in Groups 2-5 received an acute administration of MK-801 (Sigma-Aldrich, USA) dissolved in normal saline, 0.1 mg/kg for open field and Barnes maze tasks, and 0.2 mg/kg for prepulse inhibition and sucrose preference tasks by i.p. injection) 20 minutes prior to the behavioral tests. Each mouse in Groups 3-6 received an acute oral administration of tannic acids (Merck Millipore, Germany; dissolved in PBS, 10, 30, or 100 mg/kg, p.o. ) 20 minutes prior to the MK-801 administration.
- Results
- Examination of the effects of tannic acid administration on MK-801 treated mice
- All mice in this study were tested with open field task, prepulse inhibition task, Barnes maze and sucrose preference with at least 1-week interval between tasks.
- The effects of tannic acid oral administration on locomotion in MK-801 treated mice
- In this test, tannic acids were administered orally 20 minutes before the MK-801 (0.1 mg/kg) injection. As shown in Figure 14, MK-801 induced hyper-locomotion and tannic acids rescued the MK-801-induced hyper-locomotion in a dose-dependent manner.
- The effects of tannic acids on prepulse inhibition in MK-801-treated mice
- Compare to the control group, MK-801 (0.2 mg/kg) induced robust prepulse inhibition deficits. In 78 dB and 82 dB prepulse intensities, tannic acid (10, 30 and 100 mg/kg) did not rescue/protect the MK-801-induced prepulse inhibition deficits. In terms of the 90 dB prepulse intensity, compared to the MK-801 group, the tannic acid (30 mg/kg) , and tannic acid (100 mg/kg) groups displayed significantly rescue/protective effects on MK-801 induced prepulse inhibition deficit. No similar results were observed in the MK-801 and tannic acid (10 mg/kg) groups, as illustrated in Figure 15.
- The effects of tannic acids on spatial learning &memory in MK-801-treated mice
- Tannic acid dose-dependently improves the memory retrieval of Barnes maze task in the MK-801-treated mice as shown in Figure 16.
- The effects of tannic acids on depressive-like behavior (anhedonia) in MK-801 treated mice
- Compare to the control group, mice in MK-801 group did not show the preference toward the sucrose solution (2%) . Compare to the MK-801 group, mice with tannic acid 30 mg/kg and 100 mg/kg displayed rescue/protective effects on MK-801 induced depressive-like behavior (anhedonia) as shown in Figure 17. Sucrose preference test has been commonly examined in mouse models of several mental illnesses, including, but not limited to, depression, major depression disorder, anhedonia, negative symptoms of schizophrenia, chronic mild and unpredictable stress (see Anderson et al., 2006; Carvalho et al., 2013; Briones et al., 2011; Der-A vakian and Markou, 2012; Tye et al., 2013; Edwards and Koob, 2012; Brigman et al., 2010; Koo and Duman, 2007; Nestler and Hyman, 2010; Overstreet, 2012; Papp et al., 1991; Santiago et al., 2010; Skalisz et al., 2002; Szczypka et al., 2001; Taylor et al., 2010; Vardigan et al., 2010; Willner et al., 1987; You et al., 2011) .
- Example 5. Analgesic Effects of Tannic Acid in Mice
- The objective of this experiment was to assess the analgesic effects of tannic acid in mice. Tannic acids were administrated in mice by intraperitoneal (i.p. ) injections before the behavioral tests (i.e., von Frey test) .
- Experimental design
- Another cohort was used for von-Frey test (atypical assay for pain sensation) . The paw withdrawal thresholds of each mouse were sampled before drug injection and 30, 60, 90 and 120 min after drug injection as shown in Figure 22.
- Methods and Materials
- Animal and housing conditions
- C57BL/6J male mice were group housed (5 mice per cage) with food and water available ad libitum in polysulfone ventilated cages (Alternative Design, AR, USA) in the animal rooms. The colony was maintained on a 12/12-h light/dark cycle at the temperature of 22 ± 2 ℃ and all behavioral studies will be performed during the dark cycle. All animals used in this study were adult mice (at least 8 weeks of age) .
- Drug Administration
- The mice were randomly assigned into two groups:
- Group 1: PBS control; and
- Group 2: tannic acid (15 mg/kg)
- Each mouse in Groups 1 received an acute administration of PBS as a vehicle control by i.p. injection. Each mouse in Groups 2 received an acute administration of tannic acids (Merck Millipore, Germany; dissolved in PBS 15 mg/kg, i.p. ) .
- Results
- The analgesic effects of tannic acid injection in mice
- At baseline, no difference was found between groups. Compare to the PBS control, the threshold of Group 2 was significantly higher at 30 min, 60 min and 90 min after drug injection as shown in Figure 19. The von Frey test has been commonly examined in mouse models of several CNS disorders, including, but not limited to, neuropathic pain including hyperalgesia and allodynia, hypoesthesia in diabetic polyneuropathy, chronic pain syndromes (see Park et al., 2015; Savage and Ma, 2015; Caterha et al., 2000; Nicotra et al., 2014; Keizer et al., 2007; Chakrabarty et al., 2011; Obrosova et al., 2007; Orita et al., 2011; Reeve et al., 2000) .
- Example 6. Comparisons of Different Tannic Acid Compositions
- The compositions and inhibitory activities against D-amino acid oxidase (DAAO) of 3 commercial tannic acids from different suppliers were compared.
- Experimental design
- The compositions of 3 commercial tannic acids were determined by HPLC and the inhibitory activities against D-AAO were determined by the method illustrated in Example 1.
- Methods and Materials
- HPLC conditions
- - Instrument: Agilent 1260 Column: Atlantis T3 150*4.6mm, 30 μm
- - Mobile phase A: Water + 0.1%Trifluoroacetic acid
- -Mobile Phase B: Methanol: Acetonitrile 2 : 8 (v/v)
- - Column temperature: 25℃
- - Detector: DAD 280 nm
- - Flow rate: 1.5 mL/min
- - Sample preparation: 10 mg/mL
- - Injection volume: 10 μL
- - Diluent: water
- - Gradient:
-
Time (min) 0 10 25 26 34 36 40 A% 100 81 78 75 73 5 5 B% 0 19 22 25 27 95 95 - Results
- Compositions:
- The HPLC chromatograms of 3 tannic acids from different plant or botanic sources are illustrated in Figures 20-22.
- Inhibitory Activities against DAAO:
- The inhibitory activities of 3 commercial tannic acids against DAAO and their compositions are illustrated in Table 6.
- Table 6. Inhibitory activities of 3 commercial tannic acids from different plant or botanic sources
-
- Tannic acidsextractted from Rhus chinensis have much higher percentage of 6-12G and much lower 2-5G percentage than tannic acids from Quercus infectoria, and therefore higher DAAO inhibitory potency than the other two.
- Example 7. Extraction of Tannic Acid from Gallnuts of Different Plant or botanic sources for Comparison
- Tannic acids were extracted from gallnuts of different plant or botanic sources as indicated and their inhibitory activity against D-amino acid oxidase (DAAO) was investigated.
- Methods
- Gallnut Grinding Method
- Tannic acid producing gallnuts from a suitable plant or botanic source (see Table 6 below) were milled by a mechanical grinder and passed through a 40-mesh sieve to produce fine gallnut powder.
- Fine Gallnut Powder Extraction Method
- The fine gallnut powder (20.0 g) was placed in 200.0 mL of a suitable solvent (e.g., acetone, acetonitrile, methyl ethyl ketone (MEK) , ethyl acetate (EtOAc) , ethanol (EtOH) , isopropanol, tetrahydrofuran, or 1, 4-dioxane) . The mixture thus formed was stirred at either RT or 40℃ overnight. The resultant solution was filtered, and the filtrate was concentrated in vacuum to generate a composition containing tannic acids.
- Results
- Inhibitory Activities against DAAO:
- The inhibitory activities of the tannic acids extracted from gallnuts of different plant or botanic sources against DAAO, following the above method, are illustrated in Table 7. The comparison of gallnuts of various diameters and their DAAO IC50's is illustrated in Figure 23.
- Table 7. Inhibitory activities of tannic acids extracted from gallnuts of different plant or botanic sources
-
- As illustrated in Table 6 and Figure 23, either gallnuts from Rhus chinensis or Rhus potaninii have lower IC50's against DAAO (stronger inhibition) than those from Quercus infectoria. Moreover, smaller gallnuts from Rhus chinensis (diameters of 3-4 cm) and Rhus potaninii (diameters of 4-5 cm) have lower IC50's as compared to the larger (diameters of 6-7 cm) gallnuts from the same plant or botanic sources.
- Example 8. Enrichment Methods of Tannic Acid Extracted from Gallnuts of Different Plant or botanic sources
- Tannic acids extracted from gallnuts of each plant or botanic source noted herein were enriched as described below. Their inhibitory activities against DAAO were investigated.
- Enrichment Method 1
- The fine gallnut powder (20.0 g) was placed in 200.0 mL of a suitable solvent (acetone, methyl ethyl ketone, ethyl acetate, or ethanol) and the mixture thus formed was stirred at either RT or 20-60℃ for 12 hrs. The resultant solution was filtered, and the filtrate was concentrated in vacuum to form a composition containing tannic acids. The composition was mixed with 50.0 mL of 50 or 30%methyl ethyl ketone/hexane solution (50%or 30%methyl ethyl ketone in hexane) . The mixture thus formed was further stirred at RT for 12 hrs, and the resulting two organic layers were separated. The oilier layer (the lower layer) was concentrated in vacuum to produce a crude solid. The solid was dissolved in 50.0 mL of a suitable solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) , and the resulting solution was mixed with charcoal (1.6 g) . The resulting mixture was stirred at RT for 12 hrs and CaSO4 or MgSO4 (2.5 g) was added into the mixture. The mixture thus formed was further stirred at RT for 30 min and filtered through a bed of Celite, washed with a suitable solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) (100 mLx2) , and concentrated in vacuum. The resultant solid (containing tannic acids) was dissolved in acetone or ethyl acetate (12.0 mL) , and then the solution thus formed was stirred and mixed with CH2Cl2 (72.0 mL) dropwise. The solid thus formed was collected by filtration and dried under vacuum at 40℃ for 2 hrs to produce an enriched tannic acid solid.
- Enrichment Method 2
- The fine gallnut power (20.0 g) was placed in 200.0 mL of a suitable solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, ethanol) was stirred at RT for 12 hrs. The solution thus formed was filtered, and the filtrate collected was mixed with 200.0 mL of hexane. The mixture was stirred at RT for 12 hrs, and the resulting two organic layers were separated. The oiler layer (lower layer) was concentrated in vacuum and the solid thus obtained was dissolved in 50.0 mL of a suitable solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, ethanol, etc. ) . The resulting solution was mixed with charcoal (1.6 g) and further stirred at RT for 12 hrs. The mixture thus obtained was further mixed with CaSO4 or MgSO4 (2.5 g) and stirred at RT for 30 min. The mixture was filtered through a bed of Celite, washed with (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, ethanol, etc. ) (100 mLx2) , and concentrated in vacuum. The crude residues thus obtained were dissolved in acetone or ethyl acetate (12.0 mL) , and the solution thus formed was stirred and mixed with CH2Cl2 (72.0 mL) slowly. The solid thus formed was collected by filtration and dried under vacuum at 40℃ for 2 hrs to produce an enriched tannic acid composition.
- Enrichment Method 3
- The fine gallnut power (20.0 g) was placed in 200.0 mL of solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) was stirred at RTfor 12 hrs. The resultant solution was filtered, and the filtrate was collected. The filtrate was then added into 200.0 mL hexane. The mixture thus formed was stirred at RT for 12 hrs, and the resulting two organic layers were separated. The oilier layer (lower layer) was collected and mixed with 40.0 mL of solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) and charcoal (1.6 g) and the resulting mixture was stirred at RT for 12 hrs. The mixture was further mixed with CaSO4 or MgSO4 (2.5 g) and stirred at RT for 30 min, filtered through a bed of Celite, and washed with solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) (100 mLx2) . The filtrate thus collected was concentrated in vacuum and the resultant solid substances were dissolved in acetone or ethyl acetate (12.0 mL) . The solution thus formed was stirred and mixed with CH2Cl2 (72.0 mL) dropwise. The solid thus formed was collected by filtration and dried under vacuum at 40℃ for 2 hrs to form an enriched tannic acid composition.
- Enrichment Method 4
- The fine gallnut power (20.0 g) was placed in 200.0 mL of solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) to form a mixture, which was stirred at RT for 12 hrs. The mixture was mixed with charcoal (1.6 g) and stirred at RT for 12 hrs. The resultant mixture was further mixed with CaSO4 or MgSO4 (2.5 g) and stirred at RT for 30 min, filtered through a bed of Celite, washed with solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) (100 mLx2) . The filtrate was concentrated in vacuum, the resultant residue was dissolved in acetone or ethyl acetate (12.0 mL) , and the solution thus formed was stirred and mixed with CH2Cl2 (72.0 mL) slowly. The solid thus formed was collected by filtration and dried under vacuum at 40℃ for 2 hrs to produce an enriched tannic acid composition.
- Enrichment Method 5
- The fine gallnut power (20.0 g) was placed in 200.0 mL of solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) and the mixture thus formed was stirred RTfor 12 hrs. The mixture was mixed with charcoal (1.6 g) and stirred at RT for 12s hrs. The mixture was further mixed with CaSO4 or MgSO4 (2.5 g) and stirred at RT for 30 min. The mixture was filtered through a bed of Celite, and washed with solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) (100 mLx2) . The filtrate was concentrated down to about 10~15 mL and the resulting solution was mixed with CH2Cl2 (60~90 mL) dropwise. The solid thus formed was collected by filtration and dried under vacuum at 40℃ for 2 hrs to form an enriched tannic acid composition.
- Enrichment Method 6
- The fine gallnut power (20.0 g) was placed in 200.0 mL of solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) and the solution thus formed was stirred at RT for 12 hrs, and then filtered. The filtrate was collected and mixed with charcoal (1.6 g) and stirred at RT for 12 hrs. The mixture was further mixed with CaSO4 or MgSO4 (2.5 g) and stirred at RT for 30 min. The resulting mixture was then filtered through a bed Celite, washed with solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) (100 mLx2) , and the combined filtrates were concentrated by vacuum evaporation. The crude solid thus formed was dissolved in acetone or ethyl acetate (12.0 mL) , and the solution was stirred and mixed with CH2Cl2 (72.0 mL) slowly. The solid thus formed was collected by filtration and dried under vacuum at 40℃ for 2 hrs to give an enriched tannic acid composition.
- Enrichment Method 7
- The fine gallnut power (20.0 g) was placed in 50.0 mL of 50%or 30%methyl ethyl ketone/hexane and was stirred at RT for 12 hrs. The resultant mixture was filtered and solids were collected. The solids were then mixed with 200.0 mL solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) . The mixture thus formed was stirred at RTfor 12 hrs, filtered and the filtrate was collected. The filtrate was then mixed with charcoal (1.6 g) and stirred at RT for 12 hrs. The resulting mixture was further mixed with CaSO4 or MgSO4 (2.5 g) and stirred at RT for 30 min, filtered through a bed of Celite, washed with solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) (100 mLx2) , and the filtrate was concentrated by vacuum evaporation. The residue thus obtained was dissolved in acetone or ethyl acetate (12 mL) , and then the solution was stirred and mixed with CH2Cl2 (72.0 mL) dropwise. The solid thus formed was collected by filtration and dried under vacuum at 40℃ for 2 hrs to produce an enriched tannic acid composition.
- Enrichment Method 8
- The fine gallnut power (20.0 g) was placed in 50 mL of 50 or 30%methyl ethyl ketone/hexane and was stirred at RT for 12 hrs. The solution was filtered and the solid collected was mixed with 200.0 mL of solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) . The mixture was stirred at RTfor 12 hrs and filtered, and the filtrate collected was mixed with charcoal (1.6 g) and stirred at RT for 12 hrs. The resulting mixture was further mixed with CaSO4 or MgSO4 (2.5 g) and stirred at RT for 30 min. The mixture was then filtered through a bed of Celite, washed with solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) (100 mLx2) , and the filtrate was concentrated down about 10~15 mL. The residual solution was mixed with CH2Cl2 (60~90 mL) slowly and the solid thus formed was collected by filtration and dried under vacuum at 40℃ for 2 hrs to produce an enriched tannic acid composition.
- Enrichment Method 9
- The fine gallnut power (20.0 g) was placed in 200.0 mL of solvent (acetone, methyl ethyl ketone, ethyl acetate, or ethanol) and was stirred at 20~60℃for 12 hrs. The solution was filtered and the filtrate collected was placed in 200.0 mL of hexane. The mixture thus formed was stirred at RT for 12 hrs, and the two resulting organic layers were separated. The oiler layer (lower layer) was collected and mixed with 40.0 mL of solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) , and the solution thus formed was mixed with charcoal (1.6 g) and stirred at RT for 12 hrs. The mixture was further mixed with CaSO4 or MgSO4 (2.5 g) and stirred at RT for 30 min. The mixture was then filtered through a bed of Celite, washed with solvent (acetone, methyl ethyl ketone, ethyl acetate, methyl acetate, or ethanol) (100 mLx2) , and the filtrate was concentrated under vacuum. . The residue thus formed was dissolved in acetone or ethyl acetate (12 mL) , and then the solution was stirred and mixed with CH2Cl2 (72.0 mL) dropwise. The solid thus formed was collected by filtration and dried under vacuum at 40~45℃ for 2 hrs to produce an enriched tannic acid composition.
- Enrichment Method 10
- The solution of tannic acid solid (100g) , either from commercial source or crude extract from gallnut powder or small chips, in 250 mL of water was stirred at RT until the all solid was dissolved, then the solution was added with 3.0g of K2CO3 (s) dissolved in 50 mL of water. The mixture was then extracted with 600 mL of a solvent (including ethyl acetate, methyl acetate, or methyl ethyl ketone) at RT for 1hr, and this organic layer was separated. The organic layer was further added with 20g of MgSO4 (s) and stirred at RT for 0.5hr. The mixture was then filtered through a bed of Celite (20g) , washed with a solvent (including ethyl acetate, methyl acetate, or methyl ethyl ketone, 100 mL) , and the filtrate was concentrated in vacuo. The resulting residue was diluted with a solvent (including acetone, ethyl acetate, methyl acetate, or methyl ethyl ketone, 110 mL) , then 660 ml of another solvent was mixed with the resulting solution at RT and the resulting solution was stirred until the addition was completed. The mixture was stirred at RT for 12~18 hrs. The solid formed was collected by filtration and dried under vacuum at 45℃ for 12hrs. The composition of tannic acid afforded was analyzed by HPLC-MS (Figure 26) and 1H-NMR. The HPLC- MSchromatogram (Figure 26) of the composition of tannic acid from Enrichment Method #10 contains less than 0.35%of non-tannic acid impurities, compared to those of UPS Standard and Wenzhou Ouhai Fine Chemicals Corporation containing much higher quantities of non-tannic acid impurities, 15.99%and 6.46%, respectively. The1H-NMR spectrum of the composition of tannic acid from Enrichment Method #10 illustrates only peaks from gallolyl and glucose moieties while those of USP Standard and Wenzhou Ouhai Fine Chemicals Corporation show several peaks other than those from galloyl and glucose moieties. Further HPLC-MS analyses of the compositions of tannic acid from Enrichment Method #10, USP Standard, and Wenzhou Ouhai Fine Chemicals Corporation are illustrated in Table 8. Further 1H-NMR analyses of the compositions of tannic acid from Enrichment Method #10, USP Standard, and Wenzhou Ouhai Fine Chemicals Corporation are illustrated in Table 9. It was thus demonstrated that after Enrichment Method #10, the composition of tannic acid showed a much higher purity than those of tannic acid from USP Standard and Wenzhou Ouhai Fine Chemicals Corporation.
- Table 8. Further HPLC-MS analyses of composition of tannic acid from Enrichment Method #10, USP Standard, and Wenzhou Ouhai Fine Chemicals Corporation
-
-
- Table 9. Further 1H-NMR (400 MHz, acetone-d6/D2O (9: 1, v/v) ) analyses of composition of tannic acid from Enrichment Method #10, USP Standard, and Wenzhou Ouhai Fine Chemicals Corporation
-
-
- Slurrying Method
- The solid afforded from any of the Enrichment Methods described above was slurried with 2000 mL of a solvent (including heptane, CH2Cl2, or heptane/CH2Cl2 (1: 9 to 9: 1) ) at 35~60 ℃ for 8-16hrs, then the solid formed was filtered and evaporated in vacuo at 60~70 ℃ for 8hrs. The solids were then slurry with 2000 mL of a solvent (including heptane, CH2Cl2 or heptane/CH2Cl2 (1: 9 to 9: 1) ) at 35~60 ℃ for 8-16hr, then the solid was filtered and evaporated in vacuo at 60~70 ℃ for 8hrs. The solid was finally further slurried with 2000 mL of a solvent (including heptane, CH2Cl2 or heptane/CH2Cl2 (1: 9 to 9: 1) ) at 35~60 ℃ for 8-16hrs, then the solid generated was filtered and evaporated in vacuo at 60~70 ℃ for 8 hrs to give tannic acid solid (yield: 80%) .
- Enrichment Method 11 -Extraction of Gallnuts
- Gallnuts were either ground thoroughly to form fine powder or roughly to form small chips first. The solution of gallnut powder or small chips (10.0 g) in 60~100 mL of a solvent (including ethyl acetate, methyl acetate, methyl ethyl ketone, ethanol, or water) was stirred at 35-60℃ for 3 hrs, then the second batch of 10.0 g of gallnut powder or small chips were added to the solution and continued to stir at 35-60℃ for 3 hrs. The third batch of 10.0 g of gallnut powder or small chips were added to the solution followed by stirring at 35-60℃ for 8~14 hrs. After the stirring period ended, the solution was filtered and the filtrate collected was concentrated in vacuo to give the crude tannic acid solid (yield: 54~60%) .
- It was found that this multiple-batch approach significantly enhanced the yield of crude tannic acid extract. See Table 10 below for comparison results.
- Table 10. Comparison of Different Extraction Methods
-
One-Batch Approach Multiple-Batch Approach Total Gallnut 30 g powder 30 g powder/10 g for each batch Total time 9 h 9 h/3h for each batch Solvent (Ethyl acetate) 100 mL 100 mL -
Temp. 45℃ 45℃ Yield 19 % 37 % - It was also found that using gallnut power and gallnut small chips resulted in similar tannic acid extraction efficiency, as illustrated in Table 11 below.
- Table 11. Extraction Conditions Using Gallnut Power and Gallnut Chips
-
- Enrichment Method 11 -Further Enrichment of Tannic Acid
- The solution of crude tannic acid solid from above (80 g) in 700 mL of water was stirred at RT until all solid was dissolved, then the solution was added with the solution of 2.4 g of K2CO3 (s) dissolved in 100 mL of water. The mixture was then extracted with 1600 mL of a solvent (including ethyl acetate, methyl acetate, or methyl ethyl ketone) at RT for 1 hr, and this organic layer was separated. The organic layer was further added with 16 g of MgSO4 (s) and further stirred at RT for 0.5 hr. The mixture was then filtered through a bed of Celite (16 g) , washed with a solvent (including ethyl acetate, methyl acetate, or methyl ethyl ketone, 80 mL) , and the filtrate was concentrated in vacuo. The residue was diluted with a solvent (including acetone, ethyl acetate, methyl acetate, or methyl ethyl ketone, 240 mL) , then the solution was added with hexanes (720 mL) and stirred at RT for 2 hrs, and then this organic layer was separated. The resulting oily residue was diluted with a solvent (including acetone, ethyl acetate, methyl acetate, or methyl ethyl ketone, 240 mL) , then the solution was added with hexanes (720 mL) and stirred at RT for 2 hrs, and then this organic layer was separated. The resulting oily residue was diluted with a solvent (including acetone, ethyl acetate, methyl acetate, or methyl ethyl ketone, 100 mL) , then 660 ml of another solvent was mixed with the resulting solution at RT and stirred until the addition was completed. The mixture was further stirred at RT for 12~18 hrs. The solid formed was collected by filtration and dried under vacuum at 45℃ for 6 hrs. The solid was slurry with 1600 mL of a solvent (including heptane, CH2Cl2 or heptane/CH2Cl2 (1: 9 to 9: 1) ) at 35~60 ℃ for 16 hrs, then the solid was filtered and evaporated in vacuo at 60~70 ℃ for 8 hrs. The solid was then slurry with 1600 mL of a solvent (including heptane, CH2Cl2 or heptane/CH2Cl2 (1: 9 to 9: 1) ) at 35~60 ℃ for 8-16 hrs, then the solid was filtered and evaporated in vacuo at 60~70 ℃ for 8 hrs. The solid was further slurried with 1600 mL of a solvent (including heptane, CH2Cl2 or heptane/CH2Cl2 (1: 9 to 9: 1) ) at 35~60 ℃ for 8-16 hrs, then the solid was filtered and evaporated in vacuo at 60~70 ℃ for 8 hrs to give the desirable tannic acid (yield: 62%) .
- Table 12 below shows the content of tannic acids in the tannic acid composition prepared by Enrichment method 11 described herein as determined by HPLC. A tannic acid composition prepared by this method is substantially free of small tannic acids (e.g., having <4 galloyl moieties and a substantial portion is large tannic acids (e.g., having >8 galloyl moieties) . As disclosed herein, such tannic acid compositions are expected to have superior therapeutic effects.
- Table 12. Tannic Acids Content in Tannic Acid Composition Prepared by Enrichment Method 11
-
Retention time (min) Area Area (%) 1G 2.09 66461 0.05 2-3G 9.95 158862 0.11 4G 12.13 2295939 1.58 5G 15.68 21937982 15.06 6-7G 25.75 32048656 21.99 8-12G 28.28 89210765 61.22 Total 145718665 100 - A schematic illustration of the preparation process described above is provided in Figure 27.
- Results
- Inhibitory Activities against DAAO:
- The inhibitory activities of differently enriched tannic acids extracted from gallnuts of different plant or botanic sources against DAAO are illustrated in Tables 13 and 14.
- Table 13. Inhibitory activities of enriched tannic acids extracted from gallnuts of different plant or botanic sources –1
-
- As shown in Table 13, all enriched tannic acids by any of the preparation methods described herein showed lower IC50 values (indicating stronger inhibition) than those without being enriched (direct extraction only and without removal of tannic acids with 1-5 galloyl moieties, no treatment with charcoal and CaSO4 or MgSO4, and/or no further treatment with the second solvent and methylene chloride) . Moreover, enrichment methods 2 and 3 provided the enriched tannic acids with the lowest IC50's activities against DAAO, as compared with methods 1 and 7, while enrichment method 3 afforded the enriched tannic acid with a lower IC50 value than enrichment method 2. Also shown, the tannic acid from extraction with EtOH followed by enrichment method 1 showed slightly weaker inhibition than that with MEK followed by the same enrichment method.
- Table 14. Inhibitory activities of enriched tannic acids extracted from gallnuts of different plant or botanic sources –2
-
-
- As illustrated in Table 14, extraction by ethyl acetate (EtOAc) at the extraction temperature of 40℃ followed by enrichment method 3 afforded the enriched tannic acid with a much lower IC50 against DAAO than extraction by MEK at room temperature, extraction by MEK at 40℃, and extraction by MEK at 40℃ followed by enrichment method 3, respectively. Furthermore, as shown in Tables 13 and 14, gallnuts from Rhus chinensis with the diameters of no more than 6 cm showed lower IC50 values than those of more than 6 cm.
- Table 15. Inhibitory activities of various tannic acids
-
- As shown in Table 15, tannic acid from Enrichment method 10 gave the lowest DAAO IC50 with the compositions of lowest amount of 1-4G and highest amount of 5-12G as illustrated above.
- Residual Solvents:
- The residual solvents determined by 1H-NMR are illustrated in Table 16.
- Table 16. Residual solvents from further slurrying method
-
- As illustrated above, after three slurrying, the residual solvents, namely, acetone ad dichloromethane, were further reduced.
- Example 9. Rescue and Protective Effects of Enrichment #10 Tannic Acid on MK-801 Treated Mice
- The objective of this experiment was to evaluate of Enrichment #10 tannic acids in treating CNS disorders, using MK-801 model, a well-known NMDA receptor antagonist. Tannic acids and MK-801 were administrated in mice by oral gavage (p.o. ) and intraperitoneal (i.p. ) injections respectively before the behavioral tests (i.e., open field and prepulse inhibition) , respectively.
- Methods and Materials
- Animal and housing conditions
- C57BL/6J male mice were group housed (3-5 mice per cage) with food and water available ad libitum in polysulfone ventilated cages (Alternative Design, AR, USA) in the animal rooms. The colony was maintained on a 12/12-hr light/dark cycle at the temperature of 22 ± 2 ℃ and all behavioral studies will be performed during the dark cycle. All animals used in this study were adult mice (at least 2.5 months of age) .
- Drug Administration for locomotion test
- The mice were randomly assigned into five groups:
- Group 1: ddH2O + Saline control;
- Group 2: ddH2O + MK-801;
- Group 3: Merck TA (50 mg/kg) + MK-801;
- Group 4: CCBiotech TA (50 mg/kg) + MK-801; and
- Group 5: Enrichment #10 (50 mg/kg) + MK-801.
- Each mouse in Groups 2-5 received an acute administration of 0.2 mg/kg MK-801 (Sigma-Aldrich, USA) dissolved in normal saline by i.p. injection 20 minutes prior to the locomotion activity test. Each mouse in Groups 3-6 received an acute oral administration of 50 mg/kg tannic acids dissolved in ddH2O by p.o. 20 minutes prior to the MK-801 administration. Tannic acid purchased from Merch Millipore (Merck TA) and from Wufeng Chicheng Biotech (CCBiotech TA) , and tannic acid from Enrichment method 10 (Enrichment #10) at 50 mg/kg were used in this study.
- Drug Administration for prepulse inhibition test
- The mice were randomly assigned into four groups:
- Group 1: ddH2O + Saline control;
- Group 2: ddH2O + MK-801;
- Group 3: Enrichment #10 (50 mg/kg) + MK-801; and
- Group 4: Enrichment #10 (200 mg/kg) + MK-801.
- Each mouse in Groups 2-4 received an acute administration of 0.3 mg/kg MK-801 (Sigma-Aldrich, USA) dissolved in normal saline by i.p. injection 20 minutes prior to the prepulse inhibitin test. Each mouse in Groups 3-4 received an acute oral administration of 50 or 200 mg/kg Enrichment #10 tannic acids dissolved in ddH2O by p.o. 20 minutes prior to the MK-801 administration.
- Results
- The effects of Enrichment #10 tannic acid on locomotion activity in MK-801-treated mice
- The open field task is a common measurement of novelty induced exploratory behavior and general activity in both mice and rats. In this study, the mice were placed in a cage (37.5 cm × 21.5 cm × 18 cm) under 50-65 lux light intensity. Their spontaneous locomotor activities were measured for 30 minutes using the SMART video tracking system (Panlab, Harvard Apparatus) . The travel distance of each mouse was measured as an index of locomotion activity.
- The objective of this experiment was to evaluate the effects of different sources of tannic acids on locomotion activities. Compared to the control group (Group 1) , the MK-801 group (Group 2) displayed hyper-locomotion activity. In comparison to the MK-801 group (Group 2) , both tannic acid from Wufeng Chicheng Biotech (CCBiotech TA; Group 4) and from Enrichment method 10 (Enrichment #10; Group 5) groups displayed a significant lower locomotion activity whereas tannic acid from Merck Millipore (Merck TA; Group 3) did not. Moreover, Enrichment #10 (Group 5) displayed a lower locomotion activity than CCBiotech TA (Group 4) , as shown in Figure 24.
- The effects of Enrichment #10 tannic acid on prepulse inhibition in MK-801-treated mice
- Prepulse inhibition was used as an index of sensorimotor gating function using SR-LAB startle apparatus (San Diego Instruments, San Diego, CA, USA) . Under 65 dB background noise, each session was composed of 5 minutes accumulation period followed by 64 trials in four blocks. The pulse alone (PA) trial was a 40 ms, 120 dB white noise burst. In the prepulse (pp) + pulse trials, a 20 ms white noise prepulse stimuli of 71 dB (pp6) , 75 dB (pp10) , and 83 dB (pp18) were presented 100 ms before a 40 ms 120 dB pulse. The non-stimulus (NS) trials presented the background noise only. The initial and the last blocks were composed of six PA trials, respectively. Two middle blocks consisted of PA, pp + pulse, and NS trials. These trials were presented pseudo-randomly and separated by intertribal intervals of 15 seconds on average (varying between 10 to 20 s) . The percentage of prepulse inhibition was evaluated by the following formula: %PPI = 100 × [ (PA score) - (pp-P score) ] / (PA score) , where the PA score was the average of the PA value in the middle blocks
- Compare to the control group, MK-801 (0.3 mg/kg) induced robust prepulse inhibition deficits in all prepulse intensities. In 71 dB prepulse intensities, tannic acid (50 and 200 mg/kg) did not rescue/protect the MK-801-induced-prepulse inhibition deficits. In terms of the 75 dB and 83 dB prepulse intensity, compared to the MK-801 group, the tannic acid (50 mg/kg) , and tannic acid (200 mg/kg) groups displayed significantly rescue/protective effects on MK-801-induced prepulse inhibition deficit. The results obtained from the mice treated with 50 mg/kg and 200 mg/kg Enrichment #10 tannic acids were similar, as illustrated in Figure 25. It demonstrates a ceiling effect of Enrichment #10 tannic acids at a relative low dose of 50 mg/kg.
- Example 10. The acute toxicity study of Tannic Acid from different sources
- The objective of this example was to evaluate the adverse effects and to determine the maximum tolerated dose (MTD) of tannic acid purchased from Sigma (Sigma tannic acid) and tannic acid from Enrichment method 10 (Enrichment #10) after a single dose administration by oral gavage (p.o. ) following a 7-day observation period.
- Methods and Materials
- Animal and housing conditions
- C57BL/6J male mice were group housed (3-5 mice per cage) with food and water available ad libitum in polysulfone ventilated cages (Alternative Design, AR, USA) in the animal rooms. The colony was maintained on a 12/12-h light/dark cycle at the temperature of 22 ± 2 ℃ and all behavioral studies will be performed during the dark cycle. All animals used in this study were adult mice (at least 2.5 months of age) .
- Drug Administration
- Tannic acids were purchased from Sigma (Sigma tannic acid) or made from Enrichment method 10 (Enrichment #10) . For Sigma tannic acid, the adult mice were randomly assigned to four groups: (1) control, (2) tannic acid (500 mg/kg) , (3) tannic acid (750 mg/kg) , and (4) tannic acid (1000 mg/kg) which were treated, respectively, by a vehicle control (ddH2O) , tannic acid at 500 mg/kg, tannic acid at 750 mg/kg and tannic acid at 1000 mg/kg. For Enrichment #10 tannic acid, the adult mice were randomly assigned to five groups: (1) control, (2) tannic acid (200 mg/kg) , (3) tannic acid (500 mg/kg) , (4) tannic acid (1000 mg/kg) , and (5) tannic acid (2000 mg/kg) which were treated, respectively, by a vehicle control (ddH2O) , tannic acid at 200 mg/kg, tannic acid at 500 mg/kg, tannic acid at 1000 mg/kg and tannic acid at 2000 mg/kg. All mice were administrated with either the vehicle control or tannic acid by oral gavage (p.o. ) . Animals will be observed twice daily (a.m. and p.m. ) or as often as needed during study periods for signs of mortality, morbidity, respiration, secretion, feces, and capability of water and food intake. The body weight of each mouse, which served as an index of its physical development and metabolism, was recorded daily throughout the study.
- Results
- In Sigma tannic acid study, all mice received 1000 mg/kg Sigma tannic acid displayed inactivity, sternal recumbency, and altered respiration rate 35 minutes after dosing, and became moribund on day 2. The symptoms were not reversible during the study. One-third mice received 500 mg/kg or 750 mg/kg displayed sternal recumbency in 35 minutes after dosing. All mice received 500 mg/kg or 750 mg/kg survived during the study. The maximum tolerated dose of Sigma tannic acid was 750 mg/kg. In Enrichment #10 tannic acid study, all mice received 2000 mg/kg tannic acid displayed decreased activity, arching back, and heavy breathe immediately after dosing, and recovered in 10 minutes. No adverse effects were observed and the gross autopsy gave no significant finding in all groups. The maximum tolerated dose of Enrichment #10 tannic acid was at least 2000 mg/kg. In conclusion, enrichment #10 tannic acid showed a much higher maximum tolerated dose than Sigma tannic acid and is safer to be used as treatment for CNS and obesity disorders.
- OTHER EMBODIMENTS
- All of the features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.
- From the above description, one of skill in the art can easily ascertain the essential characteristics of the present disclosure, and without departing from the spirit and scope thereof, can make various changes and modifications of the disclosure to adapt it to various usages and conditions. Thus, other embodiments are also within the claims.
- EQUIVALENTS
- While several inventive embodiments have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and/or structures for performing the function and/or obtaining the results and/or one or more of the advantages described herein, and each of such variations and/or modifications is deemed to be within the scope of the inventive embodiments described herein. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the inventive teachings is/are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific inventive embodiments described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed. Inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not mutually inconsistent, is included within the inventive scope of the present disclosure.
- All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and/or ordinary meanings of the defined terms.
- All references, patents and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which each is cited, which in some cases may encompass the entirety of the document.
- The indefinite articles “a” and “an, ” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean “at least one. ”
- The phrase “and/or, ” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with “and/or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and/or B” , when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B) ; in another embodiment, to B only (optionally including elements other than A) ; in yet another embodiment, to both A and B (optionally including other elements) ; etc.
- As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and/or” as defined above. For example, when separating items in a list, “or” or “and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of, ” or, when used in the claims, “consisting of, ” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e. “one or the other but not both” ) when preceded by terms of exclusivity, such as “either, ” “one of, ” “only one of, ” or “exactly one of. ” “Consisting essentially of, ” when used in the claims, shall have its ordinary meaning as used in the field of patent law.
- As used herein in the specification and in the claims, the phrase “at least one, ” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B, ” or, equivalently “at least one of A and/or B” ) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B) ; in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A) ; in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements) ; etc.
- It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.
Claims (42)
- A composition, comprising (i) a mixture of tannic acids or an acceptable salt thereof, and (ii) a carrier, wherein ≥ 98%of the tannic acids in the composition have 4-12 galloyl moieties, ≥ 97%of the tannic acids in the composition have 5-12 galloyl moieties; ≥90%of the tannic acids in the composition have 6-12 galloyl moieties; or ≥ 60%of the tannic acids in the composition have 8-12 galloyl moieties.
- The composition of claim 1, wherein in the composition, about 4-20%of the tannic acids have 5 galloyl moieties, about 10-35%of the tannic acids have 6-7 galloyl moieties, and/or about 55-85%of the tannic acids have 8-12 galloyl moieties.
- The composition of claim 1 or claim 2, wherein the composition is a pharmaceutical composition, a nutraceutical composition, a health food, or a medical food.
- The composition of claim 3, wherein the composition is a tablet, a capsule, a soft chew, or gel.
- A composition of any one of claims 1-4 for use in inhibiting D-amino acid oxidase (DAAO) in a subject.
- A composition of any one of claims 1-4 for use in treating a central nervous system (CNS) disorder or a disorder associated with obesity in a subject.
- The composition for use of claim 6, wherein the CNS disorder is selected from the group consisting of schizophrenia, psychotic disorders, Alzheimer’s disease, frontotemporal dementia, vascular dementia, dementia with Lewy bodies, senile dementia, mild cognitive impairment, benign forgetfulness, closed head injury, autistic spectrum disorder, Asperger’s disorder, fragile X syndrome, attention deficit hyperactivity disorders, attention deficit disorder, obsessive compulsive disorder, tic disorders, childhood learning disorders, premenstrual syndrome, depression, major depressive disorder, anhedonia, suicidal ideation and/or behaviors, bipolar disorder, anxiety disorders, panic disorder, post-traumatic stress disorder, chronic mild and unpredictable stress, eating disorders, addiction disorders, personality disorders, Parkinson’s disorder, Huntington’s disorder, multiple sclerosis, amyotrophic lateral sclerosis, Tourette’s syndrome, nocturnal enuresis, non-epileptic seizures, blepharospasm, Duchenne muscular dystrophy, stroke, chronic pain, neuropathic pain including hyperalgesia and allodynia, diabetic polyneuropathy, and chronic pain syndromes.
- The composition for use of claim 6, wherein the disorder associated with obesity is selected from the group consisting of eating disorders, anorexia nervosa, bulimia nervosa, stroke, coronary heart disease, heart attack, congestive heart failure, congenital heart disease, hypertension, non-alcoholic steatohepatitis, insulin resistance, hyperuricemia, hypothyroidism, osteoarthritis, gallstones, infertility, obesity hypoventilation syndrome, obstructive sleep apnea, chronic obstructed pulmonary disease, and asthma.
- The composition for use of claim 6, wherein the disorder associated with obesity is an obesity disorder selected from the group consisting of diabetes, hyperglycemia, hyperlipidemia, and hypercholesterolemia.
- The composition for use of any one of claims 6-9, wherein the composition is formulated for administration at a frequency of three times a day to one time every two months to the subject.
- The composition for use of any one of claims 6-10, wherein the composition is for co-use with one or more additional pharmaceutical agents for treating the CNS disorder, or the disorder associated with obesity.
- The composition for use of claim 11, wherein the composition and the one or more additional pharmaceutical agent are administered to the subject concurrently or sequentially.
- A method for preparing a tannic acid composition, the method comprising:(i) providing a composition containing tannic acids;(ii) incubating multiple batches of the composition at 20-80 ℃ with a first solvent sequentially to produce a first tannic acid extract;(iii) contacting the first tannic acid extract with one or more of charcoal, metal carbonate, and metal sulfate at 20-80 ℃ to remove substances absorbed to the charcoal and/or metal carbonate, or removed by the metal sulfate, thereby producing a first tannic acid composition;(iv) mixing the first tannic acid composition with a second solvent to form a solution;(v) contacting the solution with dichloromethane, dichloroethane, pentane, hexane, heptane, or a mixture thereof at 20-40 ℃ to allow for precipitation of tannic acids in solid form; and(vi) collecting the tannic acids in solid form, thereby producing a second tannic acid composition, wherein ≤ 2%of the tannic acids in the second tannic acid composition have 1-4 galloyl moieties.
- The method of claim 13, wherein step (iii) is performed by (a) contacting the first tannic acid extract with metal carbonate at 20-60 ℃ to form a mixture, (b) extracting the mixture with ethyl acetate, methyl acetate, acetone, methyl ethyl ketone, acetonitrile, ethanol, isopropanol, 1, 4-dioxane, tetrahydrofuran, or a combination thereof at 20-50 ℃ to produce an organic solution, and (c) incubating the organic solution with the charcoal and metal sulfate at 20-60 ℃ simultaneously or sequentially.
- The method of claims 13, wherein step (ii) is performed by (a) incubating a first batch of the composition with the first solvent, (b) incubating a second batch of the composition with the mixture formed in (a) , and (c) incubating a third batch of the composition with the mixture formed in (b) to produce the first tannic acid extract.
- The method of any one of claims 13, further comprising a step of removing dextrin, gum, and resin from the first or second tannic acid composition.
- The method of claim 16, wherein the removing step is performed by a process comprising (a) mixing the first tannic acid composition or the second tannic acid composition with a polar solvent and collecting the organic layer thus formed.
- The method of claim 17, wherein the polar solvent is ethyl acetate, methyl acetate, acetone, methyl ethyl ketone, acetonitrile, ethanol, isopropanol, 1, 4-dioxane, or tetrahydrofuran.
- The method of claims 17, wherein the process of the removing step further comprises (b) contacting the organic layer with an alkyl solvent, a chlorinated solvent, or a mixture thereof at 10-70 ℃, and collecting the bottom oily layer thus formed.
- The method of claim 19, wherein the alkyl solvent is pentane, hexane, or heptane.
- The method of claim 19, wherein the chlorinated solvent is dichloromethane, or dichloroethane.
- The method of claims 13, further comprising (a) mixing the second tannic acid composition with an alkyl solvent, a chlorinated solvent, or combination thereof, and (b) stirring the mixture thus formed to remove solvent residues at 10-70 ℃.
- The method of claim 22, wherein the alkyl solvent is pentane, hexane, or heptane.
- The method of claim 22, wherein the chlorinated solvent is dichloromethane, or dichloroethane.
- The method of claim 13, wherein step (ii) is performed at a temperature of 20-60 ℃.
- The method of claim 13, wherein step (iii) further comprises contacting the mixture with silicon dioxide.
- The method of claims 13, wherein the composition containing tannic acids of step (i) is gallnut powder or gallnut chips obtained from gallnuts of a plant.
- The method of claim 27, wherein the plant is selected from the group consisting of Rhus chinensis, Rhus javanica, Rhus semialata, Rhus coriaria, Rhus potaninii, Rhus punjabensis var. sinica (Diels) Rehder &E.H. Wilson, Camellia sinensis, Berry, Bixa orellana, Vitis vinifera, Punica granatum, Quercus infectoria, Quercus cerris, Acacia mearnsii, Pseudotsuga menziesii, Caesalpinia spinosa, Fagus hayata Palib. ex Hayata, and Machilus thunbergii Sieb. &Zucc.
- The method of claim 27, wherein the plant is selected from the group consisting of Rhus chinensis, Rhus javanica, Rhus semialata, Rhus coriaria, Rhus potaninii, and Rhus punjabensis var. sinica (Diels) Rehder &E.H. Wilson.
- The method of claim 27, wherein the gallnuts have diameters ranging from 1-8 cm.
- The method of claim 27, wherein the gallnuts are Chinese belly-shaped gallnuts or horned gallnuts.
- The method of claim 31, wherein gallnuts are Chinese horned gallnuts.
- The method of claim 31, wherein the Chinese horned gallnuts have diameters ranging from 1-8 cm.
- The composition of claim 33, wherein the gallnuts have diameters ranging from 2-6 cm.
- The composition of claim 34, wherein the gallnuts have diameters ranging from 3-5 cm.
- The method of claims 13, wherein metal carbonate in step (iii) is lithium carbonate, sodium carbonate, or potassium carbonate.
- The method of claims 13, wherein metal sulfate in step (iii) is calcium sulfate or magnesium sulfate.
- The method of claims 13, wherein the first solvent in step (ii) comprises acetone, acetonitrile, methyl ethyl ketone, ethyl acetate, methyl acetate, ethanol, isopropanol, tetrahydrofuran, 1, 4-dioxane, heptane, hexane, water, or a combination thereof.
- The method of claims 13, wherein the second solvent is acetone in step (v) comprises acetone acetonitrile, ethyl acetate, methyl acetate, methyl ethyl ketone, ethanol, isopropanol, 1, 4-dioxane, tetrahydrofuran, or a combination thereof.
- A tannic acid-containing composition, wherein the composition is produced by a method of any one of claims 13-39.
- A method for removing dextrin, gum, and/or resin from a tannic acid composition, comprising:(i) providing a tannic acid composition comprising dextrin, gum, resin, or a combination thereof;(ii) mixing the tannic acid composition with a polar solvent to form an organic layer;(iii) contacting the organic layer with an alkyl solvent, a chlorinated solvent, or a combination thereof at 10-70 ℃; and(iv) collecting the bottom oily layer thus formed.
- A method for removing solvent residues from a tannic acid composition; comprising:(i) providing a tannic acid composition comprising residues of at least one solvent;(ii) mixing the tannic acid composition with an alkyl solvent, a chlorinated solvent, or a combination thereof to form a mixture, and(iii) stirring the mixture to remove residues of the at least one solvent at 10-70℃.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2017/115000 WO2019109300A1 (en) | 2017-12-07 | 2017-12-07 | Improved enrichment methods for preparing tannic acid compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3720456A1 true EP3720456A1 (en) | 2020-10-14 |
EP3720456A4 EP3720456A4 (en) | 2021-06-02 |
Family
ID=66750658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17934010.4A Pending EP3720456A4 (en) | 2017-12-07 | 2017-12-07 | Improved enrichment methods for preparing tannic acid compositions |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210162316A1 (en) |
EP (1) | EP3720456A4 (en) |
JP (2) | JP2021505577A (en) |
KR (1) | KR20200097255A (en) |
CN (1) | CN111465400A (en) |
CA (1) | CA3082916A1 (en) |
IL (1) | IL274867A (en) |
MX (1) | MX2020005934A (en) |
RU (1) | RU2020118555A (en) |
WO (1) | WO2019109300A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10927138B2 (en) * | 2018-05-29 | 2021-02-23 | Syneurx International (Taiwan) Corp. | Inhibitors of D-amino acid oxidase (DAAO) and uses thereof |
GB2596491B (en) * | 2018-12-18 | 2022-06-29 | Sang Hee Kim | Composition for preventing or treating attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients |
KR102246444B1 (en) | 2018-12-18 | 2021-04-29 | 김상희 | Composition comprising nutgall extract and fraxin as active ingredient for improvement of cognitive ability and for prevention or treatment of dementia |
US11154531B2 (en) | 2020-02-08 | 2021-10-26 | Syneurx International (Taiwan) Corp. | Compounds and pharmaceutical uses thereof |
KR20230004765A (en) | 2020-04-23 | 2023-01-06 | 신유알엑스 인터내셔널 (타이완) 코포레이션 | COMPOUNDS AND PHARMACEUTICAL USES THEREOF |
WO2024022411A1 (en) * | 2022-07-26 | 2024-02-01 | Syneurx International (Taiwan) Corp. | Compounds and compositions for treating influenza |
CN116273183A (en) * | 2023-02-20 | 2023-06-23 | 四川师范大学 | Tannic acid modified MOF/hydrogel composite porous structure photocatalytic particles and preparation method thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571551A (en) * | 1993-05-27 | 1996-11-05 | Kraft Foods, Inc. | High molecular weight gallotannins as a stain-inhibiting agent for food dyes |
CA2496912A1 (en) * | 2002-07-24 | 2004-01-29 | Ohio University | Methods and compositions for treating diabetes mellitis |
CN1193763C (en) * | 2003-04-10 | 2005-03-23 | 四川倍达尔新技术开发有限公司 | Rhodiola total tanning matter extract and use for preparing medicine for curing senile dementia |
CN101407531B (en) * | 2007-10-11 | 2012-11-21 | 首都医科大学 | Use of dimer hydrolysable tannins derivative in preparing medicament and diet additive for treating obesity |
US20090118202A1 (en) * | 2007-10-31 | 2009-05-07 | Texas Tech University | Compositions and methods of treating hypertension with tannin complexes |
CN102245180A (en) * | 2008-11-14 | 2011-11-16 | 帕金森氏病研究院 | Compositions and methods for the treatment of altered alpha-synuclein function |
CN102180917A (en) * | 2011-03-20 | 2011-09-14 | 竹山林产化工实业有限公司 | Preparation method of medicinal tannic acid |
CN102250159A (en) * | 2011-04-28 | 2011-11-23 | 贵阳单宁科技有限公司 | Method for extracting and preparing high-purity tannic acid from plant raw material containing tannin |
JP6373551B2 (en) * | 2012-05-30 | 2018-08-15 | 味の素株式会社 | Gallotannin-containing composition |
KR102476644B1 (en) * | 2016-03-28 | 2022-12-09 | 신유알엑스 인터내셔널 (타이완) 코포레이션 | Compositions containing tannic acid and uses thereof |
-
2017
- 2017-12-07 RU RU2020118555A patent/RU2020118555A/en not_active Application Discontinuation
- 2017-12-07 MX MX2020005934A patent/MX2020005934A/en unknown
- 2017-12-07 CA CA3082916A patent/CA3082916A1/en active Pending
- 2017-12-07 CN CN201780097512.6A patent/CN111465400A/en active Pending
- 2017-12-07 JP JP2020530581A patent/JP2021505577A/en active Pending
- 2017-12-07 US US16/770,530 patent/US20210162316A1/en not_active Abandoned
- 2017-12-07 WO PCT/CN2017/115000 patent/WO2019109300A1/en unknown
- 2017-12-07 EP EP17934010.4A patent/EP3720456A4/en active Pending
- 2017-12-07 KR KR1020207015968A patent/KR20200097255A/en not_active Application Discontinuation
-
2020
- 2020-05-24 IL IL274867A patent/IL274867A/en unknown
-
2022
- 2022-03-22 JP JP2022045760A patent/JP2022089831A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022089831A (en) | 2022-06-16 |
IL274867A (en) | 2020-07-30 |
MX2020005934A (en) | 2020-08-24 |
CA3082916A1 (en) | 2019-06-13 |
WO2019109300A1 (en) | 2019-06-13 |
US20210162316A1 (en) | 2021-06-03 |
RU2020118555A (en) | 2022-01-13 |
CN111465400A (en) | 2020-07-28 |
KR20200097255A (en) | 2020-08-18 |
RU2020118555A3 (en) | 2022-01-13 |
JP2021505577A (en) | 2021-02-18 |
EP3720456A4 (en) | 2021-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11202791B2 (en) | Compositions containing tannic acids and uses thereof | |
WO2019109300A1 (en) | Improved enrichment methods for preparing tannic acid compositions | |
US10617660B2 (en) | Compositions containing benzoate compound and tannic acid for treating central nervous system disorders | |
US20220273600A1 (en) | Lithium salts of n-substituted glycine compounds and uses thereof | |
TWI686192B (en) | Compositions containing tannic acids and uses thereof | |
TWI717576B (en) | Improved enrichment methods for preparing tannic acid compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200529 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210504 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 35/64 20150101AFI20210428BHEP Ipc: C07H 13/08 20060101ALI20210428BHEP Ipc: C07H 1/08 20060101ALI20210428BHEP Ipc: A61P 3/04 20060101ALI20210428BHEP Ipc: A61P 3/06 20060101ALI20210428BHEP Ipc: A61P 3/10 20060101ALI20210428BHEP Ipc: A61P 25/00 20060101ALI20210428BHEP Ipc: A61K 31/7024 20060101ALI20210428BHEP Ipc: A61K 36/22 20060101ALI20210428BHEP Ipc: A61K 36/49 20060101ALI20210428BHEP Ipc: A61K 36/82 20060101ALI20210428BHEP Ipc: A61K 45/06 20060101ALI20210428BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40038594 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20231106 |